2012 Annual Report

YEARS OF MEDICAL RESEARCH ANNUAL ANNUAL REPORT 2012 GARVAN INSTITUTE INSTITUTE GARVAN 50 CELEBRATING

GARVAN INSTITUTE OF MEDICAL RESEARCH ANNUAL REPORT 2012 CELEBRATING 50 YEARS 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

1963 1964 1970s and 80s 1981 1983 1990 1994 1998 2003 2008 The Garvan Institute was The first laboratory at Expansion of scientific staff The Garvan Research The Council of the University Professor John Shine Ken Hillier, Building Project Arthritis & Inflammation NHMRC awarded a prestigious Australian BioResources (a officially opened on 17 Garvan shared by two including the arrival of a Foundation was established of New South Wales appointed as Executive Manager, Terry Budge, Research Program initiated. and highly competitive state-of-the-art facility for February 1963, named in scientific staff assisting critical mass of key senior on 1 January 1981, with the approved the affliliation of Director. Seen in above National Australia Bank's Garvan successfully recruited Program Grant of $5 million to the breeding and holding of honour of James Patrick Drs Les Lazarus and John researchers, many of whom aim “To support, assist and the Insitute with the photo (left to right) with State Manager for NSW and one of Australia’s leading Cancer Research Program research mice) opened at Garvan (pictured), a founder Hickie – Ms Gillian Henson are now recognised as promote scientific and medical University in May 1983. Professors Rob Sutherland, Professor John Shine – expatriate scientists, Dr over a period of five years, Moss Vale, south of Sydney, of the life insurance industry (left) and Ms Margaret Stuart. ground breakers in their field. research within the Garvan John Eisman, Don Chisholm photographed on the Charles Mackay, to return forming a critical base for its on 29 July. in NSW. In 1957, after a Institute of Medical Research”. 1986 and Ms Norma Perry, Head construction site of the from a major biotechnology continued work. century of service, St 1960s and 70s 1979 Garvan received NHMRC of Administration. new building. firm in the United States to 2012 Vincent's Hospital held its Research during these years Dr Margaret Stuart 1982 ‘block funding’, one of the lead the new Program. The Australian Cancer Prime Minister Julia Gillard Centenary Appeal. The was dominated by (Assistant Director of Garvan Left: The National Health and factors that allowed it to 1992 1997 Research Foundation (ACRF) opened The Kinghorn Cancer money raised was largely endocrinology, fostered by from 1978) with Dr Anne Medical Research Council expand into a world-class Awarded one of the Federal Garvan building opened on 2001 provided a grant of $1.1 Centre on 28 August. Seen used to build Garvan. the presence of the State Underwood, leader of a team (NHMRC) awarded Garvan facility. Government’s prestigious 7 April by Prime Minister Formation of G2 Therapies million to establish a Cancer here with (left to right): Reference Laboratory for at CSIRO Division of its first Program Grant for Co-operative Research John Howard and Bob Carr, Ltd, a “spin-off” biotechnology Molecular Genetics Unit in Professor Andrew Biankin, The building was officially endocrine assays. Molecular Biology which research into Diabetes. The Centres, to focus on the Premier of New South Wales. company set up to develop collaboration with St Vincent’s Federal Health Minister Tanya opened by the 16th Duke of carried out cell fusions for photograph shows Professors development of internationally breakthroughs and Hospital. The grant enabled Plibersek, Garvan Chairman Norfolk. 1500 supporters 1969 hybridoma production in the Ted Kraegen and Don competitive products in the intellectual property of the purchase of equipment to Mr Bill Ferris AC, Professor and dignitaries attended the Dr Les Lazarus became the monoclonal antibody project Chisholm with Mr Barry biopharmaceutical field. The Garvan in the areas of cancer analyse genetic changes in Rob Sutherland AO FAA, opening ceremony. first sole Director of the which ran from 1979-1985. Jones, Commonwealth Centre was a joint venture and inflammatory diseases. different tumour biopsies. Federal Treasurer Wayne Institute. Minister for Science. between Garvan, The Swan and Chairperson, Mary University of NSW, St Formally established the 2004 Aikenhead Ministries, Mr Right: Nina Ostlund using the Vincent’s Hospital, the Peter Wills Centre for Dr Vanessa Hayes, Prime David Robinson. newly installed (1982) Fast Biomolecular Research Bioinformatics with the Minister John Howard and Protein Liquid Chromatography Institute in Melbourne, the support of $1 million from Associate Professor Susan Professor John Mattick AO FAA system to examine the purity Commonwealth Serum the Federal Government and Clark at the opening of the appointed as Executive of a human growth hormone Laboratories, Peptide the community. The Centre ACRF facility in 2004. Director in January. preparation. Technology Ltd and Johnson was created to analyse the and Johnson Research Pty Ltd. explosion of data arising 2006 from genetic approaches to Leading immunologists medical research. transferred from the Centenary Institute to Garvan, among them Professor Antony Basten AO FAA FTSE (pictured above). 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Mission 02

Who we are, What we do 03

Celebrating 50 Years at Garvan 04

Reports Chairman's Report 08 Executive Director's Report 10 Garvan Research Foundation Chairman's Report 12 TKCC Director's Report 14

Garvan at a Glance Organisation Chart 17 Patent Portfolio by Category 18 Scientific Publications 18 Philanthropic Support 18 Staff Profile 19 Operating Income 19 Peer Reviewed Grant Income 19 Research Collaborations 21

Research Highlights of Last 50 Years 23

Research Divisions/Centres Cancer 26 The Kinghorn Cancer Centre 30 Immunological Diseases 32 Metabolic Diseases 36 Diabetes Vaccine Development Centre 40 Neurological Diseases 42 Osteoporosis & Bone Biology 46

People Highlights 51

Business Development 55

Garvan Community Life Governors 57 Partners for the Future 57 Volunteers 58 Garvan Supporters 58 Gala Supporters 61 Bequests 61

Governance Garvan Institute Governance 63 Garvan Research Foundation Governance 67

Publications 71

Financial Highlights Income Statement 85 Balance Sheet 86 Garvan Research Foundation Statement of Funds 87 Mission

Garvan's mission is to make significant contributions to medical research that will change the directions of science and medicine and have major impacts on human health. Garvan strives to enhance and develop research programs that combine fundamental science with strong clinical interactions.

02MISSION Who WE ARE,

What WE DO

The Garvan Institute of Medical Research Significant breakthroughs have been achieved is a world leader in its field, pioneering by Garvan scientists in the understanding and study into some of the most widespread treatment of diseases such as: diseases affecting our community today. _ Cancer Research at Garvan is focused upon _ Diabetes and obesity understanding the role of genes and _ Neurological diseases such as Alzheimer's, molecular and cellular processes in health Parkinson's, hearing loss, mental illnesses and and disease as the basis for developing eating disorders future preventions, treatments and cures. _ Osteoporosis _ Immunological diseases such as asthma, rheumatoid arthritis, multiple sclerosis and Sjogren’s syndrome

Garvan's ultimate goal is prevention and cure of these major diseases.

WHO03 WE ARE, WHAT WE DO

Celebrating 50 YEARS AT GARVAN

Opposite: Professor John In 1957, the centenary of the founding of St Vincent's Shine AO FAA (right) and predecessor Professor Hospital by the Sisters of Charity, the hospital Les Lazarus AO with the launched a Centenary Appeal. In 1960 it decided to initial model of Garvan in spend much of the money raised to establish a 1988, the year before the funds to create the new medical research facility. building were approved by the State Government. Construction of the new building began in January This page (L to R): Mr 1962 on the corner of Victoria, Burton and Chaplin Charles Curran AC (Chair Streets. It consisted of a basement and three floors 1988-1993), Professor and allowed for the eventual development of a six- John Shine AO FAA (Exec Dir 1990-2011), Mr Peter floor building. became very prominent in this area. In 1978, a Wills AC (Chair 1993- computerised gas chromatograph / mass 2001), Professor Les In 1961, St Vincent's received a particularly spectrometer was installed, under the management Lazarus AO (Director 1968-1989), Mr Bill Ferris generous donation of £100,000 from the of Dr George Smythe, allowing researchers to AC (Chair 2001-2013), daughters of James Patrick Garvan (1843-1896), measure effects of various hormones and metabolic Professor John Mattick AO a distinguished parliamentarian and business leader. manipulations on the brains of experimental animals. FAA (Exec Dir 2012-). The family stipulated that the donation be In 1980-81, a team led by Dr Margaret Stuart The group photograph was anonymous and “for the purpose of research”, but started a collaborative project with CSIRO's taken at NSW Government House on 17 February eventually agreed that the Institute be named in Molecular and Cell Biology Unit to produce 2013, at an event memory of James Patrick Garvan, his wife and their monoclonal antibodies to human protein hormones. celebrating Garvan’s 50th son, Sir John Garvan, first Chairman of the Anniversary. It includes all executive directors of Commonwealth Bank. Several other researchers also set up labs during Garvan and all chairs, these first three decades. In the late 1960s, Drs except inaugural chair, the On 17 February 1963, the Garvan Institute of Don Chisholm and Ted Kraegen, with Les Lazarus, late Keith Cousins. Medical Research was officially opened by Bernard studied the effect of gut hormones (known as Marmaduke Fitzalan-Howard KG, GCVO GBE,16th Duke 'Incretins') on insulin secretion. Dr Kraegen started of Norfolk. The ceremony was attended by 1,500 developing a computer model to study the action of supporters and dignitaries. insulin in humans, a project that became progressively more sophisticated throughout the Over the following two years, a few research 1970s and led to life-saving improvements in the projects were initiated, lab workers appointed, and treatment of Diabetic Ketoacidosis. Dr Chisholm a Management Committee established. Between went overseas in 1969, but returned in 1978 when 1966 and 1969, three active academic members he, Dr Kraegen and Dr Lesley Campbell further of the hospital – Associate Professors John Hickie developed the Diabetes Research Program. They and Gerry Milton and Dr Les Lazarus – acted as were awarded a National Health and Medical Co-Directors. In 1969, Dr Lazarus became the first Research Council (NHMRC) Program Grant in 1982 sole Director of the Institute. and concentrated on insulin resistance, obesity and pathogenesis of type 2 diabetes. Drs Trevor Biden Over the next two decades, Garvan developed a and Greg Cooney were important later additions to strong focus on hormonal research, partly because the Program. In 2002, Professor David James, an Dr Lazarus was himself an endocrinologist. He ex-Garvan PhD student with an international established a hormone radioimmunoassay service reputation in cell biology, returned to the Institute at Garvan in 1964-1965, which was a significant as Director of the Program, adding new impetus to component of the research activity and provided a its success. steady source of funds, an important consideration before regular research grants were available. In the In August 1984, Dr John Eisman, a recognized 1970s Drs Cres Eastman, John Carter and others leader in calcium, vitamin D and bone disease, provided an additional important thrust into thyroid transferred his lab from the University of hormone assays and related research. Melbourne, extending a theme that Garvan had developed in diseases of ageing. Assisted by Drs Dr Lazarus was particularly interested in pituitary Phillip Sambrook and Nick Pocock, he established hormones and disease, and with the assistance of the Bone and Calcium Research Program and Drs Margaret Stuart, Steve Judd and later Ken Ho hospital Clinic related to the treatment and (who headed the group from 1991), the Institute prevention of osteoporosis, and measurement of CELEBRATING05 50 YEARS AT GARVAN bone density. The program gained strength in the Government, allowed Garvan to expand into a 1980s, establishing international collaborations with world-class facility. A new building, built on the old the Mayo Clinic and University of South Carolina. site and capable of accommodating over 500 Further strength in the clinical and epidemiological scientists, was officially opened in April 1997 by area was added by recruitment of Drs Tuan Nguyen Prime Minister John Howard OM AC SSI and NSW and Jackie Center, and the Dubbo Osteoporosis Premier Bob Carr. Epidemiology Study was established in the 1990s. The Dubbo study is still running today, the longest During the 1990s, Garvan scientists were the first running project of its kind anywhere in the world. In to pinpoint a gene involved in susceptibility to 2011 Professor Peter Croucher succeeded osteoporosis; the first to clone several neuropeptide Professor Eisman as head of the Program and receptor genes, including NPY, adenosine and reactivated a major thrust into bone cell, galanin; the first to decipher certain signalling osteoporosis and cancer-bone biology. pathways underlying insulin resistance; and the first Opposite: Dr David James to recognise the role of different cell cycle genes in (right) receiving the In April 1985, a new Cancer Cell Biology Group was the development of breast cancer. Sandoz Award from Mr Gilles de Weck at the 1984 established when Dr Robert Sutherland and his meeting of the Endocrine research team transferred from the Ludwig Institute After the molecular biology developments of the Society of Australia. for Cancer Research at the University of Sydney to 1990s came the 'big' science of our current century. Professor David James FAA study hormone antagonists and cancer, particularly The launch in 2000 of the first draft of the human is Head of the Metabolic breast cancer. These beginnings led to substantial genome led to huge sequence databases and gene Diseases Division. After growth of the Cancer Research Program at Garvan, arrays – no more painstaking testing of individual pursuing postdoctoral studies elsewhere, he which increased to around 120 researchers by gene activity. Gene chips allowed researchers to returned to Garvan in 2002 2013 and expanded its activity to prostate, ovarian, look at 40,000 genes at once – to determine how to take up that position. pancreatic and bowel cancers, with prominent gene expression is changed in disease. Garvan contributions over the years from Professors embraced this new research paradigm quickly and Andrew Biankin, Susan Clark, Roger Daly, Liz was the first in Australia to install the new Musgrove and Chris Ormandy. Affymetrix arrays. In a similar way, it recently embraced proteomics, epigentics and bioinformatics. An Act of Parliament established Garvan's independence in 1984. At the time, its make up still In 2000, Garvan started to grow what has become revealed its origins within the endocrine department an outstanding Immunology Program – by of St Vincent's Hospital. The Institute remained an attracting Professors Charles and Fabienne Mackay amalgam of NHMRC funded research groups and from the United States, and then Professor Tony scientists working for the NSW Reference Laboratory Basten AO FAA FTSE and other leading immunologists for Hormone Assays throughout the 1980s. from the Centenary Institute. These distinguished researchers formed a critical mass in the discipline, Professor John Shine – world-renowned for a series which permeates all other Garvan research areas. of discoveries made between 1975 and 1985 that Associate Professor Robert Brink took over ultimately led to gene cloning – was appointed leadership of this Program from Professor Mackay Executive Director of Garvan in 1990. He recognised in early 2010. that the two streams of activity were at this stage confusing the organisation's vision and purpose, so Today the gap between a research discovery and its the assay service was transferred to SydPath, the clinical application is smaller than ever. In 2012, pathology service of St Vincent's Hospital, where Garvan and St Vincent's Hospital opened The Professor Lazarus became Director after his Kinghorn Cancer Centre, a state-of-the-art retirement from Garvan. translational cancer research centre described later in this report; our Dubbo Osteoporosis Epidemiology Professor Shine's appointment reflected the fact Study is informing treatment decisions the world that by 1990 recombinant DNA and gene cloning over; and our diabetes research is seamlessly were starting to make a big impact across all fields integrated with the St Vincent's Diabetes Centre. of research, with scientists mutating genes to see what would happen in specific disease models. In January 2012, Professor John Mattick succeeded Professor Shine as Executive Director. Professor Professor Shine's interest in the neuropeptide Mattick has made a significant contribution to receptor families helped spawn Garvan's genetics and genomics through his farsighted Neuroscience Program, which is now headed by theories on large sections of the genome that Professor Herbert Herzog who joined the lab as a previously were considered functionally irrelevant. young postdoctoral fellow in 1991. Professor Mattick's arrival coincides with In 1986, Garvan became one of only five 'centres increasingly rapid and affordable genome of research excellence' in Australia to receive sequencing and the concomitant promise of NHMRC 'block funding'. That, along with 'personalised medicine' – both set to revolutionise subsequent infrastructure funding from the NSW medicine over the next 50 years.

06CELEBRATING 50 YEARS AT GARVAN

Chaiman’s REPORT

2012 2012 was a year of consolidation but also a time for fresh inspection of priorities and opportunities following the appointment of Professor John Mattick as Executive Director. The successful opening of The Kinghorn Cancer Centre in August 2012 by the Prime Minister was a milestone achievement in our commitment to accelerating the translation of Garvan research into clinical outcomes. The project partners, Garvan and St Vincent's, completed this exciting Centre on time and on budget. We record our heartfelt thanks to the many private donors who, together with the Federal Government's Health and Hospital Fund, made this vital project possible. Our ability to integrate teaching, research and clinical translation on our expanding Darlinghurst campus has never been stronger, and the links with and support from our Opposite: Mr Ferris has championed key stakeholders, St Vincents and Mater Health and University of NSW, will be The Kinghorn Cancer Centre (TKCC) from concept to completion. increasingly important to these ambitions.

Anticlockwise from top right: The Financial Performance Reflection Garden, courtesy of the Garvan's operating income grew to approximately $56m in 2012 from $51m the Ferris Family Foundation; Jill Kinghorn and Bill Ferris with children from previous year. Philanthropic support through the Garvan Research Foundation, essential the Darlinghurst Primary School, for providing critical equipment and facilitating new initiatives, continued to be strong, who created the mural Helping with over $7.1m in general and specific grants contributed to research programs and Hands, Healing Hands in 2010; Ground Breaking Ceremony on 28 approximately another $2.0m to the long term endowment fund of the Institute. May 2010; Mr Ferris with TKCC patron Delta Goodrem and Prime Looking Ahead Minister Julia Gillard at centre For the past 18 months I have participated in a panel review (the McKeon Review) opening on 28 August 2012. regarding the future of health and medical research. This panel completed its report to the Federal Government in February 2013 and makes 21 specific recommendations for optimising the health and quality of life for all Australians. Embedding research in all parts of the health system is core to these recommendations. Along with 350 other contributors, Garvan made a submission to the panel during 2012. I believe it is very important for all participants in the health sector to now encourage the Federal Government to respond promptly and wisely to this review since a healthier Australia will be a happier and more productive nation. I have been privileged to chair Garvan for the past 12 years and I thank all of the Garvan stakeholders for placing their trust in me and in my fellow board members of the Institute and the Foundation.

I am very pleased indeed to welcome and congratulate Mr John Schubert AO as the new Chairman of the Garvan Institute. From his successful time as Chief Executive of the Pioneer group, as Chairman of the Commonwealth Bank, as a Director of BHP Billiton and Chair of the Great Barrier Reef Research Foundation, John now brings a wealth of experience and wisdom to the Garvan boardroom. In this, Garvan's 50th anniversary year, I see that we have a wonderful opportunity and obligation to build on the achievements and reputation of this wonderful place of discovery. I remain confident in Garvan's continuing role as a leading and pioneering player in the future of health and medical research in this country and beyond.

Bill Ferris AC Chairman Garvan Institute of Medical Research 08CHAIRMAN’S REPORT

Executive DIRECTOR’S REPORT

2012 has been a year of significant developments and changes at the Garvan Institute, some unexpected. In taking up the directorship in early January, I arrived with an intention and mandate to build on the great strengths of the Institute, and the pioneering work of the preceding Director John Shine, by introducing and promoting the application of advanced genomic technologies and bioinformatics to the understanding and treatment of the complex diseases – cancer, diabetes, osteoporosis, immunological diseases and neurological diseases – which are the focus of the Institute's mission.

There have been three great revolutions in molecular biology. The first was the double helix in 1953, encapsulated in the central staircase of our institute, which provided the basis for understanding gene structure and expression. The second was the gene cloning revolution in the 1970s and 80s, which connected genetics with biochemistry, and thereby identified many of the genes and proteins that control human development and physiology, as well as those – like oncogenes and tumour suppressors – that are dysfunctional in complex diseases like cancer. Indeed, the identification of these aberrant genes was the basis for a whole new generation of targeted anti-cancer drugs that are now entering the clinic.

The third revolution, and a major step change, is the genomics revolution, which is enabling medical scientists to look comprehensively and holistically at the complex changes that occur in human development, in brain function, and in the aetiology of the complex diseases that comprise the major health burden of our population. Just a decade ago it cost $1 billion to sequence the first human genome, but that has since plummeted to a few thousand dollars today and will likely be a few hundred dollars in the near future. This is resulting in an explosion in the amount of information that medical science is gathering about human genetic variation, including the range of mutations that underpin cancer.

The Garvan Institute, along with the Institute for Molecular Bioscience at the University of Queensland, led one of these projects as part of the International Cancer Genome Consortium, focusing on pancreatic cancer. The results, published in October 2012 in the leading international journal Nature, not only showed that pancreatic cancer had links with molecules involved in nerve guidance pathways, which explained some of its behaviour, but also that this, like many cancers, is a heterogeneous disease, with a variety of underlying mutations that are not discernable from the cellular pathology. Most importantly, many of these mutations occur in other cancers, and some already have effective drugs available to treat them, resulting in life-saving outcomes.

During the year, we were delighted to be joined by the Prime Minister, the Federal and State Ministers of Health, His Eminence Cardinal Pell, and many other friends at the opening of The Kinghorn Cancer Centre, a joint venture between the Garvan and St Vincent's Hospital to bring leading translational research to cancer care. Sadly, we lost the inaugural Director, Professor Rob Sutherland AO FAA, to pancreatic cancer shortly afterwards. A towering figure at Garvan, internationally renowned for his pioneering research on the oestrogen receptor in breast cancer and for his leadership in translational cancer research, Rob will be sorely missed.

10EXECUTIVE DIRECTOR’S REPORT It is clear that genome sequencing will soon become routine in cancer research – identifying new mutations that can be targets for diagnostic and therapeutic development – and the standard in clinical care. To this end we are establishing the nation's first Centre for Clinical Genomics in The Kinghorn Cancer Centre, which will provide access to state-of-the-art clinical genomic services and analyses. Moreover, the same infrastructure can be deployed to investigating other diseases, and form the platform for the development of genomic medicine over the next decade and beyond.

During 2012 we continued to re-build the Division of Osteoporosis & Bone Biology, notably by appointing Professor Mike Rogers from the University of Aberdeen, internationally renowned for his work in anti-osteoporotic drugs. A member of the Division, Dr Jackie Center, was awarded one of the inaugural John Shine Research Fellowships to continue her work on the outcome of bone fractures in the elderly and identification of people at risk.

The Shine Translational Research Fellowships are jointly funded by the Garvan Institute and St Vincent's Hospital, and aim to support clinicians in undertaking translational research at Garvan. Two additional awardees were Dr Alex Viardot for his research on the management of obesity and diabetes and Dr Ann McCormack for studies on pituitary tumours.

Garvan's researchers in all of our divisions had a very successful year, making significant advances that were published in high impact journals. Space precludes listing them here but they are highlighted in the relevant sections of this annual report.

I look forward to strengthening the Institute over the coming year, with a substantial emphasis on mentoring our younger researchers and recruiting others to join us. Informed by our annual retreat and discussions with our staff, students and stakeholders, we have developed a strategic plan to guide our development over the next quinquennium.

I thank my colleagues, members of the Garvan Board, Garvan Research Foundation and Business Development Advisory Committee for their warm reception, generous support and sage advice. Finally, on behalf of the entire Garvan community, I would like to thank our outgoing Chairman Bill Ferris AC for his outstanding contributions to the Institute and the precinct over the past 12 years, and to warmly welcome our incoming Chairman, John Schubert AO.

John Mattick AO FAA FRCPA Executive Director Garvan Institute of Medical Research

EXECUTIVE DIRECTOR’S11 REPORT Garvan RESEARCH FOUNDATION CHAIRMAN’S REPORT

In Australia today, there are an increasing number of worthy charitable causes seeking vital support from the community. Despite this challenging environment, the Garvan Research Foundation had another very successful year in 2012.

We received wonderful financial and moral support from a wide cross-section of the Australian community – from passionate individuals, government and established charitable foundations.

There was strong ongoing support from the Ernest Heine Family Foundation, Mrs Janice Gibson, The Ross Trust, Mrs Jane Hemstritch, Lady (Mary) Fairfax Foundation and our ongoing partnership with MLC Community Foundation. Corporate support of Garvan also grew in 2012 in particular through a new partnership with Ridley AgriProducts.

Donations from our direct marketing campaigns increased again, as did donations from people who asked for gifts to be sent to Garvan in lieu of flowers at funerals, or gifts at celebrations.

Donations from bequests also continued and remain a very important source of income. These gifts are used to develop our core research areas and to strengthen our strategic reserves, with a view to establishing a long-term endowment and ensuring that the Institute is better positioned to meet future challenges.

We also enjoyed a significant increase in people assisting Garvan through fundraising at general community events such as the City to Surf in Sydney and the Melbourne Marathon; and special one-off events organised by supportive individuals.

The Young Garvan Committee continued to work tirelessly to raise the profile of the Institute amongst a younger demographic and also to raise funds for Young Garvan Fellowships. Along with three well-attended forums, the Committee also held its successful All Ribbons Ball, attracting 400 guests and contributing to three more Fellowships.

The year also saw an important initiative for the Institute's future - the establishment of a major new fund to focus on the recruitment of further world class researchers. Named the "Breakthrough Fund”, it will have an initial target of raising $50 million, in line with the Institute's 50th anniversary in 2013. The Fund has had an auspicious start, with the Trustees of The Alan Elder Trust contributing $2 million.

12GARVAN RESEARCH FOUNDATION CHAIRMAN’S REPORT The Kinghorn Cancer Centre was a major focus of the Foundation's work during 2012. In close collaboration with our partners at St Vincent's Hospital, the Foundation team co-ordinated a series of events for the Visionary Donors who helped to make the Centre a reality.

The Foundation co-ordinated the official opening of the Centre on 28 August by the Prime Minister The Hon Julia Gillard MP and his Eminence Cardinal George Pell AC. Within the Centre, the team also co-ordinated the opening of the Australian Cancer Research Foundation Molecular Genetics Facility by Her Excellency the Governor of NSW, Professor Marie Bashir AC CVO, and the opening of the Nelune Centre by her Excellency the Governor General of Australia, Ms Quentin Bryce AC.

A highlight of the year was our second Gala Dinner attended by around 300 people, welcoming Professor John Mattick AO FAA as the new Executive Director of Garvan, and raising more than $400,000 for our research.

The success of the dinner owes much to the Master of Ceremonies, journalist and commentator Ms Annabel Crabb; our menu designer Mr Neil Perry, and our incomparable vocalist Ms Greta Bradman.

I would particularly like to thank and praise the staff of the Foundation for their dedication, enthusiasm and unmatched expertise. Our Chief Executive Andrew Giles was supported by a small but professional team of full-time staff: Mara-Jean Tilley, Kylie Ironside, Mimy Long, Leigh Metham, Kylie Sherwood-Kelly, Maria Garcia-Cepillo, and part-time staff: Gabriella Lang, Dimity Raftos, Dianne Lavender, Pip Margan, Janice Lam and Carol O'Carroll.

Finally, I thank my fellow board members for their diligent and engaged contribution throughout the year.

Geoff Dixon Chairman Garvan Research Foundation

GARVAN RESEARCH FOUNDATION CHAIRMAN’S13 REPORT Director’s REPORT TKCC

It is with mixed feelings that I write this report. While sharing in the excitement of the opening and initial functioning of the centre, I am acutely aware that I am writing this in the capacity of Acting Director, as a direct result of the untimely passing of Professor Robert Sutherland, our inaugural Director. Rob and I worked closely to develop and deliver on the vision of The Kinghorn Cancer Centre, and it was pleasing to see him acknowledged by name for his major contribution to cancer research by Prime Minister Julia Gillard at the official opening of the Centre in August 2012.

Tribute was also paid at the opening to our extremely generous and numerous donors, including the Australian Government, the Kinghorn Foundation, the Australian Cancer Research Foundation (ACRF) and the Nelune Foundation. The St Vincent's Trustees were also acknowledged, in view of their very generous provision of the land on which the Centre was built, with due recognition at the opening ceremony of the traditional custodians of the land. The bond with St Vincent's was further demonstrated by the blessing of the Centre by His Eminence Cardinal George Pell AC, Archbishop of Sydney. Subsequent to the opening, Her Excellency Professor Marie Bashir AC CVO, Governor of NSW, opened the ACRF (Australian Cancer Research Foundation) Molecular Genetics Facility. The Centre was also graced by a visit of the Governor General, Ms Quentin Bryce AC CVO, Patron of the Nelune Foundation, late in 2012.

Much has happened since that time. The cancer clinical services moved across from St Vincent's Hospital as planned by the end of February 2013. These entail delivery of chemotherapy on an outpatient basis, a modern suite of consulting and interview rooms, blood collection services linked to the main hospital laboratory by a pneumatic tube, state-of-the-art multidisciplinary meeting rooms, a procedure room for head and neck endoscopy, an education alcove, and spacious accommodation for clinical trial staff. As a change management process, this was no mean feat. Feedback from our patients and staff has been extremely positive. The clinical services continue to function under the mission and values of St Vincent's, as established by the Sisters of Charity, whose influence permeates the building. The Wellness Centre will open as a focal point for integrative medicine approaches to patient care later in 2013.

On the research side, there has been significant change also, with highly achieving members of staff such as Professor Andrew Biankin, Professor Roger Daly and Associate Professor Liz Musgrove all moving on to excellent positions, largely made possible by their achievements obtained while working at Garvan. The Centre is optimising this opportunity to recruit new staff, while at the same time augmenting its bioinformatic analytic capacity and purchasing next generation, state-of-the-art, gene sequencing equipment, so as to be at the forefront of the era of genomic medicine. Moreover, the translational research agenda entails much closer integration between the researchers, clinicians and patients. A focal point for this will be the tumour stream multidisciplinary team meetings, where for the first time there will be formal integration of these parties. Our basic science researchers work in modern facilities, with access to a suite of laboratory facilities and plentiful workstations. Neither clinical or research staff work in isolation from other experts – with strong links to the University of NSW and the University of Sydney – the latter partly by virtue of our membership of Sydney Catalyst. This is one of seven accredited cancer translational research centres. Both clinicians and researchers have significant collaborations in train with leading Australian and overseas institutions.

It is early days – however, the foundations are now in place for the implementation of an advanced, rapid bench-to-bedside and bedside-to-bench model of care. The challenge for the staff within the Centre is “to realise the promise of personalised innovative medicine for people affected with cancer”, as is written in the atrium of our beautiful centre, and present for the world to see at tkcc.org.au.

Allan Spigelman Acting Director The Kinghorn Cancer Centre 14DIRECTOR’S REPORT TKCC

Garvan AT A GL ANCE Garvan Institute of Medical Research Board of Directors

Chairman Mr Bill Ferris AC Garvan Research Foundation Board of Directors

Executive Director Prof John Mattick AO FAA Chairman Mr Geoff Dixon

Development & Support Group Cancer & The Kinghorn Cancer Centre Garvan Research Foundation Chief Operating Officer Mr John Dakin Cancer Chief Exec Officer Andrew Giles Head Prof Rob Sutherland AO FAA (until October) Acting Head Prof Roger Daly (from October) Australian BioResources Board Committees Dr Jenny Kingham Senior Scientists _ Business Development Advisory Prof Andrew Biankin _ Finance & Audit Business Development & Legal Affairs Prof Sue Clark _ Investment Ms Christina Hardy Prof Roger Daly _ Remuneration Corporate Services A/Prof Maija Kohonen-Corish Ms Cate Smith Prof Liz Musgrove Institute Committees A/Prof Chris Ormandy _ Appointments & Promotions Finance and Accounting Dr Alex Swarbrick _ Equipment Ms Cherry Dutton Dr Charlie Watts _ Executive Management Human Resources _ Higher Degrees The Kinghorn Cancer Centre Ms Belinda Christie _ Operations Advisory Director Prof Rob Sutherland AO FAA (until October) _ Postdoc Development Information Technology Acting Director Prof Allan Spigelman _ Scientific Advisory Council Mr Jim McBride (SVH; from October) _ Seminar Program Operations _ WHS Consultation Mr David Keenan Metabolic Diseases Australian BioResources Science Communications Head Prof David James FAA Ms Alison Heather _ Board Senior Scientists _ Advisory Prof Trevor Biden Diabetes Vaccine Development Centre Prof Lesley Campbell AM Diabetes Vaccine Development Centre Prof Don Chisholm AO Chief Exec Officer Ms Rowena Tucker _ Board A/Prof Greg Cooney _ Scientific Advisory A/Prof Antony Cooper Research Facilities A/Prof Jerry Greenfield St Vincent’s Research Precinct (SVRP) Antibody Development Dr Will Hughes Committees Australian BioResources Prof Ted Kraegen _ Animal Ethics Australian Cancer Research Foundation Dr Ross Laybutt _ Human Research Ethics Unit for the Molecular Genetics of Cancer Prof Katherine Samaras _ Institutional Biosafety Biological Testing Facility Dr Carsten Schmitz-Peiffer _ SVRP Management Centre for Clinical Genomics _ SVRP WHS Clinical Research Facility Immunological Diseases MLC Community Foundation Flow Facility Garvan is a partner in the CRCs for Asthma Molecular Imaging Unit Head A/Prof Robert Brink and Biomedical Imaging Development. Garvan is a shareholder in the spin-out Peter Wills Bioinformatics Centre Senior Scientists company G2 Therapies Ltd. Prof Antony Basten AO FAA FTSE Dr Daniel Christ A/Prof Shane Grey A/Prof Jenny Gunton Dr Cecile King Prof Jonathan Sprent FRS FAA A/Prof Stuart Tangye

Neurological Diseases Head Prof Herbert Herzog Senior Scientists Dr Paul Baldock Dr Greg Neely Prof David Ryugo A/Prof Amanda Sainsbury-Salis Prof John Shine AO FAA Dr Bryce Vissel

Osteoporosis & Bone Biology Head Prof Peter Croucher Senior Scientists A/Prof Jackie Centre Prof John Eisman AO Prof Tuan Nguyen GARVAN AT A GLANCE Prof Mike Rogers 17 Patent Portfolio by Category

Portfolio Percentage Number of Patents New targets & treatments 43% 10 Research tools 26% 6 Novel diagnostics 22% 5 Platform technology 9% 2

The Garvan patent portfolio currently comprises 23 patent families covering novel treatments, diagnostics and platform technologies in cancer, diabetes metabolism, neurosciences and immunology.

250

225 Scientific Publications

223 224 200 203 Impact factor of scientific publications 175 185 Each paper published constitutes a new piece of knowledge, and Number of Publications 176 150 scientists aim to publish in the most highly regarded journal in their 153 area of research. Each journal has an “impact factor” which is a 125 common measure of its relative importance within a specific discipline. 100 Research organisations use “average impact factor” measurements to 75 determine the overall significance of their research output. For

50 example, in 2012 Garvan achieved and "average impact factor"

25 greater than 8 for the top 80% of its publications.

2007 2008 2009 2010 2011 2012

12 Philanthropic Support

Income $ Mil Income Total Income* Donations are particularly important in two respects: 8 $ 10,366,000 _ They provide seed funding for $ 5,969,000 novel work, which may not attract 6 other support for several years $ 5,446,000 _ They fund core items of 4 $ 4,064,000 equipment that are typically not covered by research grants 2 $ 6,382,000 * Excluding bequests and contributions to the construction cost of The Kinghorn Cancer Centre. 0 $ 5,370,000

2007 2008 2009 2010 2011 2012

18GARVAN AT A GLANCE 600

575 582 2012 Staff Profile 500

504 505 Number of Staff 488 Staff Breakdown 2011 2012 Demographics 400 433 Researchers 329 338 _ Average age 36 years 6 months _ Researchers from over 300 Students 106 94 63 countries Scientific facility staff 83 87 _ Research staff 46% male, 200 54% female Secretarial & admin 40 44

100 Foundation 14 15 DVDC 3 4 0 Total 575 582 2007 2008 2009 2010 2011 2012

Operating Income

2012 $56 Million* One of the major challenges facing successful research institutes Peer reviewed grants 55% around Australia remains the “gap” Donations 13% between the total costs of doing research and the funding provided NSW Government 11% by competitive research grants. For Industry partners 0.4% every dollar of research funding awarded, another 70 cents is Other income 20.6% required to carry out the research.

* Excludes donations for construction of The Kinghorn Cancer Centre.

35 Peer Reviewed Grant Income

30 $000 $000 Income $000 Income Year NHMRC Other 25 2007 16,682 8,530 20 2008 18,695 9,159 15 2009 19,094 11,061 10 2010 16,637 10,232 5 2011 18,574 10,896 0 2012 20,640 10,213 2007 2008 2009 2010 2011 2012

GARVAN19 AT A GLANCE

Research Collaborations

Opposite: Dr Liz Caldon, breast cancer researcher, who collaborates with colleagues in Scotland and New Zealand. GARVAN21 AT A GLANCE

Research HIGHLIGHTS OF LAST 50 YEARS

Opposite: PhD students 1973 Developed a life-saving insulin infusion 1991 Cloned the neuropeptide Y (NPY) Chris Ormandy and Liz Musgrove with visiting technique to treat ketoacidosis – a receptor, leading to greater scientist Masafumi Koga complication of diabetes understanding of how this potent brain from Osaka University molecule controls important functions Hospital. Circa 1987. 1973 Identified the role of brain serotonin such as the immune system and appetite and melatonin in regulating pituitary hormone secretion 1991 Established the role of retinoic acid in progesterone receptor action in 1975 Developed one of the first experimental breast cancer versions of an “artificial pancreas” 1991-94 Revealed a major benefit of 1976 Recognised for the first time that transdermal versus oral oestrogen - patients with diabetes may be unable reduction of fat accumulation in to produce hormones to prevent low menopausal women blood glucose levels 1992 Demonstrated that the variation in the 1983-87 Discovered that taking fish oil helps to vitamin D receptor gene contributes to combat insulin resistance differences in bone density and susceptibility for osteoporosis 1984 Discovered a connection between brain noradrenalin metabolism (a stress 1992-93 Elucidated the control of the prolactin response) and blood glucose levels receptor in breast cancer

1985 Used novel techniques (clamp + 1993 Reported the first randomised control tracers) to reveal differential effects trial of prevention of corticosteroid- of insulin among its target tissues such use related bone loss as muscle, heart, liver and fat 1993-04 Discovered the role of cell cycle genes 1985-89 Successfully applied artificial (cyclins) in breast cancer intelligence techniques to laboratory- based clinical diagnosis 1995-00 Showed that abdominal fat is genetically influenced, and that it 1986 Produced Australia's first genetically determines the risk of type 2 diabetes engineered human therapeutic growth and influences insulin resistance hormone 1995 Demonstrated the role of the GRB2 1986 Demonstrated the effect of tamoxifen gene in breast cancer on breast cancer growth 1997 Discovered the importance of the 1987 Demonstrated the strong heritability of enzyme Protein Kinase C in the bone density and so osteoporosis risk development of insulin resistance

1987-91 Identified fat accumulation in muscle and 1997-06 Defined many of the physiological liver cells as a major cause of defective roles of the hormone prolactin insulin action, leading to diabetes including its role in mammary development and carcinogenesis. 1989 Established the Dubbo Osteoporosis Epidemiology Study 1998 Identified the chromosomal region responsible for susceptibility to 1989 Identified the gene region that responds bipolar disorder to the active form of vitamin D 1998 Produced the first report describing 1990 Cloned human galanin, a brain HIV lipodystrophy syndrome (with the chemical that regulates appetite, National HIV Centre) anxiety and depression

RESEARCH HIGHLIGHTS23 OF LAST 50 YEARS 1998 Established the role of key oncogene 2005 Identified a pathway that reveals how c-myc in breast cancer a stress hormone in the brain can suppress the immune system 1999 Showed that accumulation of ceramides (fat derived molecules) in muscle cells 2006 Identified novel epigenetic markers for reduces the effectiveness of insulin colorectal cancer detection

1999 Reported the increased risk of 2006-10 Developed and commercialised an premature death after all types of antibody treatment for inflammatory osteoporotic fractures diseases such as rheumatoid arthritis

1999-05 Developed methods of culturing adult 2006-10 Recognised Grb proteins as novel nerve stem cells capable of generating regulators of insulin signalling and new brain cells muscle size

2000 Developed the largest prostate cancer 2006 Discovered that the NPY system links tissue bank in the world (in collaboration the nervous and immune systems, with St Vincent's Hospital) suggesting novel treatments for stress related disorders 2000-02 Showed that the hormone BAFF (B cell activating factor) controls the survival 2007 Collaborated with St Vincent's Hospital of B lymphocytes and can trigger in determining the function of MIC-1, autoimmune disease a molecule responsible for the extreme weight loss common in late stage cancer 2000-06 Made significant advances in identifying the exact role of gene mutations in 2007 Demonstrated that the death of insulin cancers through the use of large human producing cells, which occurs during tissue banks and patient databases type 2 diabetes, is associated with a cellular stress response known as 2001 Identified prognostic markers of endoplasmic reticulum stress prostate cancer progression 2007 Discovered that NPY through its Y2 2002 Discovered that Neuropeptide Y (NPY) receptor controls stress induced obesity regulates bone synthesis 2008 Developed a web-based tool to 2002 Identified the gut hormone PYY as a predict an individual's risk of bone major satiety factor fracture - since widely used by doctors and patients worldwide 2002 Identified prognostic markers of pancreatic cancer progression 2008 Joined the American Association for Cancer Research Human Epigenome 2003 Identified the role of several genes in Taskforce and played a key role in the asthma development using microarray establishment of the International technology Human Epigenome Consortium

2004-12 Collaborated with the Shanghai 2008-12 Showed that transcription factor ELF5 Institute of Materia Medica to identify is a master regulator of mammary and determine mechanisms of action development during pregnancy and of molecules derived from Chinese that levels of ELF 5 determine the traditional medicines, such as molecular subtype of breast cancer berberine and triterpenoids and the sensitivity of a tumour to anti-oestrogen treatment

24RESEARCH HIGHLIGHTS OF LAST 50 YEARS 2008-13 Played a key role in international multi- 2010 Demonstrated a signalling network in centre studies identifying novel genes basal breast cancer cells based on involved in osteoporosis tyrosine phosphorylation

2009 Successfully tested a method, in 2010-11 Discovered the cells that make IL-21 experimental mice, of adjusting the (a key regulatory molecule of the immune system for just long enough immune system) which, if blocked, to receive a tissue transplant and protects transplanted insulin-producing accept it as 'self', without the need for pancreatic cells and reverses type 1 toxic immunosuppressive drugs diabetes in mice

2009 Identified the links between diet, gut 2011 Developed an iron-chelating technique bacteria and the immune system, with the potential to enhance function highlighting the importance of dietary of transplanted insulin-producing cells fibre in keeping many diseases at bay in people with type 1 diabetes

2009 Reported the high frequency of vitamin 2011 Showed why patients with the rare D deficiency in critically ill patients immunodeficiency known as X-linked lymphoproliferative disease (XLP), who 2009 Used phosphoproteomics (large scale lack the SAP gene, become critically ill studies of proteins expressed in cells) when exposed to Epstein Barr virus to map out new actions of insulin and its signalling events 2011 Showed that the main effective treatment for osteoporosis extends 2010 Showed that the gene STAT3 is critically survival by up to five years required for the generation of memory cells in the immune system, explaining 2011 Identified a panel of ovarian epigenetic why patients with mutations are biomarkers for early detection of susceptible to recurrent infection ovarian cancer

2010 Showed for the first time that even 2012 Identified how the production of modest weight loss of 6kgs reverses autoantibodies (antibodies that attack many of the damaging changes often the 'self') is prevented during normal seen in the immune cells of obese people immune responses

2010 Demonstrated that extensive gene 2012 Sequenced the pancreatic cancer silencing is common in cancer, with up genome as part of Australia's to 3% of the genome affected by participation in the International epigenetic remodelling of DNA in Cancer Genome Consortium cancer cells 2013 Discovered how brain NPY controls 2010 Discovered a promising therapeutic temperature regulation in brown fat target for prevention of type 1 and how this affects weight loss in diabetes, a molecule known as BCMA, obese people that effectively subdues the immune cells causing the disease 2013 Discovered that remodelling of the Cancer Epigenome causes large 2010 Demonstrated that insulin resistance regions of the genome to become caused by Hepatitis C is in muscle activated and genetically unstable not liver

RESEARCH HIGHLIGHTS25 OF LAST 50 YEARS DNA sequencing technology has changed dramatically since 2000. You used to have to make large, but incredibly delicate, polyacrylamide gels to run samples on. Running the samples would take several hours, and then you had to transfer the very thin gel onto blotting paper, manually dry it, and then expose it to X-ray film.

When you were transferring the gel onto blotting paper, it often fell to pieces or got tangled up, so your whole day's work could literally fall apart in seconds.

The end product, called an 'autoradiograph', would give you information about a few hundred base pairs of DNA - or letters of the DNA code. You'd manually decode it, going up the film and writing out the sequence - G, AA, TT, CCC, for example.

Today's machines sequence millions of base pairs at a time, so the advancement is awe inspiring. These machines can sequence someone's genome in a week. Eventually they'll be doing genomes in a day.

Professor Roger Daly Cancer

DIVISION HEAD: PROFESSOR ROGER DALY (ACTING FROM OCTOBER 2012) PROFESSOR ROB SUTHERLAND AO FAA (UNTIL OCTOBER 2012)

Overview team, in association with the Australian Pancreatic Cancer cells exhibit certain hallmarks that distinguish Cancer Genome Initiative (APGI), sequenced the them from normal cells, including increased capacity genome of 142 cases of pancreatic cancer. to divide and then spread throughout the body. The overall goal of the Cancer Research Division is to The study identified more than 2000 genes understand the molecular mechanisms that involved in the cancer, adding to a few already underpin cancer development. By identifying these linked to the disease. While four genes were Above: An autoradiograph mechanisms, we help speed the development of mutated in 50 per cent of pancreatic tumours, most made from a polyacrylamide new therapeutic strategies and biomarkers to help mutations were found in less than 2 per cent, and gel. Each “lane', from left no two cancers were the same. It also showed that to right, corresponds to a individual patients. letter of the DNA code: G, several genes involved in a normal developmental A, T, then C. Each cluster The Cancer Division is organised into a series of process known as 'axon guidance' – which of four lanes represents orchestrates neuronal migration and positioning in the sequencing of a independent yet collaborative research groups. These separate sample. span major areas of basic cancer research, including an embryo – are also significant in pancreatic cancer. The important take-home message from Opposite: Professor cancer genomics, epigenetics, cell biology and Roger Daly with one of signalling, and translational cancer research, with this study is that pancreatic cancer is not one two new generation groups focusing on breast, prostate, colorectal, ovarian disease, and each cancer should be treated sequencers at TKCC. and pancreatic cancer, as well as cancer therapeutics. differently, based on its mutational spectrum, with life-saving potential. The recent opening of The Kinghorn Cancer Centre (TKCC), which houses many of the research groups The APGI is now running a clinical trial in which the from this Division, will align research activity with specific treatment for pancreatic cancer patients is best practice cancer services at St Vincent's matched to their genetic profile. Hospital, thereby facilitating rapid research translation to the clinic, the development of Regions activated by epigentics in prostate cancer innovative approaches in personalised medicine, and A second major breakthrough involved 'epigenetic' ultimately improved outcomes for cancer patients. changes that occur in cancer. Epigenetics examines modifications to the DNA and associated proteins Research Highlights that alter gene expression without altering the DNA sequence. Cancer genomics applied to pancreatic cancer Most studies to date have focused on epigenetic There were many notable achievements in the gene-silencing events and so the mechanism Cancer Research Division in 2012, including a major promoting gene-activation in carcinogenesis is still breakthrough in the field of cancer genomics. A poorly appreciated. This year, using new genome- decade after the sequencing of the first human wide sequencing technologies, Professor Susan genome, the development of new DNA sequencing Clark and her team identified a novel mechanism of technologies has provided the capability to gene deregulation in prostate cancer that involves sequence hundreds of cancer genomes, providing activation of multiple adjacent genes in large unprecedented insights into the genetic changes domains across the cancer genome. that underlie cancer development, the degree of variation that exists from patient to patient, and the The activated regions commonly contain key likelihood that a given patient will respond to a oncogenes and other tumour-associated genes, specific therapy. most notably the prostate cancer biomarker gene encoding prostate cancer specific antigen (PSA). This Professor Andrew Biankin and his team in the Cancer study, published in the elite scientific journal Cancer Research Division have been at the forefront of Cell, reveals a new paradigm in epigenetic cancer gene international research in this area, with a landmark deregulation that promotes widespread oncogenic study that was published in the elite scientific journal gene-activation in tumourigenesis; a result that will Nature. As part of the International Cancer Genome have wide ramifications for cancer diagnosis, Consortium (ICGC), which aims to identify the progression and epigenetic-based gene therapies. genetic drivers behind 50 major human cancers, his

27CANCER Molecular changes underpinning breast cancer Group Leaders subtypes Professor Andrew Biankin, During 2012, major progress was also made in our Pancreatic Cancer Research Group understanding of the molecular changes that underpin the different subtypes of breast cancer. It Dr Andrew Burgess, is now well-established that breast cancer is not Mitotic Control Group one disease but instead encompasses several different disease subtypes, each with characteristic Professor Susan Clark, prognoses and responses to specific therapy. Epigenetics Research Group

For example, 'luminal A' breast cancer usually Professor Roger Daly, responds well to therapies, such as tamoxifen, that Signal Transduction Group block oestrogen production or action, while the 'HER2 subgroup' is characterised by sensitivity to A/Professor Maija Kohonen-Corish, trastuzumab. While we can see and understand Colon and Lung Cancer Group these effects, the molecular events that drive the patterns of gene expression within these breast Professor Liz Musgrove, Top: Professor Rob cancer subgroups are poorly understood. Cell Cycle Group Sutherland and Dr Peter Ruenitz (on sabbatical from the University of Importantly, Associate Professor Chris Ormandy's A/Professor Chris Ormandy, Georgia, Athens) group demonstrated that the transcription factor – Mammary Development Group discussing synthetic anti- molecules that switch genes on or off – known as oestrogens circa 1985. 'ELF5', is responsible for much of the patterning of Dr Ilse Rooman, Above: Dr Susan Clark in gene expression that distinguishes the breast cancer 1985, at the time a Pancreatic Carcinogenesis Group Senior Scientist at subtypes. Additionally, their data indicated that Biotechnology Australia, ELF5 may also be involved in the development of Dr Goli Samimi, conducting research resistance to therapies designed to stop oestrogen that led to the first Ovarian Cancer Research Group recombinant vaccine to stimulation of breast cancer. prevent diarrhoea in Dr Darren Saunders, piglets. Professor Clark These findings highlight ELF5 as a potential now heads the Epigenetics Ubiquitin Signalling Group Cancer Research Group predictive marker and therapeutic target for anti- at Garvan. oestrogen resistant disease, recently published in Professor Rob Sutherland AO FAA, PLoS Biology. Opposite: Dr Jim Blackburn Breast Cancer Group from the Genome Prostate Cancer Group Evolution and Informatics This year also saw the sad passing of the Cancer Group assembling a Steroid Hormone Action Group Western blot to analyse Division's founder and long-serving Director, the protein content of a Professor Rob Sutherland. As the Cancer Division Dr Alex Swarbrick, tumour cell line. enters into a new phase of its development in close Tumour Progression Group The group's work is association with TKCC, a major recruitment drive currently focused on the was initiated in 2012 and is continuing in 2013. Dr Charlie Watts, generation of mutation- resistant TP53 (a key Cancer Therapeutics Development Group tumour suppressor gene), which is commonly Dr Jianmin Wu, mutated in human cancer. Cancer Bioinformatics Group

28CANCER

White Water Falls by Richard Long CBE The Kinghorn CANCER CENTRE

The Kinghorn Cancer Centre (TKCC) was officially Nine floors of the 13-floor building are dedicated to opened by Prime Minister, The Hon Julia Gillard MP, research and treatment, while the four basement levels on 28 August 2012. The 15,000 m2 Centre, now provide plenty of parking for patients and visitors. fully operational, is a joint venture between Garvan and St Vincent's Hospital, combining scientific and Teams of researchers and clinicians working in this medical expertise to provide a personalised purpose-built cancer centre will ensure that clinical medicine approach to the treatment and care of challenges drive laboratory research, and that cancer patients. research findings are applied quickly to clinical care. As well as state-of-the-art clinical and consulting The original brief to architects BVN was to create rooms and laboratories, the centre provides Above: Construction of “a non-hospital environment that encourages a workspaces and meeting rooms so that researchers The Kinghorn Cancer sense of hope and wellness”. They fulfilled this brief and clinicians can come together into multidisciplinary Centre 2010. in many ways, one of which was to create a teams to exchange information and ideas about the Opposite: Foyer of The chemotherapy suite that opens on one side onto a diagnosis, treatment and care of cancers. A Kinghorn Cancer Centre. bamboo garden, and on the other to a 'climbing Wellness Centre is also planned for this facility. garden' of bougainvillea. The bougainvillea, trained to grow up a glass partition between the clinic and The nation's first Centre for Clinical Genomics is Victoria Street, will protect patients' privacy from being established in TKCC, allowing us to sequence passers by, and at the same time will filter light, genomes on-site and identify potential targets for casting a blue glow. diagnostic and therapeutic development. Genome sequencing will soon become routine in cancer A towering 8-by-34-metre work by Turner Prize research, and the standard in clinical care. Ultimately, winning English painter Richard Long CBE – using we hope to develop a genetic sequencing service china clay from Geelong applied onto a black that will form the platform for the development of painted background– dominates the spacious genomic medicine over the coming years. pre-cast concrete atrium, creating a soothing and serene environment.

The building is the first in Australia to use 'Aircuity' energy saving air conditioning technology, which allows it to react to the presence or absence of users. The building's energy management system also turns off lights when it stops sensing movement, rather than leaving them on all the time. Other green measures include retention and use of rain water, LED lighting throughout and installation of non-PVC cabling.

THE KINGHORN31 CANCER CENTRE Back in 1969, when Jon Sprent and I were young immunologists at Melbourne's Walter and Eliza Hall Institute, our lab leader and discoverer of the thymus gland, Jacques Miller had only just shown that lymphocytes, a particular type of white blood cell, comprised two broad subsets of cells.

The first were called 'T cells' as they come from the thymus, and the second were called 'B cells' since they are derived from bone marrow.

Studying B and T cells was tricky at first, because we had no way of readily distinguishing between them. Then over time, we were able to identify just a few of the many molecules that each group expressed on the cell surface, allowing us to target them with antibodies.

This involved culturing our cells, along with the relevant antibody made in rabbits, in a 96 well plate - each well containing a different concentration of antibody. To detect binding of the antibody, we added a second protein called 'complement' which enabled the antibody to kill the cells it was bound to. We then counted the dead cells manually, under a microscope. Reasonably accurate, but very time consuming!

These days FACS machines sort and then count subsets of cells at the rate of 10,000 cells a second - using highly specific monoclonal antibodies to identify the cell surface molecules that now distinguish the many subtypes of B and T cells. These machines are so accurate that they can detect cells that are present at frequencies of 0.1% or less.

Emeritus Professor Antony Basten AO FAA FTSE Immunological DISEASES

DIVISION HEAD: ASSOCIATE PROFESSOR ROBERT BRINK

Overview Our researchers showed that these fortunate XLP The goal of the Immunological Diseases Division is patients contained large numbers of T cells (the to determine how the immune system functions to immune cells responsible for killing virally infected protect the body and how this goes wrong when cells) in which the mutation in the SH2D1A gene disease occurs. Our researchers collaborate with had spontaneously reversed. Although the clinicians at various major hospitals to devise emergence of such cells is an extraordinarily rare treatments for immunological diseases. event, strong selective pressure in the face of a Above: A 96 well plate, potentially fatal EBV infection causes the now- used in the past for The latest technologies are used to manipulate and normal T cells to multiply and protect patients from culturing cells and the virus. These findings indicate that gene therapy identifying them with analyse the behaviour of immune cells, both in the relevant antibody. body and in the laboratory. This includes may ultimately provide an effective treatment for sophisticated gene manipulation and analysis patients with XLP. Opposite: Professor Antony Basten AO FAA FTSE techniques, precise and detailed approaches for (left) with Professor analysing the rare cell populations that initiate How infection can trigger autoimmune disease Jonathan Sprent FAA FRS immune responses, and the capability to visualise Another important breakthrough came when using a flow cytometer researchers in Associate Professor Robert Brink's (FACS) to purify and individual cells – through powerful microscopes – analyse different classes as they function within the body. laboratory were able to explain why certain of white blood cells. autoimmune diseases often occur after specific The immune system protects the body from infections. dangerous attacks, whether they come from outside as infections, or inside as cancer. It must While the phenomenon has been well recognised for also differentiate between actual threats to the decades, no one has been able to explain the exact body and the healthy cells and molecules that make mechanism behind it until now. To do that, the up the body itself. When this process of group examined what happens to immune system discrimination fails, it results in autoimmune diseases cells with the ability to make “cross-reactive such as rheumatoid arthritis and type 1 diabetes, autoantibodies” – antibodies that can attack the and the body proceeds to attack its own tissue. Our body itself as well as the invader. Division looks at the wide range of different immune responses that can occur, and the They found that although the immune system processes that underpin them. could often prevent the production of these rogue autoantibodies, it was less able to perform its normal Research Highlights protective role when the autoantibodies targeted a particular organ such as the liver or kidney. Spontaneous reversal of gene mutation in rare This finding, published in the top-ranking journal disease XLP Immunity, explains how “organ-specific” autoimmune Some of our most useful work comes from diseases such as rheumatic fever and Guillame- investigating rare diseases, as they often provide Barré syndrome (where the body makes antibodies insight into the normal functioning of the body. A that attack the heart and peripheral nerves good example this year was research undertaken respectively) can occur following certain infections. by Associate Professor Stuart Tangye's laboratory, which provided a great advance in our The finding also suggests that if you know enough understanding of the inherited immunodeficiency about an infectious trigger and the autoimmune X-linked lymphoproliferative disease (XLP). The disease it can cause, it may be possible in future results were published in the prestigious Journal of to alter the way the body produces antibodies in Experimental Medicine. that instance. XLP patients typically present with severe and often fatal Epstein-Barr virus (EBV) infections due to their inability to combat this virus. Surprisingly, some patients carrying the XLP mutation (in the SH2D1A gene) mount strong immune responses against EBV and remain largely asymptomatic when infected.

IMMUNOLOGICAL33 DISEASES Making biologically active yet stable antibodies Group Leaders Monoclonal antibodies represent almost half of all Dr Marcel Batten, drugs entering clinical studies, with more than $30 Immunobiology of Cytokines Group billion sales worldwide in 2010. Unfortunately, between 30-50% of the antibody-based drugs A/Professor Robert Brink, being developed have to be put on hold because B Cell Biology Group they do not meet quality tests that the companies or regulatory agencies require. Dr Daniel Christ, Antibody Engineering Group As a result, one of the most pressing problems facing the pharmaceutical industry is how to Dr Tatyana Chtanova, create antibodies that are stable enough to meet Immunobiology of Cancer Group stringent requirements necessary for production in large quantities, injection into patients and long- A/Professor Shane Grey, term storage. Gene Therapy and Autoimmunity Group Top: Associate Professors Fabienne Mackay and Members of Garvan's Antibody Engineering A/Professor Jenny Gunton, Herbert Herzog in 2005, Laboratory, led by Dr Daniel Christ, have made a Diabetes and Transcription Factors Group collaborating on a project major contribution towards solving this problem by about stress and the immune system. developing specific mutations that universally Dr Cecile King, increase the stability of antibody molecules. Their Mucosal Autoimmunity Group Above: Rebecca Newton and results were published in the Proceedings of the Tatyana Chtanova in the cell sorting facility, 2004. National Academy of Science of the United States Dr Tri Giang Phan, of America (PNAS). Opposite: Dr Tyani Chan Intravital Microscopy Group from the B Cell Biology Group creating a protein The approach developed by the team involves the Professor Jonathon Sprent FAA FRS, complex (comprising an introduction of specific mutations into antibodies antigen and sheep red blood Cellular Immunity Group cells) capable of inducing that do not change their effectiveness but greatly an immune response. improve their stability. This approach has the A/Professor Stuart Tangye, potential not only to rescue many potentially The lab has pioneered a Immunology and Immunodeficiency Group highly sensitive valuable therapeutic antibodies from being experimental mouse model abandoned, but also to increase production that is capable of studying efficiency and so reduce the cost of therapeutic protective immune responses as well as antibody drug treatments to patients. autoimmune diseases.

The next step for the team will be to work with colleagues in the pharmaceutical industry to improve the stability of antibody therapeutics for the treatment of cancer and inflammatory conditions.

34IMMUNOLOGICAL DISEASES

Ted Kraegen was one of the first people in the world to develop a fully closed loop system to deliver insulin to patients with diabetes. It was an early prototype “artificial pancreas” and used a set of equipment about half the size of a room.

I became involved a little later, when he further developed a device for hospital use, making insulin delivery respond to blood glucose levels measured at short intervals of time.

One of the valuable things we showed in those early days was that although the closed loop system works very well, it doesn't work ideally for a meal. For a meal, you need to give a pre-planned amount of insulin according to the amount of food eaten, not according to what blood sugars do.

The concept has now been translated – with modern miniaturising technology – into small pumps that can be worn by people with diabetes. A subcutaneous sensor device measures blood glucose continuously, and the pump infuses insulin accordingly.

While the latest insulin pumps are very effective, they are not sophisticated enough to deliver the optimal dosage of insulin for a meal without manually programming the amount of food or carbohydrate to be eaten – in fact I doubt they ever will.

Professor Don Chisholm AO Metabolic DISEASES

DIVISION HEAD: PROFESSOR DAVID JAMES FAA

Overview because many of the 89,486 proteins recorded in The most recent figures indicate that obesity costs the International Protein Index are made up of the Australian economy over $58b each year, similar, or the same, peptide fragments. largely because it is a major contributor to most diseases that compromise human health including Bio-informaticians working with Professor David diabetes, cardiovascular disease, cancer, Alzheimer's James developed an algorithm last year that now Above: Professors Ted allows scientists to identify specific proteins. This Kraegen and Don Chisholm Disease and asthma. Our goal is to establish, at a demonstrating a computer biological level, the link between the environment, enables analysis of the vast quantity of data assisted insulin infusion obesity and disease and to identify a clear path for produced by an exquisitely sensitive new generation system for management of of mass spectrometers. The new software even diabetic patients in hospital early diagnosis and prevention. To achieve this we to Mr Barry Jones, study emergent properties of metabolism in cells, allows the re-processing of older data run in the lab, Commonwealth Minister different tissues, mice and humans by collecting identifying at least 25% more proteins than have for Science, circa 1983. large data sets over time. This establishes a more been identified in the past. Opposite: Professor Ted accurate picture to describe the behaviour of the Kraegen (left) and system during the development of disease. By Details of the software were published in the Professor Don Chisholm AO Journal of Proteome Research. Through its (who have shared a 45 constructing metabolic network maps we hope to year collaboration in devise better treatments and early diagnostic enhancement of protein identification, the new diabetes research) software improves the ability of scientists to comparing the new insulin markers that can be taken into the clinic. pump with the old. investigate complex diseases such as type 2 Research Highlights diabetes as they operate through time. During 2012, researchers in the Metabolic Diseases Taking a muscular approach towards diabetes Division made significant progress in many areas In other important work from the Metabolic including the understanding of pancreatic beta cell Diseases Division, members of Associate Professor function and survival, how insulin resistance Greg Cooney's lab, in collaboration with the Cancer develops in liver and muscle, and fat cell metabolism Division's Professor Roger Daly, observed that a in people and model systems of obesity. particular strain of genetically modified mice, lacking the gene Grb10, had larger muscles throughout life. Using the latest technologies to study whole body processes The results were published in The Federation of We made excellent progress by combining American Societies for Experimental Biology mathematics, computer science and biology to (FASEB) Journal, and indicate that Grb10 plays a study whole body processes, or 'systems biology'. role in regulating the size of muscles during Introduction of new technology and analysis tools embryonic development, mainly by controlling the allowed us to improve our measurement and number of muscle fibres in a muscle. interpretation of the multitude of changes that take place, moment by moment, in cells and tissues Apart from the implications for muscle regeneration when they are exposed to a stimulus – such as the during healing, the findings are important for hormone insulin. diabetes research because muscles are the biggest users of glucose in the body. A drug able to reduce The establishment of a Mass Spectrometry facility levels of the Grb10 protein may have the potential at Garvan enables the identification of the hundreds to increase muscle mass, and so increase the of thousands of protein fragments produced when capacity to transport glucose from the blood stream cells or tissues are 'digested' into a kind of peptide into cells, a major goal for any diabetes therapy. soup before analysis. Until recently, reassembling these fragments (in a virtual sense) to identify changes in specific proteins has been limited

37METABOLIC DISEASES Showing that weight loss reduces artery stiffness Group Leaders Research relevant to human disease is a key factor Professor Trevor Biden, in all studies carried out in the Division, and in 2012 Beta Cell Signalling Group members of the clinical research program made significant observations about the way obesity Professor Lesley Campbell AM, relates to diabetes and other manifestations of Appetite and Adiposity in Type 2 Diabetes and metabolic disease. Prader Willi Syndrome Group

Notably, Associate Professor Katharine Samaras Professor Don Chisholm AO, collaborated with Associate Professor Christopher Fat, infection and Insulin Resistance Group Hayward from St Vincent's Hospital to show that losing 6 kg reduces artery stiffness by 20% in A/Professor Greg Cooney, Top: Dr Lesley Campbell AM, obese people with type 2 diabetes. Molecular Metabolism Group Director of the St Vincent’s Diabetes Centre, and Dr Diabetes carries a six-fold greater risk of heart Arthur Jenkins, Deputy A/Professor Antony Cooper, Head of the Diabetes disease due to atherosclerosis, or hardening of the Stress and Protein Misfolding Group Research Group, examining arteries, with cardiovascular disease being the the data from studies of commonest cause of death in people with diabetes dietary manipulation in A/Professor Jerry Greenfield, people with type 2 – accounting for 68% of all deaths. Clinical Diabetes and Metabolism Group diabetes in 1992.

The new research demonstrated that arterial Below: Dr Trevor Biden, Dr Daniel Hesselson, Head of the Cell Signalling stiffness is directly associated with inflammation – Beta cell regeneration Group Group, adjusting that is, activation of white blood cells and genes chromatographic equipment that regulate inflammation. Weight loss reduces used in his studies of insulin Dr Will Hughes, producing cells in 1992. immune cell activation and inflammation in fat Phospholipid and Cell Biology Group tissue, which in turn allows the arteries to relax. Opposite: Dr Carsten Schmitz-Peiffer purifying Professor David James FAA, Protein Kinase C – an enzyme This study, published in Diabetes and Vascular Cellular Systems Biology Group he has shown to cause Disease Research, was the first study to link weight defects in insulin action.

loss with fat tissue inflammation and arterial stiffness. Professor Ted Kraegen, Insect cells are harnessed Diabetes and Metabolism Group to make large amounts of the enzyme, but these cells contain many other Dr Ross Laybutt, proteins. The enzyme Islet Biology Group protein is 'tagged' to make it stick to the pink affinity resin, while all the others Professor Katherine Samaras, flow through. Adipose Tissue Biology in Diabetes Group Once large quantities of the enzyme are purified, Dr Carsten Schmitz-Peiffer, the Garvan team and their collaborators plan to Insulin Signalling Group test various compounds against it, looking for a specific inhibitor.

38METABOLIC DISEASES

Diabetes VACCINE DEVELOPMENT CENTRE

Overview The Diabetes Vaccine Development Centre (DVDC) was established in 2003 through a major joint initiative of the National Health and Medical Research Council (NHMRC) and Juvenile Diabetes Research Foundation (JDRF).

With the assistance of a grant from the NSW Government, DVDC relocated from Melbourne to Garvan in 2007. It became a company limited by guarantee with Garvan as the sole member in 2008.

DVDC is governed by a board representing its major stakeholders (Garvan, JDRF and NHMRC), as well as internationally recognised scientists and biotechnology executives with expertise in the fields of diabetes and vaccine development.

The Centre's mission is to provide a platform to translate Type 1 diabetes research into improved clinical outcomes – prevention and therapy.

With in-house expertise for the conduct of clinical trials, DVDC currently manages clinical research projects (see below) and coordinates a network of ten trial sites across Australia and New Zealand. The network has focused on children and young adults, and is now expanding to include more of the adult Type 1 diabetic population. Scientific Program

Type 1 Diabetes Prevention Study, INIT II This is a Phase 2, multi-centre, randomised, double blind, placebo-controlled trial of intranasal insulin (440IU) in children and young adults at risk of Type 1 diabetes. The aim of this project is to determine whether the administration of insulin via an intranasal route will result in a protective immune response.

Study of Proinsulin Peptide Immunotherapy in New- onset Type 1 Diabetes (MonoPepT1De Study) Peptide immunotherapy represents a novel approach to preventing loss of insulin production from the pancreas in Type 1 diabetes. The MonoPepT1De Study, which is being conducted in the UK, aims to address the safety of P1 peptide administration in newly-diagnosed T1D preparatory to a larger study to determine whether this intervention promotes the survival of residual insulin-producing beta cells.

Rowena Tucker CEO, DVDC Limited

40DIABETES VACCINE DEVELOPMENT CENTRE Membership of the DVDC Board Professor Chris Goodnow FAA FRS Professor Don Chisholm AO FRACP (Chair) Director Immunogenomics Laboratory & Senior Principal Research Fellow Director Australian Phenomics Facility Metabolic Diseases Division John Curtin School of Medical Research & Garvan The Australian National University

Emeritus Professor Antony Basten AO FAA FTSE Professor Leonard C Harrison (from 21 August 2012) Head Diabetes Laboratory Senior Principal Research Fellow Walter and Eliza Hall Institute of Medical Research B Cell Biology, Immunological Diseases Division Garvan Mr Stephen Higgs Chair of the Board of Directors Mr John Dakin JDRF Australia Chief Operating Officer Garvan A/Professor Paul Hofman Liggins Institute Mr Paul Eisen New Zealand Director APAC Medical Device Consultants Dr Dorota Pawlak Head of Research & Development Dr Carla Greenbaum JDRF Australia (from 22 February 2012) Director Diabetes Clinical Research Dr Teo Staeva Benaroya Research Institute Director Immune Therapies Virginia Mason, Seattle, USA JDRFi, New York, USA

Ms Christina Hardy Dr Roland Tisch Director Business Development & Legal Affairs Department of Microbiology & Immunology Garvan University of North Carolina at Chapel Hill USA

Mr Stephen Higgs Membership of the DVDC Finance Chair of the Board of Directors Committee JDRF Australia Mr John Dakin (Chair) Chief Operating Officer Professor John Mattick AO FAA FRCPA Garvan (22 February - 21 August 2012) Executive Director Professor Don Chisholm AO FRACP Garvan Chair DVDC Board

Membership of the DVDC Scientific Mr Stephen Higgs Advisory Committee Chair JDRF Australia Dr Carla Greenbaum (Chair) Director Diabetes Clinical Research Mr Ron McNeilly Benaroya Research Institute A/g Director Research Administration Virginia Mason, Seattle, USA National Health and Medical Research Council

Professor Peter Colman Ms Rowena Tucker (alternate to Professor Harrison) CEO DVDC Department of Diabetes and Endocrinology, Royal Melbourne Hospital Mr Mike Wilson CEO JDRF Australia

DIABETES VACCINE DEVELOPMENT41 CENTRE Two-photon microscopes are allowing I am a mathematician by training, and us to understand the connectivity of for the last twenty years I have been neural networks with a precision that using electrophysiology and calcium has been impossible until now - letting image readouts to calculate the us visualise the activity, structure and activity of the nervous system. 3D placement of neurons well below the surface of a living mouse brain in Calcium ions trigger the release of a non-invasive way. neurotransmitters from nerve endings, allowing a chemical signal to In combination with older pass between one neuron and the technologies, such as confocal next. We couldn't witness this process microscopes and electrophysiology in the past, but the two-photon equipment, the two-photon microscope now shows us it in detail. microscope allows us to decode exactly what is happening at nerve My colleague Shu Lin has been using endings, where nerve other technologies to study appetite communications occur. and energy balance in mice. This new technology will allow him to refine We can activate a specific neuron, conclusions he has already drawn, as track its activity within a neuronal well as test new hypotheses. network, and measure its impact upon an animal's body or behaviour. Dr Willie Lin

If you activate a network that controls appetite, for example, and the mouse is sleeping when you activate it, the mouse will get hungry, wake up and go and feed. Neurological DISEASES

DIVISION HEAD: PROFESSOR HERBERT HERZOG

Overview they identified, and then validated this pathway The Neurological Diseases Division addresses using genetically modified mice. They published perhaps the most challenging of all human traits, their groundbreaking study in the international the complex nature and function of the brain and journal PLOS Genetics. nervous system. Fly data were also used to identify candidate genes We aim to increase the understanding of the in other aspects of the Division's research, including Above: Electrophysiology molecular mechanisms that underpin the capacity appetite, obesity, motor neuron disease, output showing two of the human brain to learn and to think, and the neurodegeneration and neural death. nerve pulses. A reading can contain many neuronal systems involved in disorders such as thousands of pulses at Parkinson's disease, Alzheimer's disease, Impact of brain signals on energy balance and different frequencies. schizophrenia, eating disorders, hearing loss and bone formation There is an intricate and delicate interplay of neural Opposite: Dr Shu Lin pain, as well as the general understanding of brain- (left) and Dr Willie Lin to-organ interactions including the control of signalling between the brain and the body, affected with a state-of-the-art metabolism and bone development. by various hormones including the fat-derived two-photon microscope. hormones leptin and adiponectin, gut-derived We use this understanding to identify potential new hormones such as peptide YY (PYY), and the therapeutic approaches in these areas, with a particular hypothalamic regulator of energy balance, interest in finding ways of regenerating the nervous neuropeptide Y (NPY). During the course of the system and to improve the regulation of energy year, we advanced our understanding about specific balance (intake and expenditure), which affects pathways that affect the body's overall energy fertility, mood, weight gain and physical fitness. balance, as well as the influence of brain signals on bone formation and strength. Research Highlights Of particular significance was a seminal study by Dr Paul Baldock that elucidated the mechanism Valuable tool for predicting pain genes in people involved in the bone loss associated with starvation, Of the many advances made within the Division and in particular, the respective roles of NPY and during 2012, one of the most critical was the leptin. Specifically, he showed that when leptin identification of a “network map” of genes involved signals to the brain indicate that there are in pain perception, showing remarkable similarity insufficient fat reserves, the body inhibits the from fruitflies to people. This map is now allowing production of bone, and that NPY is solely prediction and testing of new analgesic drugs. responsible for the loss of bone.

Fifty percent of our population will experience some The findings revealed the critical nature of NPY form of chronic pain within their life, especially signalling to bone strength. When mice were those who suffer from arthritis, cancer, diabetes, genetically engineered to lack the leptin signal to migraine, or nerve injuries. Despite the astonishing the brain, and therefore have constant activation of prevalence, there are few effective therapeutic the starvation signal, they had tiny bones. The brains options for these people. of these mice perceived that they were skinny and starving, so did not make bone. In a second model, The new study was carried out by Dr Greg Neely in where NPY was also removed from the “starving” collaboration with colleagues from Austria. The mice, the bone defect was completely corrected. group had previously screened the 14,000 genes in the fruitfly genome and identified 580 genes While NPY plays a powerful role in controlling involved in perception of heat pain. In last year's weight, many other factors can also contribute or study, using a database from the US National Centre compensate. The recent findings demonstrate that for Biotechnology Information, they noted that this is not the case in bone formation, where NPY is there are roughly 400 equivalent genes in people, the key link between energy balance and bone many of which were independently linked to pain. formation and strength. These breakthrough findings were published in the prestigious Journal of Comparing fly with human data, Neely and Bone and Mineral Research. colleagues could also see that a particular kind of molecular signalling appeared in the pain network NEUROLOGICAL43 DISEASES Dr Baldock also contributed to a review of literature Advances in our understanding of human investigating the association between bariatric gene expression (weight loss) surgery and bone mass, carried out by The human genome produces an extraordinary Garvan's Osteoporosis & Bone Biology Division and range of both protein-coding and regulatory RNAs published in the journal Obesity Reviews. In in different cells at different stages of development, particular, the review noted that the more radical especially in the brain, most of which have not yet the surgery, the greater the likelihood of bone loss, been characterised. Last year, Professor Mattick's

and urged increased awareness of surgery-induced group integrated large-scale protein and RNA Above: Dr Herbert Herzog changes in hormones that can affect the central sequencing data to identify hundreds of new and Dr Tiina Iismaa regulation of appetite and bone strength protein-coding genes, many of which appear to examining gels in 2000. produce previously unknown hormones. His group Opposite: Hovik Farghaian In addition, the initial analysis of a clinical study also developed a new method detecting changes in from the Neurosignalling investigating the effects of bariatric surgery on RNA sequence by RNA editing, which is particularly Group purifying antibodies. The group generates its bone mass identified that some forms of surgery active in the brain, and a new method for targeted own antibodies, which are produce 6 times the bone loss of others per high resolution gene expression analysis, called RNA potential predictors of kilogram of weight lost, a critical issue to be CaptureSeq, in conjunction with Dr Marcel Dinger at neurological disorders, as well as powerful research considered prior to these surgical procedures. the University of Queensland and Dr John Rinn at tools for various Advances in our understanding of neurosignalling Harvard University, which was published in the biochemical experiments and neuroplasticity prestigious journal Nature Biotechnology. and microscopy.

Neuroplasticity is the ability of the brain to change Group Leaders and refine itself in response to different experiences Dr Paul Baldock, and circumstances. This is especially important for Skeletal Neurobiology Research Group higher order functions, such as learning and memory. Dr Adam Cole, Defects in function of certain enzymes (such as Neurosignalling Research Group GSK3 and Cdk5) are implicated in the development of several neurological disorders, including Professor Herbert Herzog, Alzheimer's disease, Bipolar disorder and Eating Disorders Research Group schizophrenia. In order to understand how GSK3 and Cdk5 regulate neuroplasticity in healthy and Professor John Mattick AO FAA, diseased brains, Dr Adam Cole's lab focuses on RNA Biology & Plasticity Research Group discovering novel targets of these enzymes. Last year, Dr Cole discovered of a cluster of GSK3 Dr Greg Neely, targets in the brain that are important for trafficking The Functional Genomics Research Group proteins to synapses. His challenge will now be to define the individual roles of these molecules in Professor David Ryugo, Bipolar disorder and schizophrenia, with a goal to Hearing Research Group define new therapeutics for treatment of these serious diseases. Professor John Shine AO FAA, Adult Stem Cell Research Group Dr Cole recently established important collaborations with world leading neuroscientists to investigate the Dr Bryce Vissel, functions of these GSK3 targets in regulating Neurodegenerative Disorders - Repair and neuroplasticity, namely Professor Graham Collingridge, Regeneration Research Group University of Bristol, England and Professor Mike Cousin, University of Edinburgh, Scotland.

44NEUROLOGICAL DISEASES

Bisphosphonates are now the blockbuster drugs for treating various bone diseases, including osteoporosis, and although they were first used 40 years ago, it took us over 30 years to understand how they actually work.

Until recently, the only way we could detect the action of these drugs was to label them with a radioactive isotope, and track where they went in a mouse. This process was very slow because we used tritium – a very weak isotope that produces a very clear signal. Unfortunately, this meant we had to expose tissue samples to x- ray film for several months before we could see the result.

These days we label the drugs with fluorescent tags and use the very latest technologies – sophisticated CT scanners, microscopes and 3D fluorescence imagers – to watch the process unfold in real time, literally like watching a movie.

Not only do we see the bisphosphonate drugs adhere to the bone surface – which is where they are known to act on bone cells – we can see where they go and what they do in other parts of the body.

The reason we're so interested in finding out which cells can take up bisphosphonates in tissues outside the skeleton is because these drugs have recently been shown to prolong the survival of cancer patients, and we would like to understand how drugs that target the skeleton also appear to have anti-tumour activity in other tissues.

Professor Mike Rogers Osteoporosis AND BONE BIOLOGY

DIVISION HEAD: PROFESSOR PETER CROUCHER

Overview The group used this new technique to screen the The Osteoporosis and Bone Biology Division is first 100 'knockout mice' from the Sanger Institute's dedicated to achieving major improvements in pipeline, which is part of a global effort to examine diagnosis, treatment and quality of life for people the function of every gene in the genome one by affected by skeletal disorders through fundamental one. They found that 10 of these genes either discoveries and innovative applications in laboratory weaken or strengthen bone, 9 of which had not and clinical research. There is a particular emphasis been discovered before. Above: Autoradiograph on osteoporosis and cancers that grow in bone, images of a rat taken 1 including multiple myeloma, and breast and prostate This suggests that a large percentage of our genes, hour and 1 year after perhaps 8-10% of all our genes, affect bone strength treatment with a cancer bone metastasis. bisphosphonate tagged and may explain why we have such a limited with a radioactive isotope. Our researchers use the latest technologies to understanding of the genes that control our skeleton. Image courtesy of Jonathan Green (2002), understand the basis for common skeletal disorders. Novartis Pharmaceuticals This includes new screening techniques, advanced The systematic screening of knockout mice in this Corporation. genetic approaches, the latest methods for working way also produced the scale of data that allowed the group to describe, for the first time, four functional Opposite: Professor Mike with the critical cells that maintain our skeletons, Rogers with a new state- novel high-resolution microscopy techniques to classifications of bone. Normal bone is strong and of-the-art microCT flexible, whereas abnormal bone can be strong but scanner, the first of its study individual bone cells in living tissues and kind in Australia. sophisticated animal models of disease. This brittle, or weak and brittle, or weak but flexible. understanding is being used to develop new approaches to treatment in our model systems, This new understanding not only points to the before translating this into studies in the clinic. importance of individual genes, but also now allows There is an emphasis on utilising our large clinical us to focus on the critical molecular pathways that cohorts, established over many decades, to develop control our skeleton. This will be a critical step in new approaches to predicting those who will suffer developing new treatments for bone diseases such from fragility fractures in the future, understanding as osteoporosis. why this causes premature death and seeking to identify who will most benefit from treatment. Developing an international consensus on Importantly, we are focused on seeing our new 'secondary fracture prevention' understanding result in changes in policy and A major advance in 2012 was the development practice in order to benefit the maximum number of of an international concensus for managing individuals with these disorders. secondary bone fractures, an initiative led by Professor John Eisman AO. Research Highlights Fragility fractures caused by osteoporosis are common, affecting almost one in two older women New screening methods discovered nine new and one in three older men. Every fracture signals genes that determine bone strength increased risk of future fractures, as well as risk of An important breakthrough came this year through premature death. However, 80% of women and collaboration between Professor Peter Croucher's 90% of men who sustain a fracture do not receive laboratory, Professor Graham Williams and Dr treatment to reduce their risk of having a further Duncan Bassett from Imperial College, London and fracture. Preventing these 'secondary fractures' colleagues at the Wellcome Trust Sanger Institute, in requires capturing the people who suffer from a Cambridge. They used micro-CT and digital x-ray fragility fracture and implementing a preventative microradiography and load bearing experiments to treatment plan. develop a new screening method to identify the genes that lead to osteoporosis. Their results were published in PLoS Genetics.

OSTEOPOROSIS47 AND BONE BIOLOGY Professor Eisman led an international Task Force The fracture risk calculator is the world's first examining 'Secondary Fracture Prevention' personalised predictive model of fracture. By supported by the American Society for Bone and incorporating genetic information into its underlying Mineral Research. The report was published in the algorithm, the Garvan group is pioneering the prestigious Journal of Bone and Mineral Research. translation of genetic findings into clinical application for assessment of osteoporosis. The Task Force included 63 clinical care opinion leaders Above: Dr John Eisman from 36 countries across the world and developed (right), leader of the Group Leaders newly established Bone a toolkit for reducing secondary fracture. This makes Dr Paul Baldock, and Calcium Research it a requirement to have in place a systematic Bone Metabolism Group Program, in 1984. approach to identifying people who have had fragility Pictured with Mr Gilles de Weck of Sandoz Australia. fractures and to introduce approaches to preventative A/Professor Jackie Center, treatments to prevent further fractures. Clinical Epidemiology Group Opposite: A member of the Bone Biology group, Jenny Down uses a This consensus report will have major implications Professor Peter Croucher, microCT scanner to take for individuals that suffer fragility fractures by Bone Biology Group high-resolution X-ray ensuring they are seen while still in hospital, or at images of a mouse tibia as it is rotated through the clinic, and preventative treatment measures put Professor John Eisman AO, 360 degrees, allowing her in place. This change in policy will bring direct benefit Clinical Translation & Advanced Education to construct a 3D model to individual patients by reducing the numbers of of the bone. individuals that suffer secondary fractures and also Professor Tuan Nguyen, The lab looks at the impacting on the healthcare budget by reducing the destruction of bone Genetics & Epidemiology Group caused by various need to treat secondary fractures. diseases, including Professor Mike Rogers, osteoporosis and cancer, International consortium expands genetic and investigates ways of Bone Therapeutics Group stopping or preventing knowledge about osteoporosis that destruction. Professors John Eisman and Tuan Nguyen have been working as part of an international consortium collaborating with Icelandic genetics company, deCode, in an effort to find the genes linked to osteoporosis and fracture. Using the latest gene sequencing technologies, deCode has examined the genes of 1500 women from Garvan's Dubbo Osteoporosis Epidemiology Study as well as more than 12,000 women from Iceland and Denmark.

In 2012, the consortium made a significant breakthrough by identifying 56 genes associated with bone density and/or fracture risk. The Garvan team plans to incorporate this finding into its predictive model – accessible on the web at www.fractureriskcalculator.com – a tool that helps assess the risk of fracture for each individual.

48OSTEOPOROSIS AND BONE BIOLOGY

People HIGHLIGHTS

Cancer _ Dr Darren Saunders: Australian _ Dr Paul Timpson: Future Fellowship from Leadership Award from ADC Future the Australian Research Council. Awards and Prizes Forum 2012; Supervisor Award from _ Dr David Chang and the Pancreatic UNSW Postgraduate Council. _ Dr Fatima Valdes-Mora: National Breast Cancer Research Group: Cancer Institute Cancer Foundation / Cure Cancer NSW Wildfire Award, which recognises a _ Dr Alex Swarbrick: Novartis Australia Foundation Postdoctoral highly-cited publication where the Pharmaceuticals Award for 'Preclinical Training Fellowship. research results have significantly evaluation of smoothened inhibitors influenced how cancer is treated. for the treatment of triple-negative National and International Meetings breast cancer'. _ Professor Andrew Biankin: Invited _ Professor Susan Clark: Rotary Award for Speaker Lorne Cancer Conference, Vocational Excellence, 2012. _ Wee Siang Teo: European Association for Victoria; American Association for Cancer Research Travel Scholarship to Cancer Research (AACR) Pancreatic _ Dr David Gallego-Ortega: Post-Doctoral attend the 22nd Biennial Congress of Cancer Meeting, Tahoe Nevada, USA; Award for Excellence in Medical EACR in Barcelona, Spain; European Human Genome Meeting (HuGO), Research at the ASMR NSW Scientific Molecular Biology Laboratory travel Sydney; International Symposium on Meeting 2012. grant to attend the 14th EMBL PhD Pancreatic Cancer, Kyoto Meeting, Symposium Conference in Heidelberg, Japan; Novel Tools for the Early Detection _ Dr Brian Gloss: Best Student Poster prize Germany. of Pancreatic Cancer, Bonn, Germany; at the Lorne Cancer Conference 2012. and the TRX Translational Cancer _ Dr Fatima Valdes-Mora: 2012 Fresh Research Symposium, Brisbane. Invited _ Rae-Anne Hardie: 2012 Beth Yarrow Science State Finalist & European Speaker Opening Session Australian Memorial Scholarship from UNSW & Molecular Biology Laboratory (EMBL) Health and Medical Research Council, Seahorse Bioscience Travel Award. Travel Fellowship to attend the 10th Adelaide; Appointed to the NHMRC EMBL Conference 'Transcription and Human Genome Advisory Committee. _ Simon Junankar: Poster Prize at the Chromatin' in Heidelberg, Germany. Lorne Cancer Conference 2012. _ Professor Susan Clark: Invited Keynote _ Luxi Zhang: Castle Harlan award for Speaker at The 3rd Shanghai _ Dr Samantha Oakes: University of most outstanding early career PhD International Conference of Epigenetics Sydney Medal for Excellence in Medical student at the Garvan Institute in 2012. in Development and Diseases, Shanghai, Research for the Best Overall China; Second IMPPC Annual Conference, Presentation at the ASMR NSW Major Fellowships and Funding Barcelona, Spain; Epigenomics in the Scientific Meeting 2012; The National _ Dr Ling Liu: Australia-Chinese Exchange Capital, Canberra; Cancer Epigenetics, Breast Cancer Foundation Patrons' Early Career Development Fellowship Australian Epigenetic Alliance Annual Award for 'Excellence in Science and from the National Health and Medical Victorian Meeting, Murdoch Institute, Science Communication Award'. Research Council. Nov, 2012, Melbourne; and the Gene Expression and Regulation session, _ Mary Iconomou: Best Student Poster at _ Dr Sam Oakes: National Breast Cancer Illumina Scientific Summit, Gold Coast. the ASMR NSW Scientific Meeting, 2012. Foundation 2013 Early Career Fellowship. Invited Speaker at the First BLUEPRINT- European Union IHEC (International _ Yu Wei Phua: Best Student Oral Prize at _ A/Professor Chris Ormandy: Research Human Epigenome consortium) meeting, ComBio 2012. Fellowship from the National Health and Barcelona, Spain; and the Australia and Medical Research Council. New Zealand Breast Cancer Trials Group _ Dr Catherine Piggin: Harvey Carey (ANZBCTG) Annual General meeting, Memorial Scholarship from UNSW. _ Dr Alex Swarbrick: RD Wright Biomedical Hobart; and Human Genome Meeting Career Development Fellowship from (HUGO), Sydney. Conference Organiser _ Dr Andreia V. Pinho: Young Garvan the National Health and Medical and Invited Speaker, Wellcome Trust Award and the Australasian Pancreatic Research Council. Conference on Epigenomics of Common Club/Abbott Travel Award. Disease, Balitmore, USA. _ Dr Phillippa Tablerlay: Cancer Institute _ Dr Dessislava Mladenova: Best Early NSW Career Development and Research _ Prof Roger Daly: Invited Speaker, EMBO Career Oral Presentation at the Sydney Fellowship. Conference "Cellular Signalling and Cancer Conference 2012. Molecular Medicine", Croatia, May 2012.

PEOPLE51 HIGHLIGHTS _ A/Professor Chris Ormandy: Invited Major Fellowships and Funding _ A/Professor Stuart Tangye: Invited Speaker at the FASEB Summer Research _ Dr Tyani Chan: National Health and Speaker at the European Society of Conference, Colorado, USA; and the Medical Research Council Early Career Immunodeficiency Meeting in Florence, IABCR/Breakthrough Breast Cancer Fellowship. Italy; The X-linked Proliferative Disease Conference, Manchester, UK. (XLP) Symposium in London, England; _ Dr Daniel Christ: National Health and and the Gordon Research Conference on _ Dr Clare Stirzaker: Invited Keynote Medical Research Council Career Antibody Biology and Engineering in Speaker at the Gene Expression and Development Fellowship, Level 2. Galveston, Texas, USA. Regulation session, Illumina SE Asia Scientific Summit, Gold Coast. _ Dr Nike Krautler: Advanced Researcher Metabolic Diseases Fellowship from the Swiss National _ Dr Alex Swarbrick: Invited Speaker at Science Foundation. Awards and Prizes Combio 2012, Adelaide; Endocrine _ Dr Daniel Fazakerley: Young Garvan Award. Society of Australia Annual conference, _ Dr Sue Liu: Postdoctoral Fellowship from Gold Coast; Novartis Oncology Forum, Multiple Sclerosis Research Australia. _ Professor Katherine Samaras: Australian Melbourne; and the Hunter Cellular Diabetes Society / National Diabetes Biology meeting, Pokolbin, NSW. _ Dr Helen McGuire: National Health and Serves Scheme Award (Federal Conference committee and Invited Medical Research Council Early Career Department of Health). Speaker The Lorne Cancer Conference, Fellowship. Lorne Victoria. Major Fellowships and Funding _ Dr Mainthan Palendira: Career _ Mohammed Bensellam: European Immunological Diseases Development Fellowship by Cancer Fellowship from Alfediam (French Institute NSW. Language Association for the Study of Awards and Prizes Diabetes and Metabolic Diseases). _ Dr Marcel Batten: Young Garvan Award. _ A/Professor Stuart Tangye: National Health and Medical Research Council _ A/Professor Antony Cooper: Michael J _ A/Professor Shane Grey: The “Ian Principal Research Fellowship. Fox Foundation 'Target Validation McKenzie Prize for outstanding Program' funding. contributions in Transplantation” by the National and International Meetings Transplantation Society of Australia and _ Drs Tatyana Chtanova, Nike Krautler and _ Professor David James, Dr Daniel New Zealand. Mainthan Palendira: Invited Speakers at Hesselson and Dr Dorit Samocha-Bonet: the Gordon Research Conference on Diabetes Australia (DART) general grants. _ A/Professor Shane Grey, Ms Jeanette Immunochemistry and Immunobiology Villanueva and Mr Nathan Zammit: in Les Diablerets, Switzerland. Mentor/Mentee Awards from the _ Dr Daniel Hesselson: Packer Family International Transplantation Society. Fellowship; and a JDRF Transitional _ Dr Elissa Deenick: Invited Speaker at Fellowship. the Annual Meeting of the Federation of _ Dr Cecile King: Diabetes Australia Type- Clinical Immunology Societies (FOCIS) in _ Dr Will Hughes: UNSW MRE II Grant 1 Diabetes Millennium Award; 2012 Vancouver, Canada. Juvenile Diabetes Research Foundation with VCCRI. (JDRF) / Macquarie Group Foundation _ A/Professor Jenny Gunton: Plenary Diabetes Research Innovation Award. _ Dr Ross Laybutt: Australian Research Speaker at the Keystone Symposium, Council Future Fellowship. Advances in Hypoxic Signaling in Banff, _ Dr Daniel Suan: National Health and Canada. Medical Research Council Postgraduate _ Dr Anne McCormack and Associate Scholarship. Professor Jerry Greenfield: St. Vincent's _ Dr Cecile King: Plenary Speaker at the Clinic Foundation Tancred Research Grant. _ Ms Jeanette Villanueva and Mr Nathan Keystone Symposium, The Biology of Zammit: New Investigator Awards at the Cytokines in Keystone Colorado, USA. _ Nigel Turner: Australian Research Council Annual Meeting of the Transplantation Future Fellowship. Society of Australia and New Zealand. _ Dr Cindy Ma and Prof Jonathan Sprent: Invited Lecturers at the Congress of the _ Dr Alexander Viardot: John Shine Federation of Immunological Societies of Translational Research Fellowship. Asia-Oceania (FIMSA) in New Delhi, India.

52PEOPLE HIGHLIGHTS National and International Meetings Zealand; and the 15th Congress of the Osteoporosis and Bone Biology _ A/Professor Greg Cooney and Dr Jerry European NeuroEndocrine Association, Greenfield: Invited Speakers at ANZOS, Vienna, Austria. Conference and Major Fellowships and Funding Auckland. Symposium Organiser as well as Invited _ A/Professor Jackie Center: Shine Speaker at the 10th International NPY Translational Research Fellowship 2013. _ Professor David James: Invited Speaker PYY PP meeting, Montreal, Canada; and or chair: Novo Nordisk Prize Invited Speaker at the 2nd Asia Pacific _ Dr Michelle McDonald: IBMS Greg Symposium, Copenhagen; ADA 72nd Prader-Willi Syndrome Conference, Mundy Fellowship. Scientific Sessions, Philadelphia, Sydney, Australia. Pennsylvania, USA; APDO Meeting/KES National and International meetings meeting, Korea. _ Professor John Mattick: Plenary _ A/Professor Jackie Center: Invited Speaker at The Royal Australasian Speaker at the Australian and New _ Professor Ted Kraegen: Invited Speaker College of Physicians Annual Congress, Zealand Urological Society, Darwin. at the AMPK FASEB conference, California. Brisbane, Australia (Arthur E Mills Oration); XLI Annual Meeting of the _ Professor Peter Croucher: Invited Speaker Neurological Diseases Brazilian Biochemistry and Molecular at the 1st Asia-Pacific Bone and Mineral Society (SBBq), Foz do Iguaçu, Brazil; Research Meeting; the ANZBMS 22nd Awards and Prizes INSERM Atelier de Formation 215: Annual Scientific Meeting, Perth; the _ Professor John Mattick: Chen Award Diversity of the non-coding Australian Society for Medical Research, 2012 for Distinguished Academic transcriptome revealed by RNAseq, Sydney; and at the 4th Sydney Tissue Achievement in Human Genetic and Bordeaux, France; Non-coding Genome, Engineering Symposium. Genomic Research, Human Genome Institut Curie, Paris, France; 2012 Merck Organisation (HUGO). Millipore Asia Bioforums, Singapore, _ Professor John Eisman: Plenary Speaker Ghuangzhou and Taipei; Endocrinology at the Australian Rheumatology Major Fellowships and Funding and Diabetes Forum: Advances and Association Meeting in Perth; The _ Dr Raymond Lau: Cancer Institute NSW Future Directions, Sydney; 2012 Human Australia & New Zealand Bone & Mineral Career Development and Research Genome Meeting, Human Genome Society Meeting in Perth; The American Fellowship. Organisation (HUGO), Sydney Society for Bone and Mineral Research (President's Oration); 2012 SGI Meeting in Minneapolis, USA; The National and International Meetings (Society for Gynaecological Investigation) Sydney International Breast Cancer _ Dr Paul Baldock: Invited Speaker at the Summit, Brisbane, Australia; Philanthropy Congress, Sydney; and The Merck Sharp Conferences on Orthodontic Advances in Health and Medical Research & Dohme Scientific Symposium, Kuala in Science and Technology, North Carolina Conference 2012, Melbourne, Australia; Lumpur, Malaysia. USA; the Endocrine Society of Australia QMB Non-coding RNA, Queenstown, Annual Meeting, Gold Coast; and the New Zealand; Sydney Cancer Conference, _ Professor Tuan Nguyen: Invited Speaker Australian Health and Medical Research Sydney, Australia; Frontiers in Cancer at the Strong Bone Asia Forum, Council, Annual Meeting, Adelaide. Science, Singapore; Biology 2012 and Bangkok, Thailand. Beyond, 25th Anniversary Symposium, _ Dr Adam Cole: Invited Speaker at the CSIR Centre for Cellular and Molecular _ Professor Mike Rogers: Plenary Speaker Australian Neuroscience Society Annual Biology, Hyderabad, India; and the at the Annual Conference on Cancer- Conference in Melbourne. Private Healthcare Australia Conference Induced Bone Disease, Lyon, France. 2012, Melbourne, Australia. _ Professor Herbert Herzog: Plenary Speaker at the 3rd Meeting of the _ Dr Greg Neely: Invited Speaker at the Japan Branch of International Lorne Genome Conference in Australia; Neuropeptide Society Japan; the and The European Academy of Scandinavian Physiological Society Bozen/Bolzano Institute in Italy. Annual Meeting, Helsinki, Finland - where he also gave a State of the Art _ Professor David Ryugo: Plenary Speaker Lecture; the Japanese Society of at Frontiers 2012: The Arts, Science and Psychosomatic Medicine, Kagoshima, Future of Otorhinolaryngology, Japan; Australian and New Zealand Melbourne; and the Conference of the Obesity Society Annual Scientific College of American Veterinary (ANZOS) Meeting, Auckland, New Pathology, Seattle, USA. 53PEOPLE HIGHLIGHTS

Business DEVELOPMENT

Opposite: Endocrine assay Overview G2 Therapies lab circa 1985. Business Development undertakes four core functions Development of Garvan's most clinically advanced for the Institute – it ensures that breakthrough program was progressed through the spin-out discoveries are patented, commercialises the company G2 Therapies, a private company chaired patents to increase the likelihood of clinical use, and by Dr John Schubert AO. Its anti-C5aR antibody is assists researchers with focussed development currently in clinical development at Novo Nordisk, in projects. In addition, Garvan's Business patients with rheumatoid arthritis. Development Unit provides commercialisation services to St Vincent's Hospital Sydney Limited Business Development Advisory Council which enhances the precinct relationship. The Business Development Advisory Council (BDAC) provides strategic advice to Business Business Development maintains a global network Development and formally reviews initiatives that of contacts in the biotech/pharmaceutical sector to require Garvan Board approval. BDAC comprises ensure that the Institute is across diagnostic/ representatives with a wealth of experience from therapeutic market needs and trends. The team the biotech and pharma sector, venture capital & works with researchers to identify potential corporate finance and Garvan faculty. In 2012 biotech/pharmaceutical industry partners for membership comprised: commercially-focused development and funding opportunities. This is important as Garvan's research Dr Lisa McIntyre (Chair) sits at the first, vital, stage of the development Director, L.E.K. Consulting and Non-executive pipeline for new therapeutics and diagnostic tests. Director, Garvan

The Business Development team also looks at how Professor John Mattick AO FAA capabilities of the Institute can be leveraged to Executive Director, Garvan enter into relationships with industry, and to use the depth of expertise in all of the Research Divisions. Mr Daniel Petre (from August 2012) The Garvan patent portfolio currently comprises 23 Non-executive Director, Garvan patent families covering novel treatments, diagnostics and platform technologies in cancer, diabetes Dr George Moore metabolism, neurosciences and immunology. External Director

Special Projects Dr Merilyn Sleigh Business Development undertakes special projects Biotechnology Advisor and Company Director which require commercial, legal and strategic planning expertise from time to time. In 2012 Mr Manoj Santiago Business Development: Partner, PricewaterhouseCoopers

_ provided business planning services in the lead up Professor Trevor Biden to the establishment of the Centre for Clinical Metabolic Diseases Division, Garvan Genomics; and Professor Peter Croucher _ worked with Garvan researchers and clinicians to Chair, Osteoporosis and Bone Biology Division, identify core capabilities relevant to the needs of Garvan industry and government that can be leveraged to generate income; Mr John Dakin Chief Operating Officer, Garvan

Ms Christina Hardy Director, Business Development & Legal Affairs, Garvan

BUSINESS55 DEVELOPMENT

Garvan COMMUNITY

Life Governors Partners for the Future Ms Barbara Henderson Allind Pty Limited Mrs Margaret Adams Mr John Thomas Hill Amadeus Energy Limited Ms Ronelle Adams Ms Heather P Hindle Mr John Armati Ms Wilhelmina Antoniesen Mr Lionel Hirning ASX Group The Honorable Ian Armstrong AM OBE Mr Byram Johnston OAM and Australian Cancer Research Foundation Mr Ian A N Armstrong Mrs Deborah Johnston Mr Charles P Curran AC Mr Peter Askew Mrs Florence Jones The Curran Foundation Miss Margaret Atkinson Mrs Virginia Kahlbetzer Mr & Mrs Geoff and Dawn Dixon Dr W. Michael Baker Mrs Isabel (Rae) Kennedy Mr & Mrs Peter and Val Duncan Mr & Mrs David and Robyn Barnett Ms Lili Koch The Late Mr Alan Elder Mr Wal Barrett Ms Josie La Spina Lady (Mary) Fairfax, AC, OBE Ms James Belger Mr & Mrs Ronald Langdon Ferris Family Foundation Mr & Mrs Peter and Pamela Binnie Mr John J Lanigan Mr Laurence S Freedman AM Mr Ken Bloxsom Mr Barry Thompson and Elizabeth Fyffe Ms Linda Booth Ms Roberta Lauchlan Mr James Patrick Garvan & Family Mr & Mrs Earle and Marlene Boutwell Ms Elizabeth Lee George Patterson Pty Ltd Mr & Mrs Alan & Anne Boyle Mrs Adell Littlejohn Mrs Janice Gibson & Ernest Heine Family Dr William R Bradford Ms Maria Lydaki Foundation Ms Mary Brauer Mrs Gwenda Macdonald Mr Berel Ginges and Mrs Agnes Ginges Drs Ruth & Des Bright Dr Norman Marshall Mr Cyril Golding Mr & Mrs Bernard and Barbara Brown Mrs Doreen N Martin Mr William A Gruy Mr & Mrs Ken and Betty Brown Mr Lance Matheson Mr & Mrs Paul and Judy Hennessy Mrs Diana Bryers Mr Desmond J McCarthy HIH Insurance Dr John Campbell Mr Stuart McCulloch Mr Pieter H Huveneers Mr Angelo Casella Roslyn McDonald Luger Mrs Virginia Kahlbetzer Mrs Judith Clark Mr & Mrs Warren J and Mr Trevor Kennedy AM and Mrs Robyn Collings Pamela A McNamara Mrs Christina Kennedy Mr Rodney F Darke Mrs Mabs Melville Mr & Mrs Ralph and Lorraine Keyes Mr Kenneth Davies Miss Helen Morgan The Kinghorn Foundation Mrs Cristine Davison Mrs & Mr Mary and Herbert Morris Mr & Mrs Roy and Cindy Manassen Mrs Luise de Longueville Miss Joan Murphy Mrs Mabs Melville Mr Tom Devitt Mr & Mrs Michael and Valda Neels MLC Community Foundation Mrs Marlene Dixon Mrs Carol O'Carroll National Australia Bank Mr Peter Dixon Mr Gary Lindsay O'Leary Dr Graham O'Neill Mr John Dobies Mr Peter Olive The Late Mr K Packer AC Mr Alan Durham Mr Allan Pollock Mrs Roslyn Packer AO Mrs V J Eastment Ms Judy Radecki The Paramor Family The Evans Family Mrs Marjorie Renshaw Petersen Family Foundation Ms Daile Falconer Dr Judith Reynolds The Petre Foundation Mr & Mrs Gabriel and Joan Farago Ms Helen Richards The Lady Proud Foundation Mrs Grace Faulks Ms Kathy Rockwell The Bill and Patricia Ritchie Foundation Mr Roger Forster Ms Tanya Roddan Mr & Mrs Tim and Sally Sims Ms Jan Foster Elizabeth Rudduck Mr Robert Strauss MBE Mr & Mrs Michael and Joy Foulsham Mr & Mrs Ken and Judy Sargeant Mr Laurie Sutton Elizabeth Fyffe Ms Coral Saunders Dr John Tonkin Mr & Mrs William & Jacqueline Goodyear Miss Thelma Shepherd Westfield Holdings Ltd Mrs Helen Victoria Graham Mr & Mrs Bruce and Jean Smith E J Whitten Foundation Miss Flo Greene Kathryn Ann Smith Witchery Ms Angela Guildford Mr Steven Somlai

Justice Barry O’Keefe (ret), Chairman of Lady Mary Fairfax’s attorneys, with hearing loss researchers Catherine Connelly and Kirupa Suthakar celebrating Lady Mary’s generous gift of $1,000,000 to Garvan’s Hearing Loss Program. GARVAN57 COMMUNITY Mrs Cynthia Southwell Asthma Foundation NSW Mr Blair Cavill Mrs Liese-Lore Spring Association for International Cancer Say Center Mr Rick Stevens Research Centric Wealth Limited Mr & Mrs Peter and Diane Sturrock The Australian Ladies Variety Association Inc CHAMP Private Equity Mr Leonard Towers Australian Cancer Research Foundation Mr Robert Chapman Mr & Mrs Eric and Pauline Vail Australian Diabetes Society Mr & Mrs Stephen & Mary Charlesworth Mrs Maya Van Rol Australian New Zealand Breast Cancer Mr David Cheng Mrs Judith Wheeldon AM Trials Group Mr Denis Cleary AM Dr Yvonne White Australian Pituitary Foundation Club Cronulla Dr Eva Wicki Australian Research Council Ms Kylie Coates Ms Barbara Williams Australian Rotary Health Research Fund Coca-Cola Amatil Ms Faye Margaret Williams Avner Nahmani Pancreatic Cancer Mr Timothy Cohen In Memory of the Late Kathrin Foundation Mr Ian Cole Nell A Wilshire Bain & Company Colin Biggers & Paisley Miss Vivienne Windsor The Honourable Bruce Baird AM Commonwealth Department of Health Ms Roberta Withnall Dr & Mrs Anthony Balston and Ageing Mr Michael Barker Commonealth Department of Industry, Volunteers Mr Sean Barry Innovation, Science, Research and Mrs Janet Barkell Doug & Alison Battersby Tertiary Education Mrs Deirdre Blakemore Baxter Charitable Foundation Ms Melinda Conrad and Mr David Jones Mrs Leona C Blanco Dr Paul Beath The Corio Foundation Ms Susie Curtis Mrs Angela Belgiorno-Zegna Dr Joan Cosgrove Ms Margarita Field Dr Cameron Bell Mr Stanley Costigan Miss Lyndie Hemery Mr & Mrs Geoffrey & Marie Bennett Mr Geoff Cottle Mr Howard Houliston Mr Alex Berlee Dr & Mrs Brett and Susan Courtenay Mrs Lynne Jones Bill Burcher Foundation Craig Mostyn & Co Pty Ltd Mrs Juliet Kirkpatrick Mrs Kaye Blaiklock Mr David Craig Mr Anthony Lam Mr Simon Blair Mrs Prue Crookes Mr John McInerney The Bluesand Foundation Mrs Edith M Cuming Mr & Mrs Bob & Joan Neilson BNP Paribas Mr John Cupples Mrs Jean Pushong Bondi Junction Waverley RSL Sub Cure Cancer Australia Foundation Mrs Julie Reid Branch Mr Charles P Curran AC Mrs Ellen Singleton Mrs Dorothy Bonser The Curtis Family Mr Anthony Sun Boston Medical Centre Mr & Mrs Robert & Beryl Cusick Mr Bill Upton Mr Peter Bower Mrs Margaret Daly Braemac Pty Ltd Mr Rodney F Darke 2012 Supporters Drs Ruth & Des Bright Mr & Mrs Kamlesh and Swati Dave Ms W Brook Professor & Dr Jeremy and Jessica Davis A I Topper & Co Mr & Mrs Ken and Betty Brown Hon Mrs Ashley Dawson-Damer Abey Family Foundation Mr Norman Brunsdon Mrs P De Sauty Abrams Turner Whelan Family Lawyers Mrs Kate Buchanan Mr & Mrs Tony and Coleen De Saxe Accenture Mr Lothar Bulla Mr Ken Dean Mrs Rae Adams Burwood RSL Club Ltd Mr & Mrs John & Kylie Delano Mrs Lenore Adamson BUPA Health Foundation Mr Jonathan Denovan Mr Harold Adolphe The Michael & Andrew Buxton Deutsche Group Services Pty Ltd Mr Michael Ahrens Foundation Diabetes Australia Research Trust Mr Len Ainsworth Mr William Bylhouwer Mr & Mrs Geoff and Dawn Dixon Ake Ake Fund Mr Ian Cairns Mr Leonard Dixon Mr & Mrs A & J Alderton Mr & Mrs Alan & Cecilia Calder Mrs Bette Dolman Ms Jane Allen Mr Bruce Cameron Mrs Patricia Donovan Dr Lyn Allen Mr Rod Cameron Downer EDI Limited Mr Murray Allen Cancer Australia Mrs Joan Doyle Amgen Cancer Council NSW Duchen Family Foundation Mr & Mrs DF & KA Anderson Cancer Institute NSW Dunstan Family Foundation Mr Neil Anderson Carlton Family Foundation Mr Phil Durney Mr George Andrews Carnegie Foundation Trust Mr Gordon Edington Mr Murray Andrews Mr Alex Cartel Mr Brian Eggert ANZ Trustees Foundation - The Dalrymple Mr & Mrs Graeme R Carter Elaine Haworth Charitable Endowment Family Endowment Mr Angelo Casella The Late Mr Alan Elder Aon Charitable Foundation Dr John H Casey European Commission FP7 Arcadian Quilters Inc Ms Pauline Cash Cumming Eventide Homes NSW Mr Ian A N Armstrong Castle Harlan Inc Lady (Mary) Fairfax, AC OBE Ronald Geoffrey Arnott Foundation Mr W R Farley

58GARVAN COMMUNITY Miss Jane Farrell The Late Mr Philip Hemstritch Mrs Zoe Kominatos Fell Foundation Henry Pollack Foundation Mr Krishna Kumar Mr Jonathan Fennel Mr Lionel Hirning Mr Theodore Kyriacos Ferris Family Foundation Mr Joseph Hofmanis L & H Payne Medical Research Charitable Mr Ronald Ficarra Dr & Mrs Francis and Marie Hooper Foundation Firehold Pty Ltd Jessica B Hore Melanie Laing Mrs Margaret Fitzpatrick Dr Ronald Houghton DFC FRAS Mr Graeme Lambert Fivex Commercial Property Mr Greg Howard Mr Michael Leahy Ms Joyce Foran Mrs Sue Howieson Ms Helen Lee Ms Jane Forster & Mr Glenn Eggleton Ms Jayne Hrdlicka Mrs P Lee Mr & Mrs Michael and Joy Foulsham Human Frontier Science Program Mr Robert Leece AM RFD Mrs Maurene Fraser Mr Stanley Hunt OAM Leighton Holdings Mr & Mrs Gordon & Jeanne Frost Hunter Hall International Limited Lemoar Nominees Pty Limited Mr Sunny Fung Mr Pieter H Huveneers Mr Brian Levy Mr Elmer Funke Kupper Mrs & Mr Harry and Denise Iacovou The Lions Club of Berowra Inc. Elizabeth Fyffe IMB Ltd Lions Club of Hawkesbury Bells Line Inc. Mr Colin Galbraith International Bone and Mineral Society Mr Anthony Little Mr & Mrs Eric and Tonia Gale The Ionian Club Sydney Inc Mr John B Little Ivan Gantar Ipsen Mr Shane Lloyd Mr Justin H Gardener ISG Foundation Logan Family Foundation Garnett Passe and Rodney Williams Mr Peter Ivany AM Mrs Kathy R Lowe Memorial Foundation J Holden Family Foundation Mr Michael Lowe Gastroenterological Society of Australia The Hon Justice Peter M Jacobson Ms Margo Lowy Ms Lynette Gearing Mr Stuart Jacobson LSAF Holdings Pty Ltd Belinda Gibson Mr Cary James Ms Maria Lydaki Mrs Janice Gibson & Ernest Heine Family Mr Robert Jamieson Ms Judith Lyell Foundation Mr William Jauncey Lynch Group Australia Pty Ltd Mr Roger Gilbert John & Connie Kennedy Charitable Trust Ms Helen Lynch AM Mr Andrew D Giles Ms Margot Johnson Mr Michael Lyons Mr Berel Ginges and Mrs Agnes Ginges Mr Tom Johnston M H Carnegie & Co. Cherie Glick and Family for Joe Mrs Sheila M Johnstone Ms Alison MacDougall Ms Leone Glynn Dr G E Jordan Ms Maureen Macfarlan Mr Horace Goldsmith Juvenile Diabetes Research Foundation Mr John MacLellan Mr Peter Goodwin Mrs Virginia Kahlbetzer Macquarie Group Foundation Mr & Mrs William & Jacqueline Goodyear Dr Colleen Kane Donald and Kate Magarey Mr Murray Gordon Mr & Ms Keith & Judith Kay Mr Stephen Mahnken Ms Sundae Gordon Mr Kevin Keady Major Drilling Pty Ltd Gorokan-Kanwal Lions Club Maryann Keady Mr & Mrs Roy and Cindy Manassen Mr Neville Grace Mr & Mrs Patrick & Beryl Keane Mr Nicholas Manning Mr Malcolm Graham Mr Perce Keech The Late Mr Robert Maple-Brown AO and Mrs Michelle Graham Mrs Helen J Keir Mrs Susan Maple-Brown Grant Family Charitable Fund Professor Geoffrey Kellerman AO Mrs Sandra Marder GraysOnline Mrs Elizabeth Kelly Mr Ben Markey Sharon Green Mrs Caroline Kennedy Armin Martens Mrs Elizabeth Grenfell Mr Steve Kennedy Master Management Pty Limited Mrs Enid Griffin Mr Trevor Kennedy AM and The Hon John Matthews and Mr & Mrs Stanley and Helen Grosman Mrs Christina Kennedy Mrs Dympna Matthews Mr William A Gruy Dr Virendra Khanna Mr Ian McAlpine Mr Roger Hallaran Mrs Christine Khoudair Mrs Marjorie McAlpine Hallidays Heating & Cooling Ms Gabrielle Kibble AO Christine & Denis McConnell Hamilton Foundation The Kibblewhite Endowment Ms Catherine McElroy Miss Lisa Hando Kids Cancer Project - Oncology Childrens Mr Murray McGain Mrs Ann Hanson Foundation Linda McGovern Mr & Mrs Graeme Hargrave Mr G H Kimpton Mr Peter McGovern Harper Bernays Charitable Trust- King & Wood Mallesons Mr Peter McGrath MacDougall Family Endowment Dr David King Mr Simon McGrath Mr & Mrs H & E Harries Mr Wal King AO Ms Susan McKeon, Agrisearch Analytical Mr Donald Harris AM The Kinghorn Foundation Pty Ltd Mr Loftus Harris AM Mr & Mrs John and Jill Kinghorn Ms Cheryl McMorrine Ms Betty Haugh Mrs Ann Kirby Mr & Mrs Warren J and Mr & Mrs Bill and Alison Hayward Mr W Bruce Kirkpatrick OAM and Pamela A McNamara Heliflite Pty Limited Mrs Juliet Kirkpatrick Mrs Mabs Melville Mrs Patricia Hely Ms Lili Koch Mr Malcolm Menzies

59GARVAN COMMUNITY Merck Sharp & Dohme Mr Ian Paul Ms Jennifer Scott-Gray Mr John Mesley Rob Pedersen Mr Colin Scouler Metromix Pty Ltd Perceptor Recruitment Mr Laurie W Seaman Michael J Fox Foundation for Parkinson's Perpetual Foundation Mr Graham See Research Perpetual Trustee Company Limited Mr Julian Segal Ms Jocelyn Millett Doug Perry Mrs J Shanahan Ms Joyce Minary Petersen Family Foundation Mrs Daniela Shannon MLC Community Foundation Pfizer Australia Ms Lindsey Shaw Mr & Mrs David and Renata Money Dr Sang G Phan Mr Grant Sheldon Mrs Catherine Moroney Philiosophy Pty Ltd Mr & Mrs Robin and Jacqui Shnier Fr Alexander Morozow M. John Phillips AO Mrs Lorna Simpson Dr Kenneth Moss Phoenix Masonic Association SKILLED Group Mostyn Family Foundation Ms Suzannah Plowman Skipper-Jacobs Charitable Trust Ms Karyn Mottershead Mrs Doris E Pollock Joseph Skrzynski AO & Roslyn Horin Mr Tony Mouatt Mr John C Porter and Mrs Pamela Sleeman Mrs Catherine Moxham Mrs Susan M Mougey Mrs Jean Sloss MS Research Australia Premier Media Group Mrs Jennifer M Smith Miss Joan Murphy Prostate Cancer Foundation of Australia Mrs Marie Smith Mr Peter Murphy The Lady Proud Foundation Societe Francophone du Diabete Murrays Coaches PT. Freeport Indonesia & PT. Eksplorasi Mrs Athlene Somers Mrs Bhagavathi Naidoo Nusa Jaya Mr Karl Somers Frances and Ian Narev Qantas Flight Hostess Club Southern Cross Catholic School National Australia Bank RAAF Association St George Branch Community National Breast Cancer Foundation Incorporated Mr Paul Spackman National Health and Medical Research Mrs Elizabeth Ramsden Spinal Cure Australia Council Mr Roy Randall Spinite Pty Ltd Mrs Laura Margaret Neal Rebecca L Cooper Medical Research St Vincent's Clinic Foundation Mr Paul Neumeyer Foundation Steadfast Foundation Mr Warren Nicholl Mrs Jean Redman Miss Alison Stephen Mr Robert Nixon Mr Rodger Reed Mrs Wendy Stewart Mr Ian Norman Mr & Mrs Brad and Lisa Rees Mr Christopher Still Mr & Mrs Leigh & Binnie Norman Regeneus Mr Brian Strange Novartis Pharmaceuticals Australia Pty Ltd Josef Reisinger Foundation Pty Ltd Mr & Mrs Peter and Diane Sturrock Novartis Pharmaceuticals Global Renee Pollack Foundation Ms Grace Sugden NSW Ministry of Health Retire@Ease Financial Planning Mr Laurie Sutton NSW Office for Health and Medical Mr Rory Rhodes Mr Jim Sweeny Research Ms Jane Rich Swiss National Science Foundation NSW Women's Bowl For Others Club Richard Crookes Construction Pty Limited Sydney Catalyst Mrs Lee O'Connor Mr John Richards Tabcorp Holdings Limited Mr Peter J O'Connor Mr Andrew Richardson Mr Nick Tait OBE and Mrs Mimi Tait Mr Michael O'Dea KESG AM and Ridley AgriProducts Mr Harry Tamvakeras Mrs Marianne O'Dea Mrs Judy Roach Ms Paula Tardy Mr John O'Farrell Roche Products Pty Ltd Mrs Rosemary Taylor Ognis Pty Ltd Mr A G Rockliff Ms Victoria Taylor Dr Geoffrey S Oldfield Ms Annie T. Rose Terranovate Ondas Holdings Pty Ltd Mrs Margaret Rose AM Estate of the Late Joan Hope Thomas Janette Mary O'Neil Rosemary Pryor Foundation Thomas Hare Investments Limited The Rodney & Judith O'Neil Foundation Mr Bruce Rosenberg Mr Garry Tieck Dr Graham O'Neill Mr Lance Rosenberg Mr Sean Tieck Orange & District Breast Cancer Support The Ross Trust Mr Jamie Tomlinson Group Roth Charitable Foundation Mr Walter Turnbull Dr Harry Orenstein Mrs Nora Rowe Mr David Turner Osteoporosis Australia Mr Peter Rowe Tusa Pty Ltd Mrs Maria O'Sullivan RT Hall Estate Mr James Udy Oticon Foundation Mr Chris Rumore University of New South Wales Pacific Equity Partners Sachdev Foundation Mr Peter Unwin Mrs Roslyn Packer AO Sambalance Pty Ltd Mr Ian Vale Miss Winnie Pang Mrs Barbara A Sanders Mrs Maya Van Rol The Paramor Family Mr D & Mrs A Saul Mr Bruce Vaughan Mr Craig Parker The SBA Foundation Kay Vernon Dr Michael Pasfield Mr Daniel Schriner Victory Supermarkets Pty Ltd Dr Dinesh Patel Science and Industry Endowment Fund Mrs Sarina Vignaduzzo Patricia Dukes Foundaton Mr Warren Scott Mr Christian Vignes

60GARVAN COMMUNITY Wade Civil Engineering Pty Ltd Mr & Mrs John and Megan Wade Mr Ken Wainwright Mrs Caroline Walder Mr James Waley Mr Ian Wall Mr & Mrs J B Walsh Mr & Mrs Richard and Sue Walsh Mr Robert J Walsh Dr J R Warneford Ms Alexandra Wedutenko Mr Michael Weekes The WeirAnderson Foundation Wellcome Trust Mr Robert White Mr Leonard Harlan, Ms Luxi Zhang and Mrs Fleur Harlan Mr Craig Whitworth celebrate the presentation of the 2012 Castle Harlan Ms Jane Williams Award, presented to the most outstanding early career PhD student at Garvan in 2012. Castle Harlan Inc is a US- Mr Kim Williams AM and based private equity firm that supports medical research, Ms Catherine Dovey and Mr Harlan is the Chairman of its Executive Committee. Mrs Lyn Williams AM Mrs Terri Williams Lindt & Sprungli Mr Peter Wills AC Lindwall & Ward Printing In Memory of the Late Kathrin The London Lakes Partnership Nell A Wilshire Mr Justin Miller Mr David Wilson Mr Harley Medcalf Mrs J M Wilson Mr Simon Mordant AM and Mr Raymond Wilson Mrs Catriona Mordant Mr Peter Winters Movenpick Ice Cream Peter & Ann Wolstenholme The Only Group Mrs Susan Seck Leng Wong Opera Australia Wood Family Foundation Pages Hire Mr & Mrs Jack & Leah Woolf Paspaley Woolgoolga Lions Club Park Hyatt Sydney Mr Greg Woolley Mr Neil Perry XLP Research Trust Prime Audio Visual Mr R Yeates Qantas Airways Limited Mr J M Yorke Mr Leo Robba Mr & Mrs Derek and Caroline Young Riversdale Group Mr Harrison Young RM Williams SEL & Ghost Elite Charters Gala Supporters Mr John Singleton Accor Starwood Hotels and Resorts Accolade Wines Stringspace ANZ Stadium Sydney Theatre Company Austar Taronga Conservation Society Australia Australian Brandenburg Orchestra Wild Bush Luxury Baillie Lodges Bright Red Oranges Bequests Mr Guillaume Brahimi Estate of the Late Gloria M Backhus Ms Greta Bradman Estate of the Late Ian F Bruce Mr David Coe Estate of the Late Margaret Darbyshire Ms Annabel Crabb Estate of the Late Anna Gonda Mr Serge Dansereau Estate of the Late Alan Hellicar Dinosaur Designs Estate of the Late Ken Hooton Mr & Mrs Geoff and Dawn Dixon Estate of the Late Francis W Jones Mr Bill Ferris AC and Mrs Lea Ferris Estate of the Late John E Mayall Fresh Catering Estate of the Late Gloria B O’Hanlon Grandiflora by Saskia Havekes Estate of the Late George Quigg Hayman Estate of the Late Leslie Francis Smith Hutchings Pianos Estate of the Late Joan Hope Thomas Jetstar Estate of the Late Vera Zukerman

GARVAN61 COMMUNITY

Governance

Garvan Institute Board hospitals, district hospitals, sub-acute and aged care facilities. Mr Anderson recently spent three years as William D Ferris AC Executive Director of St Vincent's Public Health Chairman Services and prior to this position was the Executive Nominated by the Trustees of St Vincent's Hospital Director of St Joseph's Hospital and St Joseph's Mr Bill Ferris is Executive Chairman of the CHAMP Village and Executive Director of the Lottie Stewart Private Equity Group, one of Australia's leading Hospital. He has held other senior positions including Bill Ferris AC private capital groups, providing venture capital, General Manager Rachel Forster Hospital; Director expansion capital and management buyout funding of Finance and Administration at Rozelle Hospital; in Australasia. Former directorships include: Director of St Vincent's Hospital Toowoomba; and Chairman, Health and Hospitals Fund Advisory Board other senior positions at Central Sydney Area Health as part of the Federal Government's Nation-Building Service. Mr Anderson has also had responsibility for Funds initiative, Australian Trade Commission specialised corporate roles such as the Sisters of (Austrade), Austar United Communications Limited, Charity Health Service National Risk Manager and and Bradken Resources Pty Ltd. Mr Ferris joined the National Aged Care Coordinator. Mr Anderson has a Bachelor of Economics from Sydney University and Warren Scott expert panel for the Federal Government's Strategic Review of Medical Research in Australia in October a Masters of Management from MGSM. 2011. He is also a director of the Garvan Research Foundation and member of the Harvard Business Annette Cunliffe RSC School Asia Pacific Advisory Council. Mr Ferris was Nominated by the Sisters of Charity made an Officer in the Order of Australia in 1990 Sister Annette attended St Vincent's College Potts for services to the export industry and in 2008 was Point before becoming a Sister of Charity. She made Companion in the Order of Australia for his completed a BSc (UNSW), Diploma of Education philanthropic activities and his role in the establish- (UNE), Master of Education (Hons) (UNSW) and ment of the private equity sector in Australia. PhD (Griffith), meanwhile teaching in secondary Jonathan Anderson colleges in various states, then holding the position Warren Scott of Senior Lecturer at the Australian Catholic Treasurer University. From 1996-2002 and since 2002 Sister Nominated by the NSW Minister for Health Annette has been Leader of the Sisters of Charity of Mr Warren Scott is the General Counsel of the Australia. She has held the positions of President of Australian Prudential Regulation Authority and a Conference of Leaders of Religious Institutes (CLRI; former managing director and the General Counsel NSW) and Inaugural Chair of the Stewardship Board of Citigroup in Australia. Prior to that he was a of Catholic Health Australia and served on a number of incorporated boards. She is currently President of Annette Cunliffe RSC partner in an international law firm. He was formerly the Chairman of the Woolcock Institute Catholic Religious Australia. of Medical Research, as well as a delegate to the Australian American Leadership Dialogue. He is a Geoff Dixon member of the Law Society of New South Wales, Nominated by the Garvan Research Foundation the American Bar Association, the New York Bar Mr Geoff Dixon is Chairman of the Australian Association, the Australian Law Council, and the Government's major tourism marketing organisation California Bar Association. Mr Scott is admitted as Tourism Australia, and Chairman of the Garvan a solicitor in New South Wales and as a lawyer in Medical Research Foundation. He sits on the boards of publicly listed Australian companies Crown Geoff Dixon New York and California. Limited and Facilitate Digital. He is on the boards of Jonathan Anderson Voyages Indigenous Tourism Australia and the (from September) Museum of Contemporary Art and is an Nominated by the Sisters of Charity Ambassador for the Australian Indigenous Education Mr Jonathan Anderson is the Chief Executive Foundation. Mr Dixon has also worked in the media, Officer of St Vincent's Health Network, Sydney. mining and government sectors. He was Managing Mr Anderson brings to the role an extensive and Director and Chief Executive Officer of Qantas successful career in public healthcare. He has held Airways Limited from 2001-2008. He joined leadership positions across a broad range of facilities Qantas in 1994 and was also Chief Commercial and service types including tertiary referral teaching Officer and, for two years, Deputy Chief Executive.

63GOVERNANCE John Horvath AO He subsequently worked at Baylor College of Nominated by the Federal Minister for Health Medicine in Houston, the CSIRO Division of Professor John Horvath was the Australian Molecular Biology in Sydney, and the University of Government Chief Medical Officer from 2003- Queensland, where he was based from 1988- 2009. He currently has advisory roles to the CEO of 2011. He also spent research periods at the the NHMRC, the Department of Health & Ageing Universities of Cambridge, Oxford, Cologne and and the School of Medicine, University of Sydney. Strasbourg. He was Foundation Director of the John Horvath AO Professor Horvath holds the position of Honorary Australian Genome Research Facility and the Professor of Medicine at the University of Sydney, Institute for Molecular Bioscience. His honours is a Health Workforce Australia Director and chairs include Honorary Fellowship of the Royal College of the Prosthesis Listing Advisory Committee of the Pathologists of Australasia, the inaugural Gutenberg Australian Government. He is also an independent Professorship at the University of Strasbourg, the non-executive director of Crown Ltd and Crown 2011 IUBMB (International Union of Biochemistry Melbourne Ltd. Professor Horvath is a fellow of the and Molecular Biology Medal, the 2012 HUGO Royal Australasian College of Physicians and is a (Human Genome Organisation) Chen Medal, distinguished practitioner, researcher and teacher. membership of the European Molecular Biology Anne Keating Until mid 2012 Professor Horvath was a member of Organisation and Fellowship of the Australian the NHMRC Council and was Chairman of the Academy of Science. He was appointed an Officer in Healthcare Committee. He was previously a clinical the Order of Australia in 2001. professor of medicine at University of Sydney, a specialist renal physician at Royal Prince Alfred Lisa McIntyre Hospital (RPA), and the Area Director of Renal Nominated by the Federal Minister for Health Services for the RPA and Concord Repatriation Dr Lisa McIntyre is a non-executive director of the General hospitals. He is also known as a leader in a HCF Group, Silex Ltd and I-MED Australia. Dr range of medical training and workforce organisations. McIntyre was formally a senior partner with LEK John Mattick AO FAA He is also a former president of the Australian Consulting in Boston and Sydney where she led the Medical Council and the NSW Medical Board. firm's Asia Pacific Life Science and Health Care practice. She has spent the majority of her career as Anne Keating a strategy consultant advising companies and Nominated by the NSW Minister for Health organisations in the health and life sciences sector Ms Anne Keating is a company director and holds on growth strategies and performance improvement. board directorships of companies in a range of Dr McIntyre continues to serve as a senior advisor industries including financial services, property and to LEK Consulting in Australia. life sciences. She is on the boards of the Goodman Lisa McIntyre Group Ltd, Ardent Leisure Ltd, REVA Medical Inc and Annette Pantle GI Dynamics Inc. Ms Keating is also a member of Nominated by the Sisters of Charity CIMB Securities International (Australia) Pty Ltd Dr Annette Pantle completed her MBBS at the Advisory Council and a governor of the Cerebral University of Sydney before pursuing a career in Palsy Foundation. Her former boards include Insurance rural general practice and then metropolitan medical Australia Group Limited, NRMA Limited, STW administration. Dr Pantle also holds a Masters of Communications Group, ClearView Wealth Limited, Public Health, a Graduate Diploma from the the WorkCover Authority of NSW, the Tourism Task Australian Institute of Company Directors and Force. She was a trustee of the Centennial Parklands Fellowship of the Royal Australasian College of Annette Pantle and Moore Park Trust and was an inaugural director Medical Administrators. She holds a Fellowship of at the Victor Chang Cardiac Research Institute. Ms the Australasian Association for Quality in Health Keating was the General Manager, Australia for Care and is the current president of that United Airlines from 1993-2001. organisation. Dr Pantle most recently served as the Director Clinical Practice Improvement for the NSW John Mattick AO FAA Clinical Excellence Commission - a statutory health Nominated by the Garvan Board of Directors corporation with responsibility for building capacity Professor John Mattick is the Executive Director of for quality and safety improvement and reporting to the Garvan Institute of Medical Research, and the NSW Minister for Health. Dr Pantle was Conjoint Professor in the St Vincent's Hospital responsible for the development and implementation Clinical School, Faculty of Medicine, University of of clinical quality improvement projects and NSW. Most recently he was the Professor of programs across NSW Health, incorporating Molecular Biology and NHMRC Australia Fellow at evidence into practice and instituting change the Institute for Molecular Bioscience, University of management and project management processes. Queensland. He was educated at St Patrick's College Dr Pantle joined St Vincent's Health Australia in Strathfield, the University of Sydney and Monash 2010 as Group General Manager Clinical University, where he obtained his PhD. Governance and Medial Officer.

64GOVERNANCE Greg Paramor Jillian Segal AM Nominated by the Garvan Research Foundation Nominated by the University of NSW Mr Greg Paramor has been involved in the real Ms Jillian Segal is a director of the National Australia estate and funds management industry for more Bank and ASX Limited. She is also Deputy Chancellor than 35 years, and was the co-founder of Growth of the University of NSW and involved with a Equities Mutual, Paladin Australia and the James number of other community not-for-profit Fielding Group. During this time Mr Paramor was organisations, including as Chairman of the General Greg Paramor involved in more than $30 billion of real estate Sir John Monash Foundation. Ms Segal is also a transactions. Mr Paramor was the CEO of Mirvac member of the Federal Government's Remuneration Group between 2004 and 2008 after the company Tribunal. Ms Segal has had a career in law, acquired the James Fielding Group. He is a past regulation, governance and policy development. president of the Property Council of Australia and Formally she was President of the Administrative past president of Investment Funds Association, a Review Council and Chair of the Banking and fellow of the Australian Property Institute and The Financial Services Ombudsman Board. From 1997- Royal Institute of Chartered Surveyors. Mr Paramor 2002, Ms Segal was a commissioner of the is a director of a number of not-for-profit Australian Securities and Investments Commission Daniel Petre AO organisations including the National Breast Cancer (ASIC), being Deputy Chair from 2000-2002. Prior Foundation. Mr Paramor is also a board member of to joining ASIC, Ms Segal was a corporate lawyer the Sydney Swans, an Adjunct Professor of Bond specialising in corporate and environmental law, University and the Chairman of LJ Hooker. having been a partner at Allen Allen & Hemsley.

Daniel Petre AO Peter Smith Nominated by the Trustees of St Vincent's Hospital Nominated by the University of NSW Mr Daniel Petre has been at the forefront of the Professor Peter Smith is Dean of Medicine at the technology industry in Australia for more than 25 University of NSW. He specialised in cancer medicine Steven Rubic years. Currently he is Chairman of netus (a and research following study in Australia, USA and technology investment company recently acquired Germany. Peter has held senior hospital management by Fairfax Media) and prior to this role he founded posts in Brisbane and Melbourne and senior academic Australia's largest internet investment company, appointments at the universities of Queensland, ecorp, (a subsidiary of PBL; Publishing and Melbourne and Auckland. Professor Smith is currently Broadcasting Limited). Mr Petre spent nine years a board director of St Vincent's Health Australia, with Microsoft where he held a range of roles both Neuroscience Research Australia, Ingham Medical in Australia and the US. He was Managing Director Research Institute, the Sax institute for Health of the Australia subsidiary for three years before Research and the Arts and Health Foundation. Jillian Segal AM moving to the US as Vice President in the Development Group then returning to run the Asia- Bernadette Tobin Pacific region for Microsoft. Mr Petre has served in Nominated by the Trustees of St Vincent's Hospital many corporate and not-for-profit boards and the Associate Professor Bernadette Tobin is the Director advisory boards for the Private Ancillary Fund of the Plunkett Centre for Ethics at St Vincent's Service at SVA (Social Ventures Australia), CSI Hospital, Sydney, and Reader in Philosophy at the (Centre for Social Impact) at the University of NSW. Australian Catholic University. A/Prof Tobin is Mr Petre is also an adjunct professor at the Honorary Ethicist at the Children's Hospital at Business School at the University of Sydney. Westmead, an honorary associate professor in the Peter J Smith Faculty of Medicine at the University of Sydney, and Steven Rubic a conjoint associate professor in the School of (until April) Medicine at the University of NSW. She served for Nominated by the Sisters of Charity three triennia on the Australian Health Ethics Mr Steven Rubic was appointed CEO of the I-MED Committee, a principal committee of the NHMRC. Network in May 2012. Prior to this he was CEO of She also chaired the drafting group which prepared St Vincent's & Mater Health Sydney, a position he the first Code of Ethics for Catholic Health and held since 2008 following a number of hospital CEO Aged Care Services in Australia. roles within St Vincent's Health Australia. He is Bernadette Tobin currently a board member of Health Industry Superannuation, Macquarie University Council, Monte Sant' Angelo College and is a past chairman of the NSW Private Hospitals Association. Mr Rubic is a fellow of AICD and AIST.

65GOVERNANCE

Garvan Research Foundation Board Bruce Baird AM The Hon Bruce Baird has an impressive career Geoff Dixon spanning the Australian Trade Commission and the Chairman parliaments of NSW and the Commonwealth. Mr Mr Geoff Dixon is Chairman of the Australian Baird currently serves on several national boards Government's major tourism marketing organisation including as Chair of Tourism & Transport Forum and the Commonwealth's Refugee Resettlement Geoff Dixon Tourism Australia. He sits on the boards of publicly listed Australian companies Crown Limited and Advisory Council. Among his positions with the NSW Facilitate Digital. He is on the boards of the Garvan Parliament, he was a member of the NSW Legislative Institute, Voyages Indigenous Tourism Australia and Assembly from 1984-1995, serving as Shadow the Museum of Contemporary Art and is an Minister for Finance, then for Transport and Aboriginal Ambassador for the Australian Indigenous Education Affairs, as Minister for Transport and Regional Foundation. Mr Dixon has also worked in the media, Services, Minister for Sydney's Olympic Bid, and mining and government sectors. He was Managing Minister for Tourism and Roads. He was the Deputy Director and Chief Executive Officer of Qantas Leader of the Liberal Party in NSW from 1992- 1995. From 1995 he served as Managing Director Jane Allen Airways Limited from 2001-2008. He joined Qantas in 1994 and was also Chief Commercial Officer and, of the Tourism Council Australia and as Chair of for two years, Deputy Chief Executive. He joined National Rail Corporation and a director of ABN the Foundation Board as Chairman in 2009. AMRO Hoare Govett, Tourism Training Australia and Tourism Education Services. He served in Federal Jane Allen Parliament, House of Representatives, from October Ms Jane Allen is a partner in Egon Zehnder 1998 until his retirement at the 2007 election. Mr International's (EZI) Sydney office, where she Baird joined the Foundation Board in 2010. focuses on chief executive officer and board Melinda Conrad Bruce Baird AM appointments. Ms Allen has been at EZI for 13 years and has consulted with corporate boards and Ms Melinda Conrad is currently a non-executive companies of all sizes. She often attends speaking director of APN News & Media Limited, The Reject engagements and has published many articles on Shop Limited, the NSW Government's Clinical CEO succession and diversity at the executive and Excellence Commission and Agency for Clinical board level. She also leads a number of global Innovation, and the Australian Brandenburg strategy initiatives roles for one of the firm's core Orchestra. Ms Conrad is the former founder and client practices. She has been the managing partner CEO of a retail chain of stores and was previously an of the Sydney office and co-leader of the Australian executive at Colgate Palmolive. She has extensive expertise in strategy, retail, marketing and business Melinda Conrad practice as well as head of the Consumer Products Practice Group for Asia Pacific. She is a member of development. She holds an MBA from Harvard Chief Executive Women, a network of Australia's Business School and is a member of the Australian top women leaders. Prior to joining EZI she worked Institute of Company Directors. Ms Conrad joined at Procter & Gamble in the US and Australia. Ms the Foundation Board in September 2003. Allen has an MBA from Harvard Business School and a Bachelor of Arts from Smith College. Ms Allen Gabriel Farago joined the Foundation Board in 2007. Mr Gabriel Farago is a company director and consultant advising corporations on litigation management. Prior to establishing his consultancy, Gabriel Farago he practised as a solicitor and barrister for over 30 years, specialising in commercial disputes both in Australia and overseas. Mr Farago has extensive business interests, and has been involved in

Opposite: James Patrick Garvan (1843-96), a distinguished property development for more than 20 years. A parliamentarian and business leader. The embedded caption in the passion for philanthropic and charitable causes also photo recognises his position as Managing Director and founder of reaches back many years, and in 1984 he was the Citizens’ Life Assurance Company Ltd in 1886, which later became MLC. Garvan’s daughter, Mrs Helen Mills, gave £100,000 made a Member of the Knightly Order of Vitez. Mr to St Vincent’s Hospital “for the purpose of research” in 1961. Farago joined the Foundation Board in 2008.

67GOVERNANCE William D Ferris AC Wal King AO Mr Bill Ferris is Executive Chairman of the CHAMP Mr Wal King has worked in the construction Private Equity Group, one of Australia's leading industry for over 40 years and was the Chief private capital groups, providing venture capital, Executive Officer of Leighton Holdings Limited, a expansion capital and management buyout funding company with substantial operations in Australia, in Australasia. Former directorships include: Chairman, Asia and the Middle East, from 1987 until his Health and Hospitals Fund Advisory Board as part of retirement on 31 December 2010. He remains as a Bill Ferris AC the Federal Government's Nation-Building Funds consultant. Mr King is Deputy Chairman of Ausdrill initiative, Australian Trade Commission (Austrade), Limited and the University of NSW Foundation Austar United Communications Limited, and Bradken Limited, a director of Coca-Cola Amatil Limited and Resources Pty Ltd. Mr Ferris joined the expert panel Kimberley Foundation Australia Limited, and a for the Federal Government's Strategic Review of council member of the University of NSW (to June Medical Research in Australia in October 2011. Mr 2012). Mr King is an honorary fellow of the Ferris is the Chairman of the Garvan Institute and Institution of Engineers Australia; a foundation member of the Harvard Business School Asia Pacific fellow of the Australian Institute of Company Advisory Council. Mr Ferris was made an Officer in Directors, and a fellow of the Australian Institute of Lyn Gearing the Order of Australia in 1990 for services to the Management, the Australian Institute of Building export industry and in 2008 was made Companion and the Australian Academy of Technological in the Order of Australia for his philanthropic Sciences and Engineering. Mr King joined the activities and his role in the establishment of the Foundation Board in 2010. private equity sector in Australia. Mr Ferris joined the Foundation Board in 2001. John Landerer CBE AM Mr John Landerer is a solicitor specialising in Lyn Gearing corporate advisory work and is also a professional Ms Lyn Gearing was appointed to the Garvan company director. He is currently Chair of Loftus Harris AM Foundation Board as a representative of the Sisters Goldsearch Limited and other private companies. of Charity. Ms Gearing is currently a director of He has served as the Chair of the Home Purchase Queensland Investment Corporation Limited and the Assistance Authority and is on the board of Life Commonwealth Superannuation Corporation. Until Education Australia and the Royal Institute for Deaf late 2012 Ms Gearing was a director of both IMB and Blind Children as well as on the boards of Limited and Global Mining Investments Limited. Ms various charitable institutions. Mr Landerer holds an Gearing has substantial experience in superannuation, honorary doctorate from Macquarie University in funds management, corporate finance and business and commercial law. He is also a fellow of management consulting. Ms Gearing joined the the University of Sydney. Mr Landerer is a Member Wal King AO Foundation Board in 2005. of the Order of Australia and a Commander of the Most Excellent Order of the British Empire. He is Loftus Harris AM also a Commander in the Order of the Star of Italian Mr Loftus Harris is a non-executive director on Solidarity. He joined the Foundation Board in 2007. various boards, the immediate-past National Chair of the Australian Institute of Export, and Special Trade Representative to the Middle East and India for the Queensland Government. He previously held chief executive positions in the NSW and John Landerer CBE AM Queensland public sectors with responsibility for whole-of-government activities including international trade, investment, innovation, business, and regional development. He also served extensively overseas as an Australian Trade Commissioner. Mr Harris joined the Foundation Board in 2008.

68GOVERNANCE John Mattick AO FAA Clare Nolan RSC Professor John Mattick is the Executive Director of Sister Clare entered the Sisters of Charity following the Garvan Institute of Medical Research, and Conjoint nurse training at the Mater Hospital in Brisbane. She Professor in the St Vincent's Hospital Clinical School, has over 45 years experience in health and research Faculty of Medicine, University of NSW. Most recently services. Her ministry experience includes health, he was the Professor of Molecular Biology and welfare, governance and administration, serving on NHMRC Australia Fellow at the Institute for boards within the Sisters of Charity Health Service John Mattick AO FAA Molecular Bioscience, University of Queensland. He and other Church bodies. Her present Ministry is was educated at St Patrick's College Strathfield, the one of hospitality. Hospitality to women who have University of Sydney and Monash University, where loved ones in hospital within the St Vincent's he obtained his PhD. He subsequently worked at campus, to patients who come from the Solomon Baylor College of Medicine in Houston, the CSIRO Islands for health care within the St Vincent's Division of Molecular Biology in Sydney, and the campus, to women and men who suffer with University of Queensland, where he was based from mental health issues. Sister Clare joined the 1988-2011. He also spent research periods at the Foundation Board in 2010. Universities of Cambridge, Oxford, Cologne and Simon Mordant AM Strasbourg. He was Foundation Director of the Brad Rees Australian Genome Research Facility and the Mr Brad Rees is involved in a number of charitable, Institute for Molecular Bioscience. His honours arts and educational interests and is a director of a include Honorary Fellowship of the Royal College of private investment company. Until 2007, he was a Pathologists of Australasia, the inaugural Gutenberg managing director and equity partner of the Professorship at the University of Strasbourg, the investment banking firm Goldman Sachs JBWere. 2011 IUBMB (International Union of Biochemistry Mr Rees was with the firm for 23 years and worked and Molecular Biology Medal, the 2012 HUGO in the Melbourne, Sydney and London offices (Human Genome Organisation) Chen Medal, providing financial and investment banking advice to Clare Nolan RSC membership of the European Molecular Biology corporations and governments in Australia and over- Organisation and Fellowship of the Australian seas. Mr Rees joined the Foundation Board in 2008. Academy of Science. He was appointed an Officer in the Order of Australia in 2001. Professor Mattick Jeanne-Claude Strong joined the Foundation Board in 2012. Dr Jeanne-Claude Strong is a qualified medical practitioner with a post-graduate diploma in applied Simon Mordant AM finance and investment and a Bachelor of Arts in Mr Simon Mordant is Vice Chairman and Managing Literature and Philosophy. Dr Strong established and Director of Greenhill & Co Inc, a leading independent ran three medical clinics in Melbourne and Sydney, Brad Rees corporate advisory firm. Mr Mordant specialises in focusing on occupational, sports and preventative advising local and multinational companies and medicine and stressing the importance of lifestyle government on their capital markets strategy and management. She was a member of the Advisory merger and acquisitions. Mr Mordant trained as a Board of Bluearth for 10 years, a not for profit chartered accountant in London, is Chairman of the organisation which promotes greater physical Museum of Contemporary Art Australia, a director activity to reduce the incidence of disease and of the Australian Broadcasting Corporation, is increase wellbeing. She is a pilot with a command Australian Commissioner for the 2013 Venice Biennale, multi-engine instrument rating and has flown her a member of the International Leadership Council of own plane from California to Australia. Dr Strong Jeanne-Claude Strong the New Museum and a member of the International has a passion for yacht racing with an occasional Council of The Museum of Modern Art in New York, foray in international regattas. She illustrates that a a member of the Executive Committee of the Tate successful life must be balanced, and the success of International Council, a director of the Sydney Theatre her full professional and personal life is testimony to Company, and a member of the Wharton Executive her principles. Dr Strong joined the Foundation Board for Asia. Mr Mordant was awarded an AM Board in 2011. being made a Member in the General Division of the Order of Australia for 'Services to the Arts and to the cultural environment of Australia through philanthropic and executive roles, and to the community'. Mr Mordant joined the Foundation Board in 2009. 69GOVERNANCE

Publications

Batten M, Ghilardi N. Bystanders not so Nourbakhsh E, Manning S, Wani S, innocent after all. Immunity. 2012; Gongora M, Pajic M, Scarlett CJ, Gill AJ, 36:901-3. Pinho AV, Rooman I, Anderson M, Holmes A O, Leonard C, Taylor D, Wood S, Xu Q, Achard CS, Laybutt DR. Lipid-induced Baud'huin M, Solban N, Cornwall-Brady Nones K, Fink JL, Christ A, Bruxner T, endoplasmic reticulum stress in liver cells M, Sako D, Kawamoto Y, Liharska K, Lath Cloonan N, Kolle G, Newell F, Pinese M, results in two distinct outcomes: D, Bouxsein ML, Underwood KW, Ucran J, Mead RS, Humphris JL, Kaplan W, Jones adaptation with enhanced insulin signaling Kumar R, Pobre E, Grinberg A, Seehra J, MD, Colvin EK, Nagrial AM, Humphrey ES, or insulin resistance. Endocrinology. Canalis E, Pearsall RS, Croucher PI. A Chou A, Chin VT, Chantrill LA, Mawson A, 2012; 153:2164-77. soluble bone morphogenetic protein type Samra JS, Kench JG, Lovell JA, Daly RJ, IA receptor increases bone mass and bone Merrett ND, Toon C, Epari K, Nguyen NQ, Al-Sohaily S, Biankin A, Leong R, strength. Proceedings of the National Barbour A, Zeps N, Kakkar N, Zhao F, Wu Kohonen-Corish M, Warusavitarne J. Academy of Sciences USA. 2012; YQ, Wang M, Muzny DM, Fisher WE, Molecular pathways in colorectal cancer. 109:12207-12. Brunicardi FC, Hodges SE, Reid JG, Journal of Gastroenterology and Drummond J, Chang K, Han Y, Lewis LR, Hepatology. 2012; 27:1423-31. Baune BT, Smith E, Reppermund S, Air T, Dinh H, Buhay CJ, Beck T, Timms L, Sam Samaras K, Lux O, Brodaty H, Sachdev P, M, Begley K, Brown A, Pai D, Panchal A, Trollor JN. Inflammatory biomarkers Buchner N, De Borja R, Denroche RE, predict depressive, but not anxiety Yung CK, Serra S, Onetto N, symptoms during aging: the prospective Mukhopadhyay D, Tsao MS, Shaw PA, Sydney Memory and Aging Study. Petersen GM, Gallinger S, Hruban RH, B Psychoneuroendocrinology. 2012; Maitra A, Iacobuzio-Donahue CA, Schulick Baldock PA, Driessler F, Lin S, Wong IP, Shi 37:1521-30. RD, Wolfgang CL, Morgan RA, Lawlor RT, Y, Yulyaningsih E, Castillo L, Janmaat S, Capelli P, Corbo V, Scardoni M, Tortora G, Enriquez RF, Zengin A, Kieffer BL, Beattie K, Symons J, Chopra S, Yuen C, Tempero MA, Mann KM, Jenkins NA, Schwarzer C, Eisman JA, Sainsbury A, Savdie R, Thanigasalam R, Haynes A-M, Perez-Mancera PA, Adams DJ, Herzog H. The endogenous opioid Matthews J, Brenner PC, Rasiah K, Largaespada DA, Wessels LF, Rust AG, dynorphin is required for normal bone Sutherland RL, Stricker PD. A novel Stein LD, Tuveson DA, Copeland NG, homeostasis in mice. Neuropeptides. method of bladder neck imbrication to Musgrove EA, Scarpa A, Eshleman JR, 2012; 46:383-94. improve early urinary continence following Hudson TJ, Sutherland RL, Wheeler DA, robot-assisted radical prostatectomy. Pearson JV, McPherson JD, Gibbs RA, Barry G, Mattick JS. The role of regulatory Journal of Robotic Surgery. 2012:doi: Grimmond SM. Pancreatic cancer RNA in cognitive evolution. Trends in 10.1007/s11701-012-0371-2. genomes reveal aberrations in axon Cognitive Sciences. 2012; 16:497-503. guidance pathway genes. Nature. 2012; Bensellam M, Duvillie B, Rybachuk G, 491:399-405. Bassett JH, Gogakos A, White JK, Evans H, Laybutt DR, Magnan C, Guiot Y, Jacques RM, van der Spek AH, Ramirez- Pouyssegur J, Jonas JC. Glucose-induced Birzniece V, Ho KK. Growth and Solis R, Ryder E, Sunter D, Boyde A, O(2) consumption activates hypoxia development: Patching up a better pill for Campbell MJ, Croucher PI, Williams GR. inducible factors 1 and 2 in rat insulin- GH-deficient women. Nature Reviews Rapid-throughput skeletal phenotyping of secreting pancreatic beta-cells. PloS One. Endocrinology. 2012; 8:197-8. 100 knockout mice identifies 9 new 2012; 7:e29807. genes that determine bone strength. Birzniece V, Meinhardt UJ, Gibney J, PLoS Genetics. 2012; 8:e1002858. Bensellam M, Laybutt DR, Jonas JC. The Johannsson G, Armstrong N, Baxter RC, molecular mechanisms of pancreatic Ho KK. Differential effects of raloxifene Bassett JH, Logan JG, Boyde A, Cheung beta-cell glucotoxicity: Recent findings and estrogen on body composition in MS, Evans H, Croucher P, Sun XY, Xu S, and future research directions. Molecular growth hormone-replaced hypopituitary Murata Y, Williams GR. Mice lacking the and Cellular Endocrinology. 2012; women. The Journal of Clinical calcineurin inhibitor Rcan2 have an 364:1-27. Endocrinology and Metabolism. 2012; isolated defect of osteoblast function. 97:1005-12. Endocrinology. 2012; 153:3537-48. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Birzniece V, Sutanto S, Ho KK. Gender Opposite: Computer terminal room in the old Garvan building Miller DK, Wilson PJ, Patch AM, Wu J, difference in the neuroendocrine circa 1985. Front to back: The late Stuart Furler, Paul Compton, Robynne McGinley (standing), Bobbie Walker, Chang DK, Cowley MJ, Gardiner BB, Song regulation of growth hormone axis by Dr Bjorn Borjesson, Greg Egan and Arthur Jenkins (standing). S, Harliwong I, Idrisoglu S, Nourse C, selective estrogen receptor modulators. 71PUBLICATIONS The Journal of Clinical Endocrinology and replication in mammalian cells. PloS One. Chang PP, Barral P, Fitch J, Pratama A, Ma Metabolism. 2012; 97:E521-7. 2012; 7:e45726. CS, Kallies A, Hogan JJ, Cerundolo V, Tangye SG, Bittman R, Nutt SL, Brink R, Boden MJ, Brandon AE, Tid-Ang JD, Buske FA, Bauer DC, Mattick JS, Bailey TL. Godfrey DI, Batista FD, Vinuesa CG. Preston E, Wilks D, Stuart E, Cleasby ME, Triplexator: detecting nucleic acid triple Identification of Bcl-6-dependent Turner N, Cooney GJ, Kraegen EW. helices in genomic and transcriptomic data. follicular helper NKT cells that provide Overexpression of manganese superoxide Genome Research. 2012; 22:1372-81. cognate help for B cell responses. Nature dismutase ameliorates high-fat diet- Immunology. 2012; 13:35-43. induced insulin resistance in rat skeletal muscle. American Journal of Physiology, Chang PP, Lee SK, Hu X, Davey G, Duan Endocrinology and Metabolism. 2012; G, Cho JH, Karupiah G, Sprent J, Heath 303:E798-805. WR, Bertram EM, Vinuesa CG. Breakdown C in repression of IFN-gamma mRNA leads Boslem E, Meikle PJ, Biden TJ. Roles of Caldon CE, Sergio CM, Kang J, to accumulation of self-reactive effector ceramide and sphingolipids in pancreatic Muthukaruppan A, Boersma MN, Stone A, CD8+ T cells. Journal of Immunology. beta-cell function and dysfunction. Islets. Barraclough J, Lee CS, Black MA, Miller 2012; 189:701-10. 2012; 4:177-87. LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Cyclin E2 Charchar FJ, Bloomer LD, Barnes TA, Boyman O, Krieg C, Homann D, Sprent J. overexpression is associated with Cowley MJ, Nelson CP, Wang Y, Denniff Homeostatic maintenance of T cells and endocrine resistance but not insensitivity M, Debiec R, Christofidou P, Nankervis S, natural killer cells. Cellular and Molecular to CDK2 inhibition in human breast cancer Dominiczak AF, Bani-Mustafa A, Life Sciences. 2012; 69:1597-608. cells. Molecular Cancer Therapeutics. Balmforth AJ, Hall AS, Erdmann J, 2012; 11:1488-99. Cambien F, Deloukas P, Hengstenberg C, Boyman O, Krieg C, Letourneau S, Packard C, Schunkert H, Ouwehand WH, Webster K, Surh CD, Sprent J. Selectively Campbell PD, Weinberg A, Chee J, Ford I, Goodall AH, Jobling MA, Samani NJ, expanding subsets of T cells in mice by Mariana L, Ayala R, Hawthorne WJ, Tomaszewski M. Inheritance of coronary injection of interleukin-2/antibody O'Connell PJ, Loudovaris T, Cowley MJ, artery disease in men: an analysis of the complexes: implications for Kay TW, Grey ST, Thomas HE. Expression role of the Y chromosome. Lancet. 2012; transplantation tolerance. Transplantation of pro- and antiapoptotic molecules of 379:915-22. Proceedings. 2012; 44:1032-4. the Bcl-2 family in human islets postisolation. Cell Transplantation. 2012; Chen Z, Sheng L, Shen H, Zhao Y, Wang S, Boyman O, Sprent J. The role of 21:49-60. Brink R, Rui L. Hepatic TRAF2 regulates interleukin-2 during homeostasis and glucose metabolism through enhancing activation of the immune system. Nature Chan CW, Kaplan W, Parish CR, Khachigian glucagon responses. Diabetes. 2012; Reviews Immunology. 2012; 12:180-90. LM. Reduced retinal microvascular 61:566-73. density, improved forepaw reach, Breit SN, Carrero JJ, Tsai VW, Yagoutifam comparative microarray and gene set Cheng K, Delghingaro-Augusto V, Nolan N, Luo W, Kuffner T, Bauskin AR, Wu L, enrichment analysis with c-jun targeting CJ, Turner N, Hallahan N, Andrikopoulos S, Jiang L, Barany P, Heimburger O, Murikami DNA enzyme. PLoS One 2012; Gunton JE. High passage MIN6 cells have MA, Apple FS, Marquis CP, Macia L, Lin S, 7:e39160. impaired insulin secretion with impaired Sainsbury A, Herzog H, Law M, Stenvinkel glucose and lipid oxidation. PloS One. P, Brown DA. Macrophage inhibitory Chan JY, Biden TJ, Laybutt DR. Cross-talk 2012; 7:e40868. cytokine-1 (MIC-1/GDF15) and between the unfolded protein response mortality in end-stage renal disease. and nuclear factor-kappaB signalling Chesi A, Kilaru A, Fang X, Cooper AA, Nephrology, Dialysis, Transplantation. pathways regulates cytokine-mediated Gitler AD. The role of the Parkinson's 2012; 27:70-5. beta cell death in MIN6 cells and isolated disease gene PARK9 in essential cellular mouse islets. Diabetologia. 2012; pathways and the manganese Brennan-Speranza TC, Henneicke H, 55:2999-3009. homeostasis network in yeast. PloS One. Gasparini SJ, Blankenstein KI, Heinevetter 2012; 7:e34178. U, Cogger VC, Svistounov D, Zhang Y, Chan MY, Nguyen ND, Center JR, Eisman Cooney GJ, Buttgereit F, Dunstan CR, JA, Nguyen TV. Absolute fracture-risk Chesworth R, Yulyaningsih E, Cappas E, Gundberg C, Zhou H, Seibel MJ. prediction by a combination of calcaneal Arnold J, Sainsbury A, Karl T. The response Osteoblasts mediate the adverse effects quantitative ultrasound and bone mineral of neuregulin 1 mutant mice to acute of glucocorticoids on fuel metabolism. The density. Calcified Tissue International. restraint stress. Neuroscience Letters. Journal of Clinical Investigation. 2012; 2012; 90:128-36. 2012; 515:82-6. 122:4172-89. Chan TD, Brink R. Affinity-based selection Christie MP, Whitten AE, King GJ, Hu SH, Buckle CH, De Leenheer E, Lawson MA, and the germinal center response. Jarrott RJ, Chen KE, Duff AP, Callow P, Yong K, Rabin N, Perry M, Vanderkerken K, Immunological Reviews. 2012; 247:11-23. Collins BM, James DE, Martin JL. Low- Croucher PI. Soluble rank ligand produced resolution solution structures of by myeloma cells causes generalised bone Chan TD, Wood K, Hermes JR, Butt D, Munc18:Syntaxin protein complexes loss in multiple myeloma. PloS One. 2012; Jolly CJ, Basten A, Brink R. Elimination of indicate an open binding mode driven by 7:e41127. germinal-center-derived self-reactive B the Syntaxin N-peptide. Proceedings of cells is governed by the location and the National Academy of Sciences USA. Burgess A, Lorca T, Castro A. Quantitative concentration of self-antigen. Immunity. 2012; 109:9816-21. live imaging of endogenous DNA 2012; 37:893-904.

72PUBLICATIONS Clark I, Atwood C, Bowen R, Paz-Filho G, Crequer A, Troeger A, Patin E, Ma CS, docking. Journal of Chemical Information Vissel B. Tumor necrosis factor-induced Picard C, Pedergnana V, Fieschi C, Lim A, and Modeling. 2012; 52:844-56. cerebral insulin resistance in Alzheimer's Abhyankar A, Gineau L, Mueller- disease links numerous treatment Fleckenstein I, Schmidt M, Taieb A, Dikic I, Daly RJ. Signalling through the rationales. Pharmacological Reviews. Krueger J, Abel L, Tangye SG, Orth G, grapevine. EMBO Reports. 2012; 2012; 64:1004-26. Williams DA, Casanova JL, Jouanguy E. 13:178-80. Human RHOH deficiency causes T cell Clark MB, Johnston RL, Inostroza-Ponta defects and susceptibility to EV-HPV Doyle KL, Hort YJ, Herzog H, Shine J. M, Fox AH, Fortini E, Moscato P, Dinger infections. The Journal of Clinical Neuropeptide Y and peptide YY have ME, Mattick JS. Genome-wide analysis of Investigation. 2012; 122:3239-47. distinct roles in adult mouse olfactory long noncoding RNA stability. Genome neurogenesis. Journal of Neuroscience Research. 2012; 22:885-98. Cunha C, Hort Y, Shine J, Doyle KL. Research. 2012; 90:1126-35. Morphological and behavioural changes Cliffe ST, Bloch DB, Suryani S, Kamsteeg occur following the X-ray irradiation of Dudgeon K, Rouet R, Famm K, Christ D. EJ, Avery DT, Palendira U, Church JA, the adult mouse olfactory Selection of human VH single domains Wainstein BK, Trizzino A, Lefranc G, neuroepithelium. BMC Neuroscience. with improved biophysical properties by Akatcherian C, Megarbane A, Gilissen C, 2012; 13:134. phage display. Methods in Molecular Moshous D, Reichenbach J, Misbah S, Biology. 2012; 911:383-97. Salzer U, Abinun M, Ong PY, Stepensky P, Curtis J, Newall H, Myles N, Shiers D, Ruga E, Ziegler JB, Wong M, Tangye SG, Samaras K. Considering metformin in Dudgeon K, Rouet R, Kokmeijer I, Schofield Lindeman R, Buckley MF, Roscioli T. cardiometabolic protection in psychosis. P, Stolp J, Langley D, Stock D, Christ D. Clinical, molecular, and cellular Acta Psychiatrica Scandinavica. 2012; General strategy for the generation of immunologic findings in patients with 126:302-3. human antibody variable domains with SP110-associated veno-occlusive disease increased aggregation resistance. with immunodeficiency syndrome. The Curtis J, Newall HD, Samaras K. The heart Proceedings of the National Academy of Journal of Allergy and Clinical of the matter: cardiometabolic care in Sciences USA. 2012; 109:10879-84. Immunology. 2012; 130:735-42 e6. youth with psychosis. Early Intervention in Psychiatry. 2012; 6:347-53. Duong JK, Roberts DM, Furlong TJ, Kumar Coates AS, Millar EK, O'Toole SA, Molloy SS, Greenfield JR, Kirkpatrick CM, Graham TJ, Viale G, Goldhirsch A, Regan MM, GG, Williams KM, Day RO. Metformin Gelber RD, Sun Z, Castiglione-Gertsch M, therapy in patients with chronic kidney Gusterson B, Musgrove EA, Sutherland disease. Diabetes, Obesity & Metabolism. RL. Prognostic interaction between 2012; 14:963-5. expression of p53 and estrogen receptor D in patients with node-negative breast Daly RJ. Targeting the human kinome for cancer: results from IBCSG Trials VIII and cancer therapy. Critical Reviews in IX. Breast Cancer Research. 2012; Oncogenesis. 2012; 17:vi-vii. 14:R143. Davey JR, Humphrey SJ, Junutula JR, Mishra AK, Lambright DG, James DE, E Cole AR. GSK3 as a sensor determining Stockli J. TBC1D13 is a Rab35 specific Eisman JA, Bogoch ER, Dell R, Harrington cell fate in the brain. Frontiers in gap that plays an important role In GLUT4 JT, McKinney RE, Jr., McLellan A, Mitchell Molecular Neuroscience. 2012; 5:4. trafficking in adipocytes. Traffic. 2012; PJ, Silverman S, Singleton R, Siris E. 13:1429-41. Making the first fracture the last fracture: Cooley N, Cowley MJ, Lin RC, Marasco S, ASBMR task force report on secondary Wong C, Kaye DM, Dart AM, Woodcock de Bock CE, Ardjmand A, Molloy TJ, Bone fracture prevention. Journal of Bone and EA. Influence of atrial fibrillation on SM, Johnstone D, Campbell DM, Shipman Mineral Research. 2012; 27:2039-46. microRNA expression profiles in left and KL, Yeadon TM, Holst J, Spanevello MD, right atria from patients with valvular Nelmes G, Catchpoole DR, Lincz LF, Boyd El-Hoss J, Sullivan K, Cheng T, Yu NY, heart disease. Physiological Genomics. AW, Burns GF, Thorne RF. The Fat1 cadherin Bobyn JD, Peacock L, Mikulec K, Baldock 2012; 44:211-9. is overexpressed and an independent P, Alexander IE, Schindeler A, Little DG. A prognostic factor for survival in paired murine model of neurofibromatosis type 1 Cowley MJ, Pinese M, Kassahn KS, diagnosis-relapse samples of precursor B- tibial pseudarthrosis featuring proliferative Waddell N, Pearson JV, Grimmond SM, cell acute lymphoblastic leukemia. Leukemia fibrous tissue and osteoclast-like cells. Biankin AV, Hautaniemi S, Wu J. PINA v2.0: 2012; 26:918-26. Journal of Bone and Mineral Research. mining interactome modules. Nucleic 2012; 27:68-78. Acids Research. 2012; 40:D862-5. Decressac M, Pain S, Chabeauti PY, Frangeul L, Thiriet N, Herzog H, Vergote J, Chalon Esapa CT, Head RA, Jeyabalan J, Evans H, Cowley MJ, Weinberg A, Zammit N, S, Jaber M, Gaillard A. Neuroprotection by Hough TA, Cheeseman MT, McNally EG, Walters SN, Hawthorne WJ, Loudovaris T, neuropeptide Y in cell and animal models Carr AJ, Thomas GP, Brown MA, Croucher Thomas H, Kay T, Gunton JE, Alexander SI, of Parkinson's disease. Neurobiology of PI, Brown SD, Cox RD, Thakker RV. A Kaplan W, Chapman J, O'Connell PJ, Grey Aging. 2012; 33:2125-37. mouse with an N-Ethyl-N-Nitrosourea ST. Human islets express a marked pro- (ENU) induced Trp589Arg Galnt3 inflammatory molecular signature prior to Dietzen M, Zotenko E, Hildebrandt A, mutation represents a model for transplantation. Cell Transplantation Lengauer T. On the applicability of elastic hyperphosphataemic familial tumoural 2012; 21:2063-78 network normal modes in small-molecule calcinosis. PloS One. 2012; 7:e43205.

73PUBLICATIONS Estrada K, Styrkarsdottir U, Evangelou E, (GPR)40-dependent potentiation of Gloss BS, Patterson KI, Barton CA, Hsu YH, Duncan EL, Ntzani EE, Oei L, insulin secretion in mouse islets is Gonzalez M, Scurry JP, Hacker NF, Albagha OM, Amin N, Kemp JP, Koller DL, mediated by protein kinase D1. Sutherland RL, O'Brien PM, Clark SJ. Li G, Liu CT, Minster RL, Moayyeri A, Diabetologia. 2012; 55:2682-92. Integrative genome-wide expression and Vandenput L, Willner D, Xiao SM, Yerges- promoter DNA methylation profiling Armstrong LM, Zheng HF, Alonso N, identifies a potential novel panel of Eriksson J, Kammerer CM, Kaptoge SK, ovarian cancer epigenetic biomarkers. Leo PJ, Thorleifsson G, Wilson SG, Wilson Cancer Letters. 2012; 318:76-85. JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, F Gray EE, Friend S, Suzuki K, Phan TG, Garcia M, Garcia-Giralt N, Giroux S, Ferrari S, Bianchi ML, Eisman JA, Foldes Cyster JG. Subcapsular sinus macrophage Hallmans G, Hocking LJ, Husted LB, AJ, Adami S, Wahl DA, Stepan JJ, de fragmentation and CD169(+) Bleb Jameson KA, Khusainova R, Kim GS, Vernejoul MC, Kaufman JM. Osteoporosis acquisition by closely associated IL-17- Kooperberg C, Koromila T, Kruk M, in young adults: pathophysiology, committed innate-like lymphocytes. PloS Laaksonen M, Lacroix AZ, Lee SH, Leung diagnosis, and management. Osteoporosis One. 2012; 7:e38258. PC, Lewis JR, Masi L, Mencej-Bedrac S, International. 2012; 23:2735-48. Nguyen TV, Nogues X, Patel MS, Prezelj J, Greenfield JR, McCormack AI. Medication Rose LM, Scollen S, Siggeirsdottir K, Smith Fisher A, Bonner C, Biankin AV, Juraskova to prevent breast cancer - too much to AV, Svensson O, Trompet S, Trummer O, I. Factors influencing intention to undergo swallow? The Medical Journal of van Schoor NM, Woo J, Zhu K, Balcells S, whole genome screening in future Australia. 2012; 196:314. Brandi ML, Buckley BM, Cheng S, healthcare: A single-blind parallel-group Christiansen C, Cooper C, Dedoussis G, randomised trial. Preventive Medicine. Gregersen S, Samocha-Bonet D, Ford I, Frost M, Goltzman D, Gonzalez- 2012; 55:514-20. Heilbronn LK, Campbell LV. Inflammatory Macias J, Kahonen M, Karlsson M, and oxidative stress responses to high- Khusnutdinova E, Koh JM, Kollia P, Fiume M, Smith EJ, Brook A, Strbenac D, carbohydrate and high-fat meals in Langdahl BL, Leslie WD, Lips P, Ljunggren Turner B, Mezlini AM, Robinson MD, healthy humans. Journal of Nutrition and O, Lorenc RS, Marc J, Mellstrom D, Wodak SJ, Brudno M. Savant Genome Metabolism. 2012; 2012:e238056. Obermayer-Pietsch B, Olmos JM, Browser 2: visualization and analysis for Pettersson-Kymmer U, Reid DM, Riancho population-scale genomics. Nucleic Acids Gudjonsson T, Altmeyer M, Savic V, JA, Ridker PM, Rousseau F, Slagboom PE, Research. 2012; 40:W615-21. Toledo L, Dinant C, Grofte M, Bartkova J, Tang NL, Urreizti R, Van Hul W, Viikari J, Poulsen M, Oka Y, Bekker-Jensen S, Zarrabeitia MT, Aulchenko YS, Castano- Forbes S, Herzog H, Cox HM. A role for Mailand N, Neumann B, Heriche JK, Betancourt M, Grundberg E, Herrera L, neuropeptide Y in the gender-specific Shearer R, Saunders D, Bartek J, Lukas J, Ingvarsson T, Johannsdottir H, Kwan T, Li gastrointestinal, corticosterone and Lukas C. TRIP12 and UBR5 suppress R, Luben R, Medina-Gomez C, Palsson ST, feeding responses to stress. British spreading of chromatin ubiquitylation at Reppe S, Rotter JI, Sigurdsson G, van Journal of Pharmacology. 2012; damaged chromosomes. Cell. 2012; Meurs JB, Verlaan D, Williams FM, Wood 166:2307-16. 150:697-709. AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Gunton JE, Sisavanh M, Stokes RA, Satin Clark GR, Cummings SR, Danoy P, J, Satin LS, Zhang M, Liu SM, Cai W, Dennison EM, Eastell R, Eisman JA, Cheng K, Cooney GJ, Laybutt DR, So T, Gudnason V, Hofman A, Jackson RD, Molero JC, Grey ST, Andres DA, Rolph Jones G, Jukema JW, Khaw KT, Lehtimaki G MS, Mackay CR. Mice deficient in GEM T, Liu Y, Lorentzon M, McCloskey E, Gascoigne DK, Cheetham SW, Cattenoz GTPase show abnormal glucose Mitchell BD, Nandakumar K, Nicholson PB, Clark MB, Amaral PP, Taft RJ, Wilhelm homeostasis due to defects in beta-cell GC, Oostra BA, Peacock M, Pols HA, D, Dinger ME, Mattick JS. Pinstripe: a calcium handling. PloS One. 2012; Prince RL, Raitakari O, Reid IR, Robbins J, suite of programs for integrating 7:e39462. Sambrook PN, Sham PC, Shuldiner AR, transcriptomic and proteomic datasets Tylavsky FA, van Duijn CM, Wareham NJ, identifies novel proteins and improves Cupples LA, Econs MJ, Evans DM, Harris differentiation of protein-coding and non- TB, Kung AW, Psaty BM, Reeve J, Spector coding genes. Bioinformatics. 2012; TD, Streeten EA, Zillikens MC, 28:3042-50. Thorsteinsdottir U, Ohlsson C, Karasik D, H Richards JB, Brown MA, Stefansson K, Girgis CM, Cheng K, Scott CH, Gunton JE. Heng SC, Slavin MA, Chen SC, Heath CH, Uitterlinden AG, Ralston SH, Ioannidis JP, Novel links between HIFs, type 2 diabetes, Nguyen Q, Billah B, Nation RL, Kong DC. Kiel DP, Rivadeneira F. Genome-wide and metabolic syndrome. Trends in Hospital costs, length of stay and meta-analysis identifies 56 bone mineral Endocrinology and Metabolism. 2012; mortality attributable to invasive density loci and reveals 14 loci associated 23:372-80. scedosporiosis in haematology patients. with risk of fracture. Nature Genetics. The Journal of Antimicrobial 2012; 44:491-501. Girgis CM, Gunton JE, Cheung NW. The Chemotherapy. 2012; 67:2274-82. influence of ethnicity on the development Ferdaoussi M, Bergeron V, Zarrouki B, of type 2 diabetes mellitus in women with Ho-Pham LT, Vu BQ, Lai TQ, Nguyen ND, Kolic J, Cantley J, Fielitz J, Olson EN, gestational diabetes: a prospective study Nguyen TV. Vegetarianism, bone loss, Prentki M, Biden T, MacDonald PE, and review of the literature. ISRN fracture and vitamin D: a longitudinal Poitout V. G protein-coupled receptor Endocrinology. 2012; 2012:e?341638. study in Asian vegans and non-vegans.

74PUBLICATIONS European Journal of Clinical Nutrition. Hurtado MD, Acosta A, Riveros PP, Baum Joo SY, Chung YS, Choi B, Kim M, Kim JH, 2012; 66:75-82. BJ, Ukhanov K, Brown AR, Dotson CD, Jun TG, Chang J, Sprent J, Surh CD, Joh Herzog H, Zolotukhin S. Distribution of y- JW, Kim SJ. Systemic human T cell Hoehn KL, Turner N, Cooney GJ, James receptors in murine lingual epithelia. PloS developmental processes in humanized DE. Phenotypic discrepancies in acetyl- One. 2012; 7:e46358. mice cotransplanted with human fetal CoA carboxylase 2-deficient mice. The thymus/liver tissue and hematopoietic Journal of Biological Chemistry. 2012; stem cells. Transplantation. 2012; 287:15801; author reply 15802. 94:1095-1102.

Hoinka J, Zotenko E, Friedman A, Sauna ZE, Przytycka TM. Identification of I sequence-structure RNA binding motifs Iyoda T, Zhang F, Sun L, Hao F, Schmitz- for SELEX-derived aptamers. Peiffer C, Xu X, Cui MZ. Lysophosphatidic Bioinformatics. 2012; 28:i215-23. acid induces early growth response-1 K (Egr-1) protein expression via protein Kalyuga M, Gallego-Ortega D, Lee HJ, Holmes FE, Armenaki A, Iismaa TP, kinase Cdelta-regulated extracellular Roden DL, Cowley MJ, Caldon CE, Stone Einstein EB, Shine J, Picciotto MR, Wynick signal-regulated kinase (ERK) and c-Jun A, Allerdice SL, Valdes-Mora F, D, Zachariou V. Galanin negatively N-terminal kinase (JNK) activation in Launchbury R, Statham AL, Armstrong N, modulates opiate withdrawal via galanin vascular smooth muscle cells. The Journal Alles MC, Young A, Egger A, Au W, Piggin receptor 1. Psychopharmacology (Berl) of Biological Chemistry. 2012; CL, Evans CJ, Ledger A, Brummer T, 2012; 220:619-25. 287:22635-42. Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Holt LJ, Turner N, Mokbel N, Trefely S, Clark SJ, Carroll JS, Ormandy CJ. ELF5 Kanzleiter T, Kaplan W, Ormandy CJ, Daly suppresses estrogen sensitivity and RJ, Cooney GJ. Grb10 regulates the underpins the acquisition of antiestrogen development of fiber number in skeletal resistance in luminal breast cancer. PLoS muscle. FASEB Journal. 2012; 26:3658-69. J Biology. 2012; 10:e1001461. Jackson KJ, Wang Y, Gaeta BA, Pomat W, Hossack T, Patel MI, Huo A, Brenner P, Siba P, Rimmer J, Sewell WA, Collins AM. Kao SC, Armstrong N, Condon B, Griggs K, Yuen C, Spernat D, Mathews J, Haynes Divergent human populations show McCaughan B, Maltby S, Wilson A, AM, Sutherland R, del Prado W, Stricker P. extensive shared IGK rearrangements in Henderson DW, Klebe S. Aquaporin 1 is an Location and pathological characteristics peripheral blood B cells. Immunogenetics. independent prognostic factor in pleural of cancers in radical prostatectomy 2012; 64:3-14. malignant mesothelioma. Cancer. 2012; specimens identified by transperineal 118:2952-61. biopsy compared to transrectal biopsy. The Jacovetti C, Abderrahmani A, Parnaud G, Journal of Urology. 2012; 188:781-5. Jonas JC, Peyot ML, Cornu M, Laybutt R, Kastenberger I, Lutsch C, Herzog H, Meugnier E, Rome S, Thorens B, Prentki Schwarzer C. Influence of sex and genetic Hu SH, Whitten AE, King GJ, Jones A, M, Bosco D, Regazzi R. MicroRNAs background on anxiety-related and Rowland AF, James DE, Martin JL. The contribute to compensatory beta cell stress-induced behaviour of weak complex between RhoGAP protein expansion during pregnancy and obesity. prodynorphin-deficient mice. PloS One. ARHGAP22 and signal regulatory protein The Journal of Clinical Investigation. 2012; 7:e34251. 14-3-3 has 1:2 stoichiometry and a 2012; 122:3541-51. single peptide binding mode. PloS One. Khor EC, Baldock P. The NPY System and 2012; 7:e41731. Jankova L, Robertson G, Chan C, Tan KL, its Neural and Neuroendocrine Regulation Kohonen-Corish M, Fung CL, Clarke C, Lin of Bone. Current Osteoporosis Reports. Humphrey SJ, James DE. Uncaging akt. BP, Molloy M, Chapuis PH, Bokey L, Dent 2012; 10:160-8. Science Signaling. 2012; 5:pe20. OF, Clarke SJ. Glutathione S-transferase Pi expression predicts response to adjuvant King C, Sprent J. Emerging cellular Humphris JL, Chang DK, Johns AL, chemotherapy for stage C colon cancer: a networks for regulation of T follicular Scarlett CJ, Pajic M, Jones MD, Colvin EK, matched historical control study. BMC helper cells. Trends in Immunolog y. 2012; Nagrial A, Chin VT, Chantrill LA, Samra JS, Cancer. 2012; 12:196. 33:59-65. Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV. Johnson JL, Hall TE, Dyson JM, Sonntag C, King GJ, Stockli J, Hu SH, Winnen B, The prognostic and predictive value of Ayers K, Berger S, Gautier P, Mitchell C, Duprez WG, Meoli CC, Junutula JR, Jarrott serum CA19.9 in pancreatic cancer. Hollway GE, Currie PD. Scube activity is RJ, James DE, Whitten AE, Martin JL. Annals of Oncology. 2012; 23:1713-22. necessary for Hedgehog signal Membrane curvature protein exhibits transduction in vivo. Developmental interdomain flexibility and binds a small Huo AS, Hossack T, Symons JL, Pebenito Biology. 2012; 368:193-202. GTPase. The Journal of Biological R, Delprado WJ, Brenner P, Stricker PD. Chemistry. 2012; 287:40996-1006. Accuracy of primary systematic template Jonsson B, Strom O, Eisman JA, guided transperineal biopsy of the Papaioannou A, Siris ES, Tosteson A, Kanis Kirschner MB, Cheng YY, Badrian B, Kao prostate for locating prostate cancer: a JA. Comment on: Cost-effectiveness of SC, Creaney J, Edelman JJ, Armstrong NJ, comparison with radical prostatectomy denosumab for the treatment of Vallely MP, Musk AW, Robinson BW, specimens. The Journal of Urology. 2012; postmenopausal osteoporosis. McCaughan BC, Klebe S, Mutsaers SE, 187:2044-50. Osteoporosis International. 2012; van Zandwijk N, Reid G. Increased 23:2063-5. circulating miR-625-3p: a potential

75PUBLICATIONS biomarker for patients with malignant BMP and activin membrane-bound Maple-Brown LJ, Hughes J, Piers LS, Ward pleural mesothelioma. Journal of Thoracic inhibitor (BAMBI) as a potent negative LC, Meerkin J, Eisman JA, Center JR, Oncology. 2012; 7:1184-91. regulator of adipogenesis and modulator Pocock NA, Jerums G, O'Dea K. Increased of autocrine/paracrine adipogenic factors. bone mineral density in Aboriginal and Krautler NJ, Kana V, Kranich J, Tian Y, Diabetes. 2012; 61:124-36. Torres Strait Islander Australians: impact Perera D, Lemm D, Schwarz P, Armulik A, of body composition differences. Bone. Browning JL, Tallquist M, Buch T, Oliveira- 2012; 51:123-30. Martins JB, Zhu C, Hermann M, Wagner U, Brink R, Heikenwalder M, Aguzzi A. Marino E, Grey ST. B cells as effectors and Follicular dendritic cells emerge from regulators of autoimmunity. ubiquitous perivascular precursors. Cell. M Autoimmunity. 2012; 45:377-87. 2012; 150:194-206. Ma CS, Avery DT, Chan A, Batten M, Bustamante J, Boisson-Dupuis S, Marino E, Tan B, Binge L, Mackay CR, Arkwright PD, Kreins AY, Averbuch D, Grey ST. B-cell cross-presentation of Engelhard D, Magdorf K, Kilic SS, autologous antigen precipitates diabetes. Minegishi Y, Nonoyama S, French MA, Diabetes. 2012; 61:2893-905. Choo S, Smart JM, Peake J, Wong M, L Gray P, Cook MC, Fulcher DA, Casanova Mattick JS. Rocking the foundations of Lauer AM, Fuchs PA, Ryugo DK, Francis JL, Deenick EK, Tangye SG. Functional molecular genetics. Proceedings of the HW. Efferent synapses return to inner hair STAT3 deficiency compromises the National Academy of Sciences USA. cells in the aging cochlea. Neurobiology of generation of human T follicular helper 2012; 109:16400-1. Aging. 2012; 33:2892-902. cells. Blood. 2012; 119:3997-4008. McDonald MM, Morse A, Mikulec K, Lee HJ, Ormandy CJ. Interplay between Ma CS, Deenick EK, Batten M, Tangye SG. Peacock L, Yu N, Baldock PA, Birke O, Liu progesterone and prolactin in mammary The origins, function, and regulation of T M, Ke HZ, Little DG. Inhibition of development and implications for breast follicular helper cells. The Journal of sclerostin by systemic treatment with cancer. Molecular and Cellular Experimental Medicine. 2012; sclerostin antibody enhances healing of Endocrinology. 2012; 357:101-7. 209:1241-53. proximal tibial defects in ovariectomized rats. Journal of Orthopaedic Research. Lee HJ, Ormandy CJ. Elf5, hormones and Macia L, Thorburn AN, Binge LC, Marino 2012; 30:1541-8. cell fate. Trends in Endocrinology and E, Rogers KE, Maslowski KM, Vieira AT, Metabolism. 2012; 23:292-8. Kranich J, Mackay CR. Microbial influences Milinkeviciute G, Gentile C, Neely GG. on epithelial integrity and immune Drosophila as a tool for studying the Lee P, Greenfield JR, Gilbert K, Campbell function as a basis for inflammatory conserved genetics of pain. Clinical LV. Recreational drug use in type 1 diseases. Immunological Reviews. 2012; Genetics. 2012; 82:359-66. diabetes: an invisible accomplice to poor 245:164-76. glycaemic control? Internal Medicine Mladenova D, Kohonen-Corish MR. Journal. 2012; 42:198-202. Macia L, Tsai VW, Nguyen AD, Johnen H, Mouse models of inflammatory bowel Kuffner T, Shi YC, Lin S, Herzog H, Brown disease - insights into the mechanisms of Lo JC, Jamsai D, O'Connor AE, Borg C, DA, Breit SN, Sainsbury A. Macrophage inflammation-associated colorectal Clark BJ, Whisstock JC, Field MC, Adams inhibitory cytokine 1 (MIC-1/GDF15) cancer. In Vivo. 2012; 26:627-46. V, Ishikawa T, Aitken RJ, Whittle B, decreases food intake, body weight and Goodnow CC, Ormandy CJ, O'Bryan MK. improves glucose tolerance in mice on Montavon C, Gloss BS, Warton K, Barton RAB-Like 2 has an essential role in male normal & obesogenic diets. PloS One. CA, Statham AL, Scurry JP, Tabor B, fertility, sperm intra-flagellar transport, 2012; 7:e34868. Nguyen TV, Qu W, Samimi G, Hacker NF, and tail assembly. PLoS Genetics. 2012; Sutherland RL, Clark SJ, O'Brien PM. 8:e1002969. Macia L, Yulyaningsih E, Pangon L, Prognostic and diagnostic significance of Nguyen AD, Lin S, Shi YC, Zhang L, Bijker DNA methylation patterns in high grade Locke WJ, Clark SJ. Epigenome M, Grey S, Mackay F, Herzog H, Sainsbury serous ovarian cancer. Gynecologic remodelling in breast cancer: insights from A. Neuropeptide y1 receptor in immune Oncology. 2012; 124:582-8. an early in vitro model of carcinogenesis. cells regulates inflammation and insulin Breast Cancer Research. 2012; 14:215. resistance associated with diet-induced Montgomery MK, Buttemer WA, Hulbert obesity. Diabetes. 2012; 61:3228-38. AJ. Does the oxidative stress theory of Loebbermann J, Thornton H, Durant L, aging explain longevity differences in Sparwasser T, Webster KE, Sprent J, Mann KM, Ward JM, Yew CC, Kovochich birds? II. Antioxidant systems and Culley FJ, Johansson C, Openshaw PJ. A, Dawson DW, Black MA, Brett BT, oxidative damage. Experimental Regulatory T cells expressing granzyme B Sheetz TE, Dupuy AJ, Chang DK, Biankin Gerontology. 2012; 47:211-22. play a critical role in controlling lung AV, Waddell N, Kassahn KS, Grimmond inflammation during acute viral infection. SM, Rust AG, Adams DJ, Jenkins NA, Montgomery MK, Hulbert AJ, Buttemer Mucosal Immunology. 2012; 5:161-72. Copeland NG. Sleeping Beauty WA. Metabolic rate and membrane fatty mutagenesis reveals cooperating acid composition in birds: a comparison Luo X, Hutley LJ, Webster JA, Kim YH, Liu mutations and pathways in pancreatic between long-living parrots and short- DF, Newell FS, Widberg CH, Bachmann A, adenocarcinoma. Proceedings of the living fowl. Journal of Comparative Turner N, Schmitz-Peiffer C, Prins JB, National Academy of Sciences USA. Physiology. 2012; 182:127-37. Yang GS, Whitehead JP. Identification of 2012; 109:5934-41.

76PUBLICATIONS Montgomery MK, Hulbert AJ, Buttemer Sainsbury A. Y1 and y5 receptors are both linked lymphoproliferative disease caused WA. Does the oxidative stress theory of required for the regulation of food intake by selective pressure from Epstein-Barr aging explain longevity differences in and energy homeostasis in mice. PloS virus. The Journal of Experimental birds? I. Mitochondrial ROS production. One. 2012; 7:e40191. Medicine. 2012; 209:913-24. Experimental Gerontology. 2012; 47:203-10. Nguyen HT, Pourian M, Bystrom B, Dahlin Pangon L, Van Kralingen C, Abas M, Daly I, Duc PT, Nguyen TV, von Schoultz B, RJ, Musgrove EA, Kohonen-Corish MR. Moore BM, Savdie R, Pebenito RA, Hirschberg AL. Low aglycone content in The PDZ-binding motif of MCC is Haynes AM, Matthews J, Delprado W, commercial soy drink products. Asia phosphorylated at position -1 and Rasiah KK, Stricker PD. The impact of Pacific Journal of Clinical Nutrition. 2012; controls lamellipodia formation in colon nerve sparing on incidence and location of 21:52-6. epithelial cells. Biochimica et Biophysica positive surgical margins in radical Acta. 2012; 1823:1058-67. prostatectomy. BJU International. 2012; Nguyen HT, von Schoultz B, Nguyen TV, 109:533-8. Dzung DN, Duc PT, Thuy VT, Hirschberg Patel SA, Hoehn KL, Lawrence RT, AL. Vitamin D deficiency in northern Sawbridge L, Talbot NA, Tomsig JL, Turner Moran-Jones K, Ledger A, Naylor MJ. Vietnam: Prevalence, risk factors and N, Cooney GJ, Whitehead JP, Kraegen EW, beta1 integrin deletion enhances associations with bone mineral density. Cleasby ME. Overexpression of the progression of prostate cancer in the Bone. 2012; 51:1029-34. adiponectin receptor AdipoR1 in rat TRAMP mouse model. Scientific Reports. skeletal muscle amplifies local insulin 2012; 2:526. Nguyen TV, Eisman JA. Genetics and the sensitivity. Endocrinology. 2012; individualized prediction of fracture. 153:5231-46. Muniak MA, Mayko ZM, Ryugo DK, Current Osteoporosis Reports. 2012; Portfors CV. Preparation of an awake 10:236-44. Perez-Mancera PA, Rust AG, van der mouse for recording neural responses and Weyden L, Kristiansen G, Li A, Sarver AL, injecting tracers. Journal of Visualized Nguyen TV, Eisman JA, Center JR, Pocock Silverstein KA, Grutzmann R, Aust D, Experiments. 2012; 64. NA, Jones G, March L, Clifton-Bligh R, Rummele P, Knosel T, Herd C, Stemple DL, Naganathan V, Seibel MJ. In memoriam: Kettleborough R, Brosnan JA, Li A, Morgan Myint KS, Greenfield JR, Farooqi IS, Philip Neil Sambrook. Osteoporosis R, Knight S, Yu J, Stegeman S, Collier LS, Henning E, Holst JJ, Finer N. Prolonged International. 2012; 23:1835-6. ten Hoeve JJ, de Ridder J, Klein AP, successful therapy for hyperinsulinaemic Goggins M, Hruban RH, Chang DK, Biankin hypoglycaemia after gastric bypass: the AV, Grimmond SM, Wessels LF, Wood SA, pathophysiological role of GLP1 and its Iacobuzio-Donahue CA, Pilarsky C, response to a somatostatin analogue. Largaespada DA, Adams DJ, Tuveson DA. European Journal of Endocrinology. The deubiquitinase USP9X suppresses 2012; 166:951-5. O pancreatic ductal adenocarcinoma. O'Donnell L, Rhodes D, Smith SJ, Merriner Nature. 2012; 486:266-70. DJ, Clark BJ, Borg C, Whittle B, O'Connor AE, Smith LB, McNally FJ, de Kretser DM, Peters KM, Edwards SL, Nair SS, French Goodnow CC, Ormandy CJ, Jamsai D, JD, Bailey PJ, Salkield K, Stein S, Wagner S, O'Bryan MK. An essential role for katanin Francis GD, Clark SJ, Brown MA. Androgen N p80 and microtubule severing in male receptor expression predicts breast Neely GG, Rao S, Costigan M, Mair N, gamete production. PLoS Genetics. 2012; cancer survival: the role of genetic and Racz I, Milinkeviciute G, Meixner A, 8:e1002698. epigenetic events. BMC Cancer. 2012; Nayanala S, Griffin RS, Belfer I, Dai F, 12:132. Smith S, Diatchenko L, Marengo S, Omsland TK, Holvik K, Meyer HE, Center Haubner BJ, Novatchkova M, Gibson D, JR, Emaus N, Tell GS, Schei B, Tverdal A, Pierroz DD, Bonnet N, Bianchi EN, Maixner W, Pospisilik JA, Hirsch E, Gjesdal CG, Grimnes G, Forsmo S, Eisman Bouxsein ML, Baldock PA, Rizzoli R, Ferrari Whishaw IQ, Zimmer A, Gupta V, Sasaki J, JA, Sogaard AJ. Hip fractures in Norway SL. Deletion of beta-adrenergic receptor Kanaho Y, Sasaki T, Kress M, Woolf CJ, 1999-2008: time trends in total 1, 2, or both leads to different bone Penninger JM. Construction of a global incidence and second hip fracture rates. A phenotypes and response to mechanical pain systems network highlights NOREPOS study. European Journal of stimulation. Journal of Bone and Mineral phospholipid signaling as a regulator of Epidemiology. 2012; 27:807-14. Research. 2012; 27:1252-62. heat nociception. PLoS Genetics. 2012; 8:e1003071. Pineda SS, Wilson D, Mattick JS, King GF. The lethal toxin from Australian funnel- Newall H, Myles N, Ward PB, Samaras K, web spiders is encoded by an intronless Shiers D, Curtis J. Efficacy of metformin gene. PloS One. 2012; 7:e43699. for prevention of weight gain in psychiatric P populations: a review. International Palendira U, Low C, Bell AI, Ma CS, Abbott Piret SE, Esapa CT, Gorvin CM, Head R, Clinical Psychopharmacology. 2012; RJ, Phan TG, Riminton DS, Choo S, Smart Loh NY, Devuyst O, Thomas G, Brown SD, 27:69-75. JM, Lougaris V, Giliani S, Buckley RH, Brown M, Croucher P, Cox R, Thakker RV. Grimbacher B, Alvaro F, Klion AD, Nichols A mouse model of early-onset renal Nguyen AD, Mitchell NF, Lin S, Macia L, KE, Adelstein S, Rickinson AB, Tangye SG. failure due to a xanthine dehydrogenase Yulyaningsih E, Baldock PA, Enriquez RF, Expansion of somatically reverted nonsense mutation. PloS One. 2012; Zhang L, Shi YC, Zolotukhin S, Herzog H, memory CD8+ T cells in patients with X- 7:e45217.

77PUBLICATIONS Pjetri E, Adan RA, Herzog H, de Haas R, Rooman I, Real FX. Pancreatic ductal Samaras K, Sachdev PS. Diabetes and the Oppelaar H, Spierenburg HA, Olivier B, Kas adenocarcinoma and acinar cells: a matter elderly brain: sweet memories? MJ. NPY receptor subtype specification of differentiation and development? Gut. Therapeutic Advances in Endocrinology for behavioral adaptive strategies during 2012; 61:449-58. and Metabolism. 2012; 3:189-96. limited food access. Genes, Brain, and Behavior. 2012; 11:105-12. Roring M, Herr R, Fiala GJ, Heilmann K, Samimi G, Ring BZ, Ross DT, Seitz RS, Braun S, Eisenhardt AE, Halbach S, Capper Sutherland RL, O'Brien PM, Hacker NF, Polhill T, Zhang GY, Hu M, Sawyer A, Zhou D, von Deimling A, Schamel WW, Huh WK. TLE3 expression is associated JJ, Saito M, Webster KE, Wang Y, Wang Y, Saunders DN, Brummer T. Distinct with sensitivity to taxane treatment in Grey ST, Sprent J, Harris DC, Alexander SI, requirement for an intact dimer interface ovarian carcinoma. Cancer Epidemiology, Wang YM. IL-2/IL-2Ab complexes induce in wild-type, V600E and kinase-dead B- Biomarkers & Prevention. 2012; 21:273-9. regulatory T cell expansion and protect Raf signalling. The EMBO Journal. 2012; against proteinuric CKD. Journal of the 31:2629-47. Samocha-Bonet D, Campbell LV, Mori TA, American Society of Nephrology. 2012; Croft KD, Greenfield JR, Turner N, 23:1303-8. Rouet R, Dudgeon K, Christ D. Generation Heilbronn LK. Overfeeding reduces insulin of human single domain antibody sensitivity and increases oxidative stress, Poursoltan P, Currey N, Pangon L, van repertoires by kunkel mutagenesis. without altering markers of mitochondrial Kralingen C, Selinger CI, Mahar A, Cooper Methods in Molecular Biology. 2012; content and function in humans. PloS WA, Kennedy CW, McCaughan BC, Trent 907:195-209. One. 2012; 7:e36320. R, Kohonen-Corish MR. Loss of heterozygosity of the Mutated in Colorectal Rouet R, Lowe D, Dudgeon K, Roome B, Samocha-Bonet D, Chisholm DJ, Tonks K, Cancer gene is not associated with Schofield P, Langley D, Andrews J, Campbell LV, Greenfield JR. Insulin- promoter methylation in non-small cell lung Whitfeld P, Jermutus L, Christ D. sensitive obesity in humans - a 'favorable cancer. Lung Cancer. 2012; 77:272-6. Expression of high-affinity human fat' phenotype? Trends in Endocrinology antibody fragments in bacteria. Nature and Metabolism. 2012; 23:116-24. Protter D, Lang C, Cooper AA. Protocols. 2012; 7:364-73. alphaSynuclein and mitochondrial Saunders DN, Tindall EA, Shearer RF, dysfunction: A pathogenic partnership in Ryugo DK, Menotti-Raymond M. Feline Roberson J, Decker A, Wilson JA, Hayes Parkinson's Disease? Parkinson's Disease. deafness. The Veterinary Clinics of North VM. A novel SERPINA1 mutation causing 2012; 2012:829207. America. Small Animal Practice. 2012; serum alpha(1)-antitrypsin deficiency. 42:1179-207. PloS One. 2012; 7:e51762.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, R Sutherland RL, Kench JG. High Gleason Raddatz K, Frangioudakis G, Diakanastasis S grade carcinoma at a positive surgical B, Liao BM, Leitges M, Schmitz-Peiffer C. Sainsbury A, Zhang L. Role of the margin predicts biochemical failure after Deletion of protein kinase Cepsilon in mice hypothalamus in the neuroendocrine radical prostatectomy and may guide has limited effects on liver metabolite regulation of body weight and adjuvant radiotherapy. BJU International. levels but alters fasting ketogenesis and composition during energy deficit. 2012; 109:1794-800. gluconeogenesis. Diabetologia. 2012; Obesity Reviews. 2012; 13:234-57. 55:2789-93. Savdie R, Symons J, Spernat D, Yuen C, Pe Samaras K. The burden of diabetes and Benito RA, Haynes AM, Matthews J, Ren LP, Chan SM, Zeng XY, Laybutt DR, hyperlipidemia in treated HIV infection Rasiah KK, Jagavkar RS, Yu C, Fogarty G, Iseli TJ, Sun RQ, Kraegen EW, Cooney GJ, and approaches for cardiometabolic Kattan MW, Brenner P, Sutherland RL, Turner N, Ye JM. Differing endoplasmic care. Current HIV/AIDS Reports. 2012; Stricker PD. High-dose rate reticulum stress response to excess 9:206-17. brachytherapy compared with open lipogenesis versus lipid oversupply in radical prostatectomy for the treatment relation to hepatic steatosis and insulin Samaras K, Connolly SM, Lord RV, of high-risk prostate cancer: 10 year resistance. PloS One. 2012; 7:e30816. Macdonald P, Hayward CS. Take heart: biochemical freedom from relapse. BJU bariatric surgery in obese patients with International. 2012; 110 Suppl 4:71-6. Reznick J, Preston E, Wilks DL, Beale SM, severe heart failure. Two case reports. Turner N, Cooney GJ. Altered feeding Heart, Lung & Circulation. 2012; Schmid E, Nogalo M, Bechrakis NE, differentially regulates circadian rhythms 21:847-9. Fischer-Colbrie R, Tasan R, Sperk G, and energy metabolism in liver and Theurl M, Beer AG, Kirchmair R, Herzog H, muscle of rats. Biochimica et Biophysica Samaras K, Crawford J, Baune BT, Troger J. Secretoneurin, substance P and Acta. 2012; 1832:228-238. Campbell LV, Smith E, Lux O, Brodaty H, neuropeptide Y in the oxygen-induced Trollor JN, Sachdev P. The value of the retinopathy in C57Bl/6N mice. Peptides. Robinson MD, Strbenac D, Stirzaker C, metabolic syndrome concept in elderly 2012; 37:252-7. Statham AL, Song J, Speed TP, Clark SJ. adults: is it worth less than the sum of its Copy-number-aware differential analysis parts? Journal of the American Geriatrics Schonrock N, Harvey RP, Mattick JS. Long of quantitative DNA sequencing data. Society. 2012; 60:1734-41. Noncoding RNAs in Cardiac Development Genome Research. 2012; 22:2489-96. and Pathophysiology. Circulation Research. 2012; 111:1349-62.

78PUBLICATIONS Shi YC, Baldock PA. Central and peripheral Stone A, Sutherland RL, Musgrove EA. Tangye SG, Brink R. A helping hand from mechanisms of the NPY system in the Inhibitors of cell cycle kinases: recent neutrophils in T cell-independent antibody regulation of bone and adipose tissue. advances and future prospects as cancer responses? Nature Immunology. 2012; Bone. 2012; 50:430-6. therapeutics. Critical Reviews in 13:111-3. Oncogenesis. 2012; 17:175-98. Shi YC, Hammerle CM, Lee IC, Turner N, Tangye SG, Deenick EK, Palendira U, Ma Nguyen AD, Riepler SJ, Lin S, Sainsbury A, Stone A, Valdes-Mora F, Gee JM, Farrow CS. T cell-B cell interactions in primary Herzog H, Zhang L. Adult-onset PYY L, McClelland RA, Fiegl H, Dutkowski C, immunodeficiencies. Annals of the New overexpression in mice reduces food McCloy RA, Sutherland RL, Musgrove EA, York Academy of Sciences. 2012; intake and increases lipogenic capacity. Nicholson RI. Tamoxifen-induced 1250:1-13. Neuropeptides. 2012; 46:173-82. epigenetic silencing of oestrogen- regulated genes in anti-hormone resistant Tirko NN, Ryugo DK. Synaptic plasticity in Shim DS, Schilter HC, Knott ML, Almeida breast cancer. PloS One. 2012; 7:e40466. the medial superior olive of hearing, deaf, RA, Short RP, Mackay CR, Dent LA, and cochlear-implanted cats. The Journal Sewell WA. Protection against Surh CD, Sprent J. TGF-beta puts the of Comparative Neurology. 2012; Nippostrongylus brasiliensis infection in brakes on homeostatic proliferation. 520:2202-17. mice is independent of GM-CSF. Nature Immunology. 2012; 13:628-30. Immunology & Cell Biology. 2012; Toussaint ND, Pedagogos E, Tan SJ, Badve 90:553-8. Swaminathan S, Suzuki K, Seddiki N, SV, Hawley CM, Perkovic V, Elder GJ. Kaplan W, Cowley MJ, Hood CL, Clancy Phosphate in early chronic kidney disease: Sigglekow ND, Pangon L, Brummer T, JL, Murray DD, Mendez C, Gelgor L, associations with clinical outcomes and a Molloy M, Hawkins NJ, Ward RL, Anderson B, Roth N, Cooper DA, Kelleher target to reduce cardiovascular risk. Musgrove EA, Kohonen-Corish MR. AD. Differential regulation of the Let-7 Nephrology. 2012; 17:433-44. Mutated in colorectal cancer protein family of microRNAs in CD4+ T cells alters modulates the NFkappaB pathway. IL-10 expression. Journal of Immunology. Trollor JN, Smith E, Agars E, Kuan SA, Anticancer Research. 2012; 32:73-9. 2012; 188:6238-46. Baune BT, Campbell L, Samaras K, Crawford J, Lux O, Kochan NA, Brodaty H, Song S, Nones K, Miller D, Harliwong I, Swarbrick A, Daly RJ. New insights into Sachdev P. The association between Kassahn KS, Pinese M, Pajic M, Gill AJ, signalling networks regulating breast systemic inflammation and cognitive Johns AL, Anderson M, Holmes O, cancer stem cells. Breast Cancer performance in the elderly: the Sydney Leonard C, Taylor D, Wood S, Xu Q, Research. 2012; 14:321. Memory and Ageing Study. Age. 2012; Newell F, Cowley MJ, Wu J, Wilson P, Fink 34:1295-308. L, Biankin AV, Waddell N, Grimmond SM, Pearson JV. qpure: A tool to estimate Tsai VW, Husaini Y, Manandhar R, Lee-Ng tumor cellularity from genome-wide KK, Zhang HP, Harriott K, Jiang L, Lin S, single-nucleotide polymorphism profiles. Sainsbury A, Brown DA, Breit SN. PloS One. 2012; 7:e45835. T Anorexia/cachexia of chronic diseases: a Tactacan CM, Chang DK, Cowley MJ, role for the TGF-beta family cytokine Sousa DM, Baldock PA, Enriquez RF, Humphrey ES, Wu J, Gill AJ, Chou A, MIC-1/GDF15. Journal of Cachexia Zhang L, Sainsbury A, Lamghari M, Nones K, Grimmond SM, Sutherland RL, Sarcopenia and Muscle. 2012; 3:239-43. Herzog H. Neuropeptide Y Y1 receptor Biankin AV, Daly RJ. RON is not a antagonism increases bone mass in mice. prognostic marker for resectable Tsoli M, Moore M, Burg D, Painter A, Bone. 2012; 51:8-16. pancreatic cancer. BMC Cancer. 2012; Taylor R, Lockie SH, Turner N, Warren A, 12:395. Cooney G, Oldfield B, Clarke S, Robertson Sprent J, Surh CD. Interleukin 7, maestro G. Activation of thermogenesis in brown of the immune system. Seminars in Tan SX, Ng Y, Burchfield JG, Ramm G, adipose tissue and dysregulated lipid Immunology. 2012; 24:149-50. Lambright DG, Stockli J, James DE. The metabolism associated with cancer Rab GTPase-activating protein cachexia in mice. Cancer Research. 2012; Statham AL, Robinson MD, Song JZ, TBC1D4/AS160 contains an atypical 72:4372-82. Coolen MW, Stirzaker C, Clark SJ. Bisulfite phosphotyrosine-binding domain that sequencing of chromatin interacts with plasma membrane immunoprecipitated DNA (BisChIP-seq) phospholipids to facilitate GLUT4 directly informs methylation status of trafficking in adipocytes. Molecular and histone-modified DNA. Genome Cellular Biology. 2012; 32:4946-59. Research. 2012; 22:1120-7. V Tan SX, Ng Y, Meoli CC, Kumar A, Khoo Valdes-Mora F, Song JZ, Statham AL, Stolp J, Chen YG, Cox SL, Henck V, Zhang PS, Fazakerley DJ, Junutula JR, Vali S, Strbenac D, Robinson MD, Nair SS, W, Tsaih SW, Chapman H, Stearns T, James DE, Stockli J. Amplification and Patterson KI, Tremethick DJ, Stirzaker C, Serreze DV, Silveira PA. Subcongenic demultiplexing in insulin-regulated Akt Clark SJ. Acetylation of H2A.Z is a key analyses reveal complex interactions protein kinase pathway in adipocytes. The epigenetic modification associated with between distal chromosome 4 genes Journal of Biological Chemistry. 2012; gene deregulation and epigenetic controlling diabetogenic B cells and CD4 T 287:6128-38. remodeling in cancer. Genome Research. cells in nonobese diabetic Mice. Journal of 2012; 22:307-21. Immunology. 2012; 189:1406-17.

79PUBLICATIONS Verma D, Tasan R, Herzog H, Sperk G. Zhang L, Yagi M, Herzog H. The role of NPY controls fear conditioning and fear NPY and ghrelin in anorexia nervosa. extinction by combined action on Y(1) Current Pharmaceutical Design. 2012; and Y(2) receptors. British Journal of X 18:4766-78. Pharmacology. 2012; 166:1461-73. Xiong B, Bayat V, Jaiswal M, Zhang K, Sandoval H, Charng WL, Li T, David G, Zheng HF, Tobias JH, Duncan E, Evans Viardot A, Heilbronn LK, Samocha-Bonet Duraine L, Lin YQ, Neely GG, Yamamoto S, DM, Eriksson J, Paternoster L, Yerges- D, Mackay F, Campbell LV, Samaras K. Bellen HJ. Crag Is a GEF for Rab11 Armstrong LM, Lehtimaki T, Bergstrom U, Obesity is associated with activated and required for rhodopsin trafficking and Kahonen M, Leo PJ, Raitakari O, insulin resistant immune cells. maintenance of adult photoreceptor cells. Laaksonen M, Nicholson GC, Viikari J, Diabetes/Metabolism Research and PLoS Biology. 2012; 10:e1001438. Ladouceur M, Lyytikainen LP, Medina- Reviews. 2012; 28:447-54. Gomez C, Rivadeneira F, Prince RL, Sievanen H, Leslie WD, Mellstrom D, Vitovski S, Chantry AD, Lawson MA, Eisman JA, Moverare-Skrtic S, Goltzman Croucher PI. Targeting tumour-initiating D, Hanley DA, Jones G, St Pourcain B, Xiao cells with TRAIL based combination Y, Timpson NJ, Smith GD, Reid IR, Ring therapy ensures complete and lasting Y SM, Sambrook PN, Karlsson M, Dennison eradication of multiple myeloma tumours Yang P, Humphrey SJ, Fazakerley DJ, Prior EM, Kemp JP, Danoy P, Sayers A, Wilson in vivo. PloS One. 2012; 7:e35830. MJ, Yang G, James DE, Yang JY. Re- SG, Nethander M, McCloskey E, fraction: a machine learning approach for Vandenput L, Eastell R, Liu J, Spector T, deterministic identification of protein Mitchell BD, Streeten EA, Brommage R, homologues and splice variants in large- Pettersson-Kymmer U, Brown MA, scale MS-based proteomics. Journal of Ohlsson C, Richards JB, Lorentzon M. Proteome Research. 2012; 11:3035-45. WNT16 influences bone mineral density, W cortical bone thickness, bone strength, Waterloo S, Ahmed LA, Center JR, Eisman Yang S, Nguyen ND, Eisman JA, Nguyen and osteoporotic fracture risk. PLoS JA, Morseth B, Nguyen ND, Nguyen T, TV. Association between beta-blockers Genetics. 2012; 8:e1002745. Sogaard AJ, Emaus N. Prevalence of and fracture risk: A Bayesian meta- vertebral fractures in women and men in analysis. Bone. 2012; 51:969-74. the population-based Tromso Study. BMC Opposite: Dr Margaret Stuart (Assistant Director of Musculoskeletal Disorders. 2012; 13:3. Garvan from 1978) with Dr Anne Underwood, leader of Yuen C, Hossack T, Haynes A-M, Pe a team at CSIRO Division of Molecular Biology which Waterloo S, Nguyen T, Ahmed LA, Center Benito RA, Matthews J, Fogarty G, carried out cell fusions for hybridoma production in the monoclonal antibody project which ran from 1979-1985. JR, Morseth B, Nguyen ND, Eisman JA, Jagavkar R, Brenner P, Stricker P. Impact Sogaard AJ, Emaus N. Important risk of percentage of positive biopsy cores on factors and attributable risk of vertebral biochemical outcome in patients treated fractures in the population-based Tromso with low-dose rate (Iodine-125) study. BMC Musculoskeletal Disorders. brachytherapy for prostate cancer. Open 2012; 13:163. Prostate Cancer Journal. 2012; 5:15-19. Wee EJ, Peters K, Nair SS, Hulf T, Stein S, Wagner S, Bailey P, Lee SY, Qu WJ, Brewster B, French JD, Dobrovic A, Francis GD, Clark SJ, Brown MA. Mapping the regulatory sequences controlling 93 Z breast cancer-associated miRNA genes Zeng XY, Wang YP, Cantley J, Iseli TJ, leads to the identification of two Molero JC, Hegarty BD, Kraegen EW, Ye Y, functional promoters of the Hsa-mir- Ye JM. Oleanolic acid reduces hyperglycemia 200b cluster, methylation of which is beyond treatment period with Akt/FoxO1- associated with metastasis or hormone induced suppression of hepatic receptor status in advanced breast cancer. gluconeogenesis in type-2 diabetic mice. Oncogene. 2012; 31:4182-95. PloS One. 2012; 7:e42115.

Wong IP, Driessler F, Khor EC, Shi YC, Zhang L, Daly RJ. Targeting the human Hormer B, Nguyen AD, Enriquez RF, kinome for cancer therapy: current Eisman JA, Sainsbury A, Herzog H, perspectives. Critical Reviews in Baldock PA. Peptide YY regulates bone Oncogenesis. 2012; 17:233-46. remodeling in mice: a link between gut and skeletal biology. PloS One. 2012; Zhang L, Nguyen AD, Lee IC, Yulyaningsih 7:e40038. E, Riepler SJ, Stehrer B, Enriquez RF, Lin S, Shi YC, Baldock PA, Sainsbury A, Herzog Wright A, Vissel B. The essential role of H. NPY modulates PYY function in the AMPA receptor GluR2 subunit RNA editing regulation of energy balance and glucose in the normal and diseased brain. Frontiers homeostasis. Diabetes, Obesity & in Molecular Neuroscience. 2012; 5:34. Metabolism. 2012; 14:727-36.

80PUBLICATIONS

Electronic PUBLICATIONS AHEAD OF PRINT

Chiam K, Ricciardelli C, Bianco-Miotto T. asymptomatic (undiagnosed) vertebral Epigenetic biomarkers in prostate cancer: fracture in Vietnamese men and women. Current and future uses. Cancer Letters Archives of Osteoporosis Epub B Epub 2012/03/07. 2012/11/08. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland Chtanova T, Hampton HR, Waterhouse Hulf T, Sibbritt T, Wiklund ED, Patterson K, RL, Coolen MW, Stirzaker C, Clark SJ. LA, Wood K, Tomura M, Miwa Y, Mackay Song JZ, Stirzaker C, Qu W, Nair S, Regional activation of the cancer genome CR, Brink R, Phan TG. Real-time Horvath LG, Armstrong NJ, Kench JG, by long-range epigenetic remodeling. interactive two-photon photoconversion Sutherland RL, Clark SJ. Epigenetic- Cancer Cell Epub 2012/12/19. of recirculating lymphocytes for induced repression of microRNA-205 is discontinuous cell tracking in live adult associated with MED1 activation and a Brzozowska MM, Sainsbury A, Eisman JA, mice. Journal of Biophotonics Epub poorer prognosis in localized prostate Baldock PA, Center JR. Bariatric surgery, 2012/11/28. cancer. Oncogene Epub 2012/08/08. bone loss, obesity and possible mechanisms. Obesity Reviews Epub Cowley MJ, Weinberg A, Zammit N, 2012/10/26. Walters SN, Hawthorne WJ, Loudovaris T, Thomas H, Kay T, Gunton JE, Alexander SI, Burchfield JG, Lu J, Fazakerley DJ, Tan SX, Kaplan W, Chapman J, O'Connell PJ, Grey Ng Y, Mele K, Buckley MJ, Han W, Hughes ST. Human islets express a marked pro- K WE, James DE. Novel systems for inflammatory molecular signature prior to Kang ZF, Deng Y, Zhou Y, Fan RR, Chan dynamically assessing insulin action in live transplantation Cell Transplantation Epub JC, Laybutt DR, Luzuriaga J, Xu G. cells reveals heterogeneity in the insulin 2012/03/13. Pharmacological reduction of NEFA response. Traffic Epub 2012/12/21. restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Diabetologia Epub G 2012/11/29. C Ganda K, Puech M, Chen JS, Speerin R, Koese M, Rentero C, Kota BP, Hoque M, Cantley J, Walters SN, Jung MH, Weinberg Bleasel J, Center JR, Eisman JA, March L, Cairns R, Wood P, Vila de Muga S, A, Cowley MJ, Whitworth PT, Kaplan W, Seibel MJ. Models of care for the Reverter M, Alvarez-Guaita A, Hawthorne WJ, O'Connell PJ, Weir G, Grey secondary prevention of osteoporotic Monastyrskaya K, Hughes WE, Swarbrick ST. A pre-existent hypoxic gene signature fractures: a systematic review and meta- A, Tebar F, Daly RJ, Enrich C, Grewal T. predicts impaired islet graft function and analysis. Osteoporosis International Epub Annexin A6 is a scaffold for PKCalpha to glucose homeostasis. Cell Transplantation 2012/07/26. promote EGFR inactivation. Oncogene Epub 2012/11/07. Epub 2012/07/17. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Cattenoz PB, Taft RJ, Westhof E, Mattick Holick MF, Gunton JE. The roles of vitamin JS. Transcriptome-wide identification of A D in skeletal muscle: form, function, and > I RNA editing sites by inosine specific metabolism. Endocrine Reviews Epub cleavage. RNA Epub 2012/12/25. 2012/11/22. L Chan MY, Nguyen ND, Center JR, Eisman Gloss BS, Samimi G. Epigenetic biomarkers Lam M, Hull L, McLachlan R, Snidvongs K, JA, Nguyen TV. Quantitative ultrasound in epithelial ovarian cancer. Cancer Letters Chin D, Pratt E, Kalish L, Sacks R, Earls P, and fracture risk prediction in non- Epub 2012/01/17. Sewell W, Harvey RJ. Clinical severity and osteoporotic men and women as defined epithelial endotypes in chronic by WHO criteria. Osteoporosis rhinosinusitis. International Forum of International Epub 2012/08/11. Allergy & Rhinology Epub 2012/10/06. Cheng K, Andrikopoulos S, Gunton JE. First phase insulin secretion and Type 2 Lee P, Day RO, Greenfield JR, Ho KK. Diabetes. Current Molecular Medicine H Formoterol, a highly beta(2)-selective Epub 2012/07/28. Ho-Pham LT, Mai LD, Pham HN, Nguyen agonist, increases energy expenditure and ND, Nguyen TV. Reference ranges for fat utilisation in men. International Journal vertebral heights and prevalence of of Obesity Epub 2012/05/30. 82PUBLICATIONS Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, P T Cheung BB, Kumar S, Marshall GM, Plummer PN, Freeman R, Taft R, Vider J, Tan BM, Zammit NW, Yam AO, Slattery R, Biankin AV, Liu T. The histone deacetylase Sax M, Umer BA, Gao D, Johns CA, Walters SN, Malle E, Grey ST. Baculoviral SIRT2 stabilizes Myc oncoproteins. Cell Mattick JS, Wilton SD, Ferro V, McMillan inhibitors of apoptosis repeat containing Death and Differentiation Epub NA, Swarbrick A, Mittal V, Mellick AS. (BIRC) proteins fine-tune TNF-induced 2012/11/24. MicroRNAs regulate tumor angiogenesis nuclear factor kappaB and c-Jun N- modulated by endothelial progenitor cells. terminal kinase signalling in mouse Cancer Research Epub 2012/07/28. pancreatic beta cells. Diabetologia Epub 2012/12/20. Purtell L, Jenkins A, Viardot A, Herzog H, Sainsbury A, Smith A, Loughnan G, M Steinbeck K, Campbell LV, Sze L. Moleirinho S, Chang N, Sims AH, Tilston- Postprandial cardiac autonomic function in Lunel AM, Angus L, Steele A, Boswell V, prader-willi syndrome. Clinical Barnett SC, Ormandy C, Faratian D, Endocrinology (Oxf) Epub 2012/10/31. W Gunn-Moore FJ, Reynolds PA. KIBRA Wohrle FU, Halbach S, Aumann K, exhibits MST-independent functional Schwemmers S, Braun S, Auberger P, regulation of the Hippo signaling pathway Schramek D, Penninger JM, Lassmann S, in mammals. Oncogene Epub Werner M, Waller CF, Pahl HL, Zeiser R, 2012/05/23. Daly RJ, Brummer T. Gab2 signaling in R chronic myeloid leukemia cells confers Muniak MA, Rivas A, Montey KL, May BJ, Reznick J, Preston E, Wilks DL, Beale SM, resistance to multiple Bcr-Abl inhibitors. Francis HW, Ryugo DK. A 3-dimensional Turner N, Cooney GJ. Altered feeding Leukemia Epub 2012/08/04. model of frequency representation in the differentially regulates circadian rhythms cochlear nucleus of the CBA/J mouse. The and energy metabolism in liver and Wong IP, Nguyen AD, Khor EC, Enriquez Journal of Comparative Neurology Epub muscle of rats. Biochim Biophys Acta RF, Eisman JA, Sainsbury A, Herzog H, 2012/10/11. Epub 2012/09/07; 1832:228-38. Baldock PA. Neuropeptide Y is a critical modulator of leptin's regulation of cortical bone. Journal of Bone and Mineral N S Research Epub 2012/10/10. Nair P, Lee P, Reynolds C, Nguyen ND, Samaras K, Viardot A, Lee PN, Jenkins A, Myburgh J, Eisman JA, Center JR. Botelho NK, Bakopanos A, Lord RV, Significant perturbation of vitamin D- Hayward CS. Reduced arterial stiffness Z parathyroid-calcium axis and adverse after weight loss in obese type 2 diabetes Zammit NW, Tan BM, Walters SN, clinical outcomes in critically ill patients. and impaired glucose tolerance: The role Liuwantara D, Villanueva JE, E KM, Grey Intensive Care Medicine Epub of immune cell activation and insulin ST. Low-dose rapamycin unmasks the 2012/10/16. resistance. Diabetes & Vascular Disease protective potential of targeting intragraft Research Epub 2012/04/27. NF-kappaB for islet transplants. Cell Transplantation Epub 2012/11/07. Shields BJ, Wiede F, Gurzov EN, Wee K, Hauser C, Zhu HJ, Molloy TJ, O'Toole SA, Zengin A, Nguyen AD, Wong IP, Zhang L, Daly RJ, Sutherland RL, Mitchell CA, Enriquez RF, Eisman JA, Herzog H, Baldock O McLean CA, Tiganis T. TCPTP regulates PA, Sainsbury A. Neuropeptide Y mediates Omsland TK, Emaus N, Tell GS, Ahmed LA, SFK and STAT3 signaling and is lost in the short-term hypometabolic effect of Center JR, Nguyen ND, Gjesdal CG, triple-negative breast cancers. Molecular estrogen deficiency in mice. International Forsmo S, Schei B, Sogaard AJ, Meyer HE. and Cellular Biology Epub 2012/11/21. Journal of Obesity Epub 2012/05/09. Ten-year risk of second hip fracture. A NOREPOS study. Bone Epub Stokes RA, Cheng K, Deters N, Lau SM, 2012/09/25. Hawthorne WJ, O'Connell PJ, Stolp J, Grey S, Loudovaris T, Kay TW, Thomas HE, Ortiz-Padilla C, Gallego-Ortega D, Gonzalez FJ, Gunton JE. Hypoxia-inducible Browne BC, Hochgrafe F, Caldon CE, factor 1alpha (HIF-1alpha) potentiates Lyons RJ, Croucher DR, Rickwood D, beta-cell survival after islet Ormandy CJ, Brummer T, Daly RJ. transplantation of human and mouse Functional characterization of cancer- islets. Cell Transplantation Epub associated Gab1 mutations. Oncogene 2012/06/20. Epub 2012/07/04.

83PUBLICATIONS

Financial HIGHLIGHTS

Garvan Institute of Medical Research 2008 2009 2010 2011 2012 Income Statement $'000 $'000 $'000 $'000 $'000

NHMRC Grants 18,695 19,094 16,637 18,574 20,640 Other Peer Reviewed Grants 9,159 11,061 10,232 10,896 10,213 Other Grants 4,811 1,624 - 1,869 452 NSW Government Grant 4,026 3,797 2,600 4,135 6325 Commercial Collaborations 1,289 737 202 347 226 Garvan Research Foundation 4,689 4,120 5,174 6,113 7,110 Other Income 4,050 7,470 6,872 9,167 11,098 Other Income (Insurance Claim Facade) - - 2,750 - - Total Operating Income 46,719 47,903 44,467 51,101 56,064

Commonwealth Government Grant (TKCC* Construction) - 14,900 7,567 10,173 3,935 Garvan Research Foundation (TKCC* Construction) - 1,170 3,528 4,723 8,630 Other Income (TKCC* Construction) - - - 2,750 250 Total Income for TKCC Construction** - 16,070 11,095 17,646 12,815

Remuneration Costs 27,337 28,322 29,196 32,215 35,134 Research Expenditure 9,377 7,883 7,517 6,828 8,747 Administration and Information Technology 5,331 4,822 3,989 5.115 5,507 Building and Scientific Operations 2,753 3,324 6,272 4,743 4,057 Total Operating Expenses 44,798 44,351 46,974 48,901 53,445

Building Asset Amortisation (1,189) (1,657) (1,659) (1,723) (2,456) Property, Plant and Equipment Depreciation (2,390) (2,597) (2,670) (3,939) (4,945) Transfer from Building Reserve 1,047 1,047 1,047 1,047 1,047 Endowment Grants from Garvan Research Foundation 3,953 6,388 1,604 3,586 2,000 Endowment Earnings 1,700 958 1,192 1,665 1,368 Donations & Bequests direct to/(from) Endowment Fund 5,393 (5,000) - - - Unrealised gain/(loss) on investment (7,407) 1,922 (142) (2,504) 2,264

Net Income 3,028 20,683 7,960 17,978 14,712 Accumulated Surplus Brought Forward 11,109 16,571 32,512 43,128 62,509 Transfer from/(to) Research Program Reserve 380 (2,189) 1,133 (2,090) (951) Transfer from/(to) Endowment Reserve 1,847 (2,530) 1,190 3,493 (706) Transfer from/(to) Infrastructure Expense Reserve 207 (23) 333 - - Accumulated Surplus Carried Forward*** 16,571 32,512 43,128 62,509 75,564

* The Kinghorn Cancer Centre (TKCC). ** The costs for TKCC construction are capitalised (refer balance sheet - Asset Under Construction (TKCC)). *** Prior year included funds for the construction of TKCC. TKCC is completed in 2012 and shown as a fixed asset.

Opposite: Nina Ostlund using the newly installed (1982) Fast Protein Liquid Chromatography system to examine the purity of a human growth hormone preparation. 85FINANCIAL HIGHLIGHTS Garvan Instititute of Medical Research 2008 2009 2010 2011 2012 Balance Sheet $'000 $’000 $’000 $’000 $’000

Current Assets 21,114 52,136 59,765 62,379 33,604 Property, Plant and Equipment 60,085 60,325 57,060 58,369 64,834 Property, Plant and Equipment (TKCC*) - - - - 45,980 Asset Under Constuction (TKCC*) - 1,731 8,399 29,660 - Endowment Fund** 25,255 27,786 26,597 23,103 22,833 Investment in associates 84 84 84 84 84 Total Assets 106,538 142,062 151,905 173,595 167,335

Payables 7,860 23,372 26,187 30,087 10,142 Provisions 3,545 3,986 4,125 5,010 5,049 Borrowings 18,144 18,078 18,054 18,028 18,010 Total Liabilities 29,549 45,436 48,366 53,125 33,201

Accumulated Surplus*** 16,571 32,512 43,128 62,509 75,564 Reserves 60,419 64,114 60,411 57,961 58,570 Total Net Funds 76,990 96,626 103,539 120,470 134,134

*The Kinghorn Cancer Centre (TKCC). ** Including cash and investments at market value. *** Prior year included funds for the construction of TKCC. TKCC is completed in 2012 and shown as a fixed asset.

86FINANCIAL HIGHLIGHTS Garvan Research Foundation 2008 2009 2010 2011 2012 Statement of Funds $'000 $’000 $’000 $’000 $’000

Donations & Pledges 6,277 4,026 5,231 4,696 9,476 Donations & Pledges (for TKCC*) 584 1,742 7,126 9,390 8,638 Events 105 38 215 1,273 890 Bequests 3,132 7,764 2,981 6,356 712 Interest and Other Income 55 19 44 37 31 Total Income 10,153 13,589 15,597 21,752 19,747

Fundraising Expenses (1,114) (1,268) (1,496) (2,152) (2,607)

Grants to TKCC Joint Venture Partner - (1,170) (3,528) (4,723) - Net Funds Raised 9,039 11,151 10,573 14,877 17,140

Accumulated Funds Prior Years 109 507 (20) 248 701 Funds Available for Grants to Institute: 9,148 11,658 10,553 15,125 17,841

General Research 926 1,010 1,200 1,200 1,400 Specific Research 3,762 4,280 7,501 9,638 14,340 Endowment Funds 3,953 6,388 1,604 3,586 2,000 Total Grants 8,641 11,678 10,305 14,424 17,740

Accumulated Funds Carried Forward 507 (20) 248 701 101 Represented By: Assets 1,391 164 401 907 354 Less: Liabilities (884) (184) (153) (206) (253) Net Assets 507 (20) 248 701 101

* The Kinghorn Cancer Centre (TKCC).

87FINANCIAL HIGHLIGHTS Garvan Institute of Medical Research 384 Victoria Street Darlinghurst Sydney NSW 2010 Australia T +61 2 9295 8100 F +61 2 9295 8101 www.garvan.org.au

Project Manager: Alison Heather Design: Jason McDonald Photography: Penelope Clay

Published April 2013 Copies of the Annual Report can be obtained by contacting: Gabriella O’Neil [email protected] T +61 2 9295 8135 YEARS OF MEDICAL RESEARCH ANNUAL ANNUAL REPORT 2012 GARVAN INSTITUTE INSTITUTE GARVAN 50 CELEBRATING

GARVAN INSTITUTE OF MEDICAL RESEARCH ANNUAL REPORT 2012 CELEBRATING 50 YEARS